Document:

EX-10.14

 Exhibit 10.14 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

COLLABORATION AGREEMENT 

between 
 BIONTECH RNA
PHARMACEUTICALS GMBH AND BIONTECH AG 
 and 

GENENTECH, INC. AND F. HOFFMANN-LA ROCHE LTD 

Dated as of September 20, 2016 

			
	Confidential	  	Execution Copy

  

 TABLE OF CONTENTS 

 

							
	 RECITALS
	  	 	1	 
	 ARTICLE 1. DEFINITIONS 1
	  			
	 ARTICLE 2. GOVERNANCE
	  	 	26	 
	 2.1
	 	Establishment of Governance Committees	  	 	26	 
	 2.2
	 	Committee Membership	  	 	26	 
	 2.3
	 	Team Membership	  	 	27	 
	 2.4
	 	Meetings; Participation	  	 	27	 
	 2.5
	 	Minutes; Other Documentation	  	 	27	 
	 2.6
	 	Joint Research Committee	  	 	28	 
	 2.7
	 	Joint Development Committee	  	 	29	 
	 2.8
	 	Joint Manufacturing Committee	  	 	31	 
	 2.9
	 	Joint Commercialization Committee	  	 	33	 
	 2.10
	 	Joint Research Team	  	 	33	 
	 2.11
	 	Joint Development Team	  	 	34	 
	 2.12
	 	Joint Manufacturing Team	  	 	35	 
	 2.13
	 	Alliance Managers	  	 	37	 
	 2.14
	 	Limitations on Authority	  	 	37	 
	 2.15
	 	Interactions Between Committees, Teams and Internal Teams	  	 	37	 
	 2.16
	 	Working Groups	  	 	37	 
	 2.17
	 	Expenses	  	 	38	 
	 2.18
	 	Consequences of BioNTech Opt-Out	  	 	38	 
	 2.19
	 	Technical and Knowledge Transfer	  	 	38	 
	 2.20
	 	[***] Activities	  	 	40	 
	 ARTICLE 3. RESEARCH PROGRAM
	  	 	41	 
	 3.1
	 	Research Plan and Activities	  	 	41	 
	 3.2
	 	Subcontracting	  	 	41	 
	 3.3
	 	Records and Results	  	 	42	 
	 ARTICLE 4. DEVELOPMENT
	  	 	43	 
	 4.1
	 	Generally	  	 	43	 
	 4.2
	 	GDP	  	 	43	 
	 4.3
	 	BioNTech Ongoing Clinical Studies and Related Follow-Up Studies	  	 	43	 
	 4.4
	 	Development Under the Global Development Plan	  	 	44	 
	 4.5
	 	BioNTech Proposed New Indications; BioNTech Studies	  	 	45	 
	 4.6
	 	Genentech’s Conduct of Genentech Studies; [***] for Genentech Collaboration Products	  	 	49	 
	 4.7
	 	Collaboration Product Improvements	  	 	49	 
	 4.8
	 	Records and Reports; Study Data	  	 	49	 
	 4.9
	 	Investigator-Sponsored Studies	  	 	50	 
	 4.10
	 	Compliance	  	 	50	 
	 ARTICLE 5. REGULATORY
	  	 	50	 
	 5.1
	 	General	  	 	50	 
	 5.2
	 	Lead Regulatory Parties	  	 	50	 
	 5.3
	 	BioNTech Study under [***]	  	 	50	 

  

			
	Confidential	  	Execution Copy

  

							
	 5.4
	 	Regulatory Activities	  	 	51	 
	 5.5
	 	CMC Regulatory Support	  	 	52	 
	 5.6
	 	Regulatory Correspondence	  	 	53	 
	 5.7
	 	Regulatory Data; Annual Report	  	 	54	 
	 5.8
	 	Pharmacovigilance	  	 	54	 
	 5.9
	 	BioNTech Platform Product	  	 	54	 
	 ARTICLE 6. COMMERCIALIZATION AND MEDICAL AFFAIRS
	  	 	55	 
	 6.1
	 	Generally	  	 	55	 
	 6.2
	 	Booking of Sales; Distribution	  	 	55	 
	 6.3
	 	Product Trademarks	  	 	56	 
	 6.4
	 	Product Labeling; Markings and Co-Branding	  	 	56	 
	 6.5
	 	Co-Promotion Option	  	 	56	 
	 6.6
	 	Medical Affairs	  	 	58	 
	 ARTICLE 7. MANUFACTURING
	  	 	59	 
	 7.1
	 	Manufacturing Development and Supply Agreement	  	 	59	 
	 7.2
	 	Conflicts Between MDSA and Current Agreement	  	 	59	 
	 7.3
	 	Effect of Opt-Out	  	 	59	 
	 ARTICLE 8. PAYMENTS AND RECORDS
	  	 	60	 
	 8.1
	 	Upfront Payments	  	 	60	 
	 8.2
	 	Development Costs	  	 	61	 
	 8.3
	 	BioNTech Indication Opt-In Fee; Genentech Indication Co-Funding Fee	  	 	63	 
	 8.4
	 	Profit or Loss Share	  	 	63	 
	 8.5
	 	BioNTech Opt-Out Right	  	 	64	 
	 8.6
	 	Royalties	  	 	65	 
	 8.7
	 	Royalty Payments and Reports	  	 	66	 
	 8.8
	 	Apportionment of Compulsory Sublicensee Consideration	  	 	66	 
	 8.9
	 	Mode of Payment; Offsets	  	 	66	 
	 8.10
	 	Accounting Procedures	  	 	67	 
	 8.11
	 	Taxes	  	 	67	 
	 8.12
	 	Interest on Late Payments	  	 	68	 
	 8.13
	 	Tax Returns	  	 	68	 
	 8.14
	 	Financial Records	  	 	68	 
	 8.15
	 	Invoices	  	 	68	 
	 8.16
	 	Audit	  	 	69	 
	 8.17
	 	Audit Dispute	  	 	69	 
	 8.18
	 	Confidentiality	  	 	69	 
	 ARTICLE 9. GRANT OF RIGHTS
	  	 	69	 
	 9.1
	 	Licenses to Genentech	  	 	69	 
	 9.2
	 	Licenses to BioNTech	  	 	70	 
	 9.3
	 	Sublicenses; Exercise of Licensed Rights by Third Parties or Affiliates	  	 	71	 
	 9.4
	 	Trademark and Corporate Names Licenses	  	 	71	 
	 9.5
	 	Rights of Reference or Use	  	 	72	 
	 9.6
	 	Genentech Rights of First Negotiation	  	 	72	 
	 9.7
	 	Exclusivity	  	 	73	 
	 ARTICLE 10. INTELLECTUAL PROPERTY
	  	 	74	 
	 10.1
	 	Disclosure	  	 	74	 

  
 - ii - 

			
	Confidential	  	Execution Copy

  

							
	 10.2
	 	Ownership; Assignment and Cooperation; Inventorship	  	 	74	 
	 10.3
	 	Patent Prosecution and Maintenance	  	 	75	 
	 10.4
	 	[***]	  	 	76	 
	 10.5
	 	Enforcement and Defense of Patents; Defense of Claims by Third Parties	  	 	76	 
	 10.6
	 	Third Party Licenses	  	 	78	 
	 10.7
	 	Corporate Names and Product Trademarks	  	 	80	 
	 10.8
	 	[***]	  	 	81	 
	 10.9
	 	Third Party Materials and Software	  	 	81	 
	 10.10
	 	Attorney-Client Privilege	  	 	81	 
	 ARTICLE 11. CONFIDENTIALITY AND
NON-DISCLOSURE
	  	 	81	 
	 11.1
	 	Disclosure and Use of Confidential Information	  	 	81	 
	 11.2
	 	Permitted Disclosures	  	 	83	 
	 11.3
	 	Use of Name	  	 	84	 
	 11.4
	 	Press Releases and Other Public Disclosures	  	 	84	 
	 11.5
	 	Scientific Publications	  	 	85	 
	 11.6
	 	Restriction on Disclosure of [***]	  	 	85	 
	 11.7
	 	Restriction on Disclosure of [***]	  	 	85	 
	 ARTICLE 12. REPRESENTATIONS AND WARRANTIES
	  	 	85	 
	 12.1
	 	Mutual Representations and Warranties	  	 	85	 
	 12.2
	 	Additional Representations and Warranties of BioNTech	  	 	86	 
	 12.3
	 	Additional Representations and Warranties by Genentech	  	 	93	 
	 12.4
	 	DISCLAIMER OF WARRANTIES	  	 	96	 
	 12.5
	 	Disclosures	  	 	97	 
	 ARTICLE 13. INDEMNITY AND INSURANCE
	  	 	97	 
	 13.1
	 	Indemnification of BioNTech	  	 	97	 
	 13.2
	 	Indemnification of Genentech	  	 	98	 
	 13.3
	 	Certain Losses	  	 	98	 
	 13.4
	 	Notice of Claim	  	 	98	 
	 13.5
	 	Control of Defense	  	 	99	 
	 13.6
	 	Limitation of Liability	  	 	100	 
	 13.7
	 	Insurance	  	 	101	 
	 ARTICLE 14. TERM AND TERMINATION
	  	 	102	 
	 14.1
	 	Term	  	 	102	 
	 14.2
	 	Termination by Either Party for Material Breach	  	 	103	 
	 14.3
	 	Additional Termination Rights by Genentech	  	 	104	 
	 14.4
	 	Termination for Insolvency	  	 	104	 
	 14.5
	 	Effects of Termination	  	 	104	 
	 14.6
	 	Rights in Bankruptcy	  	 	107	 
	 14.7
	 	Remedies	  	 	108	 
	 14.8
	 	Accrued Rights; Surviving Obligations	  	 	108	 
	 ARTICLE 15. MISCELLANEOUS
	  	 	108	 
	 15.1
	 	Force Majeure	  	 	108	 
	 15.2
	 	Change in Control of BioNTech	  	 	108	 
	 15.3
	 	Export Control	  	 	112	 
	 15.4
	 	Assignment	  	 	112	 
	 15.5
	 	Severability	  	 	112	 

  
 - iii - 

			
	Confidential	  	Execution Copy

  

							
	 15.6
	 	Governing Law and Service	  	 	113	 
	 15.7
	 	Dispute Resolution	  	 	113	 
	 15.8
	 	Notices	  	 	115	 
	 15.9
	 	Entire Agreement	  	 	116	 
	 15.10
	 	English Language	  	 	117	 
	 15.11
	 	Equitable Relief	  	 	117	 
	 15.12
	 	Amendment; Waiver	  	 	117	 
	 15.13
	 	No Benefit to Third Parties	  	 	117	 
	 15.14
	 	Further Assurance	  	 	117	 
	 15.15
	 	Relationship of the Parties	  	 	118	 
	 15.16
	 	Counterparts; Facsimile Execution	  	 	118	 
	 15.17
	 	References	  	 	118	 
	 15.18
	 	Schedules	  	 	118	 
	 15.19
	 	Construction	  	 	118	 
	 15.20
	 	Actions of Affiliates	  	 	119	 

  
 - iv - 

			
	Confidential	  	Execution Copy

  

 SCHEDULES     

 

			
	1.8	  	Financial Schedule
	1.20	  	BioNTech Core Patents
	1.42	  	BNT and RNP Existing Shareholders
	1.43	  	[***]
	1.97	  	Corporate Names
	1.132	  	Existing Third Party In-License Agreement Royalty Payments
	1.150	  	Estimated GDP Budget through 2019
	1.156	  	Genentech Core Patents
	1.167	  	Genentech Tumor Types
	1.190	  	IVAC Trademark
	1.248	  	[***]
	2.2	  	Initial Committee Membership
	2.19.1(a)	  	BioNTech Initial Knowledge Transfer Items
	2.19.1(c)	  	Genentech Initial Knowledge Transfer Items
	2.19.3	  	[***]
	3.1.2	  	Research Plan
	4.3.1	  	Ongoing Clinical Studies
	4.4.1	  	Initial GDP
	5.3	  	Key Terms for the Amendment of the Agreement in the event of a BioNTech [***]
	6.5.3	  	Key Terms of Co-Promotion Agreement
	8.4	  	Example Quarterly Net Profit/Net Loss Calculation
	8.4.1	  	[***]
	8.9	  	Bank Accounts
	10.3.1(c)(i)	  	Certain BioNTech Core Patents
	11.2.4	  	[***]
	11.4.2	  	Form of Press Release
	12.2.1(a)	  	BioNTech Core Patent Encumbrances
	12.2.1(c)	  	BioNTech Core Patents—Rights Granted to Third Parties
	12.2.1(i)	  	[***]
	12.2.2(a)	  	Existing Third Party In-License Agreements
	12.2.3(e)	  	Safety Reporting
	12.2.3(g)	  	[***]
	12.3.1(h)	  	[***]
	14.1.2	  	Closing Conditions
	14.3.1	  	[***]
	14.5.4	  	[***]
	15.7.2(g)	  	Expedited Arbitration Provisions

  

  
 - v - 

			
	Confidential	  	Execution Copy

  

 COLLABORATION AGREEMENT 

This Collaboration Agreement (the “Agreement”) is made and entered into as of September 20, 2016 (the
“Execution Date”) by and between BioNTech RNA Pharmaceuticals GmbH, a limited liability company organized under the laws of Germany (“RNP”) and BioNTech AG, a stock corporation organized under the laws of Germany
(“BNT”) (RNP and BNT collectively, “BioNTech”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (“GNE”) and F.
Hoffmann-La Roche Ltd, a corporation organized under the laws of Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). BioNTech and Genentech are sometimes
referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, BioNTech Controls certain intellectual property rights with respect to Pharmaceutical Products comprising one or more
Neoepitope RNA(s) in the Territory; 
 WHEREAS, BioNTech and Genentech wish to conduct joint research activities, engage in a shared
(50%:50%) co-development program, and conduct coordinated manufacturing activities, in each case to enable the commercialization of Collaboration Products in the Territory (each capitalized term as defined
herein), and subject to certain exceptions set forth herein, wish to share (50%:50%) the profits and losses associated therewith; 

WHEREAS, BioNTech and Genentech wish to enter into the Manufacturing Development and Supply Agreement as described herein and executed
on the Execution Date; and 
 WHEREAS, BioNTech wishes to grant an exclusive license to Genentech, and Genentech wishes to take, an
exclusive license under such intellectual property rights to Develop and commercialize Collaboration Products in the Territory, in each case in accordance with the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1. 
 DEFINITIONS

 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1 “Accelerated Marketing Authorization” means a Marketing Authorization other than a
Non-Accelerated Marketing Authorization. 

  

			
	Confidential	  	Execution Copy

  

 1.2 “Accounting Standards” has the meaning set forth in Schedule
1.8. 
 1.3 “Additional Jurisdictions” has the meaning set forth in Section 10.3.1(c)(ii). 

1.4 “Adverse Ruling” has the meaning set forth in Section 14.2.  

1.5 “Affiliate” of a Party means any corporation or other business entity that, during the Term, directly or
indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such Party. For purposes of this definition, the term “control” (including, the correlative meanings, “controlled by” and
“under common control with”) means (a) the direct or indirect ownership of more than fifty percent (50%) of (i) the stock or other equity interests having the right to vote for directors (supervisory, management or otherwise)
thereof or (ii) any general partnership interests or (b) the ability to otherwise control the management and policies of such corporation or other business entity, whether through control of the decisions of the managing directors or of
the board of directors, supervisory board or equivalent governing body thereof or otherwise. Notwithstanding the foregoing, for purposes of this Agreement, [***] and all business entities directly or indirectly controlled by [***], shall not be
considered Affiliates of Genentech, unless and until GNE elects to include one or more of such business entities as an Affiliate of Genentech, by providing written notice to BioNTech of such election, (B) Ganymed Pharmaceuticals AG and all
business entities directly or indirectly controlled by Ganymed shall not be considered an Affiliate of RNP or BNT, and (C) AT Impf GmbH, having its place of business at Rosenheimer Platz 6, 81669 Munich, Germany, and any person or entity that,
during the Term, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with AT Impf GmbH (other than BNT or any person or entity that is directly or indirectly controlled by BNT) shall not
be considered an Affiliate of BNT. 
 1.6 “Agreement” has the meaning set forth in the preamble hereto. 

1.7 “Alliance Manager” has the meaning set forth in Section 2.13. 

1.8 “Allowable Expenses” has the meaning set forth in Schedule 1.8. 

1.9 “Ancillary Agreements” means (a) the Manufacturing Development and Supply Agreement, the Commercial
Manufacturing Agreement and the Quality Agreement(s), and any agreement that is entered into by the Parties or their respective Affiliates pursuant to such agreement, (b) any agreement that is entered into by the Parties or their respective
Affiliates pursuant to this Agreement (e.g. the Co-Promotion Agreement or Pharmacovigilance Agreement) and (c) any agreement that is designated in writing by the Parties as an “Ancillary
Agreement” to this Agreement. 
 1.10 “Applicable Law” means applicable laws, rules, and regulations,
including any rules, regulations, guidelines, or other requirements of the Regulatory Authorities (including Compliance Requirements) that may be in effect from time to time. 

  
 - 2 - 

			
	Confidential	  	Execution Copy

  

 1.11 “Applicable Promotional Law” means all Applicable Laws
applicable to the marketing, promotion, distribution and sale of Co-Promotion Products, including (if applicable) the FFDCA, the American Medical Association Guidelines on Gifts to Physicians from Industry and
the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code on Interactions with Healthcare Professionals. 
 1.12
“Arbitrator” has the meaning set forth in Section 8.17. 
 1.13 “Assignee” has the meaning
set forth in Section 10.2.2. 
 1.14 “Assignor” has the meaning set forth in Section 10.2.2. 

1.15 “Batch” has the meaning set forth in the MDSA. 

1.16 “BioNTech” has the meaning set forth in the preamble hereto. 

1.17 “BioNTech Co-Funding Rejection” has the meaning set forth in
Section 2.7.2(c). 
 1.18 “BioNTech Collaboration Products” means Collaboration Products being Developed by
BioNTech in a BioNTech Indication pursuant to Section 4.5 or Commercialized under [***]; provided that Genentech has not paid a BioNTech Indication Opt-In Fee with respect to the applicable Indication.
For clarity, in the event that Genentech pays a BioNTech Indication Opt-In Fee with respect to the applicable Indication, Collaboration Products with respect to such Indication shall be GDP Collaboration
Products. 
 1.19 “[***]” has the meaning set forth in Schedule 1.8. 

1.20 “BioNTech Core Patents” means the Patents listed on Schedule 1.20 and all Patents claiming priority
thereto or claiming priority to a priority document thereof. 
 1.21 “BioNTech Development and [***]
Activities” has the meaning set forth in Section 5.3.3. 
 1.22 “BioNTech [***]” has the meaning set
forth in Section 5.3.1. 
 1.23 “BioNTech Indication” has the meaning set forth in Section 4.5.1. 

1.24 “BioNTech Indication Opt-In Fee” has the meaning set forth in
Section 8.3. 
 1.25 “BioNTech Initial Knowledge Transfer Items” has the meaning set forth in
Section 2.19.1(a). 
 1.26 “BioNTech IP” means, collectively, BioNTech
Know-How, BioNTech Patents, and BioNTech Core Patents. 

  
 - 3 - 

			
	Confidential	  	Execution Copy

  

 1.27 “BioNTech Know-How”
means any Neoepitope Prediction Algorithms, Neoepitope RNAs, any liposome formulations, components of product comprising one or more Neoepitope RNA(s) (including [***]) and all other Know-How, in each case,
that (a) is Controlled by BioNTech or any of its Affiliates as of the Execution Date or at any time thereafter until the end of the Term; and (b) is necessary or useful to research, develop, manufacture, commercialize, make, have made,
use, offer for [***]; provided, however, that BioNTech Know-How specifically excludes Collaboration Know-How. 

1.28 “BioNTech Opt-Out Period” means the period commencing as of [***] and
ending with [***] 
 1.29 “BioNTech Patents” means all Patents that (a) are Controlled by BioNTech or any of its
Affiliates as of the Execution Date or at any time thereafter until the end of the Term; and (b) are necessary or useful to research, develop, manufacture, commercialize, make, have made, use, offer for sale, sell and import Pharmaceutical
Products that comprise (i) one or more Neoepitope RNA(s), [***] provided, however, that BioNTech Patents specifically exclude Collaboration Patents and BioNTech Core Patents. 

1.30 “BioNTech Platform Product” means any product researched, developed or commercialized by BioNTech (in each case,
whether directly or indirectly through a Third Party) that uses BioNTech IP and is substantially similar to any material aspect of the Collaboration Manufacturing Process such that a Regulatory Authority could reasonably require reporting of safety
data from such product in connection with Collaboration Product. As of the Effective Date, such BioNTech Platform Products may include products researched, developed or commercialized by BioNTech pursuant to collaboration agreements with Bayer
Animal Health GmbH and Sanofi. 
 1.31 “BioNTech [***]” has the meaning set forth in Section 5.1. 

1.32 “BioNTech Study” has the meaning set forth in Section 4.5.1. 

1.33 “BioNTech Study Conduct Requirements” has the meaning set forth in Section 4.5.2. 

1.34 “Biosamples” means patient-specific normal (e.g., whole blood or peripheral blood mononuclear cells (PBMC)) and
tumor tissue (fresh frozen (FF) or formalin-fixed, paraffin-embedded (FFPE) blocks) which are subsequently processed and sequenced to identify Neoepitopes. 

1.35 “BLA” means Biologics License Application and amendments thereto filed pursuant to the requirements of the FDA, as
defined in 21 C.F.R. § 600 et seq., for FDA approval of a biological Pharmaceutical Product as well as any foreign equivalent thereof. 

1.36 “Board of Directors” has the meaning set forth in the definition of “Change in Control.” 

1.37 “Breaching Party” has the meaning set forth in Section 14.2. 

  
 - 4 - 

			
	Confidential	  	Execution Copy

  

 1.38 “Business Day” means a day, other than a Saturday, Sunday or day
on which commercial banks located in the United States or Germany are authorized or required by law or regulation to close. 
 1.39
“Calendar Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on
the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. 

1.40 “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and
ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on
January 1 of the year in which the Term ends and end on the last day of the Term. 
 1.41 “Capacity” has the
meaning set forth in the MDSA. 
 1.42 “Change in Control” with respect to BNT or RNP, shall be deemed to have
occurred if any of the following occurs after the Effective Date: 
 (a) any “person” or “group” (as such terms are
defined below) (a) becomes the “beneficial owner” (as defined below), directly or indirectly, of shares of capital stock or other interests (including partnership interests) of such Party then outstanding and normally entitled
(without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions (“Voting Stock”) of such Party representing more than fifty percent (50%) of the total voting
power of all outstanding classes of Voting Stock of such Party or (b) has the power, directly or indirectly, to appoint a majority of the Party’s managing directors or to elect a majority of the members of the Party’s board of
directors, supervisory board or similar governing body (“Board of Directors”); or 
 (b) such Party enters into a merger,
consolidation or similar transaction with another Person (whether or not such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (a) the managing directors or the members of the Board of
Directors of such Party immediately prior to such transaction constitute less than a majority of the managing directors or the members of the Board of Directors of such Party or such surviving Person immediately following such transaction or
(b) the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of such Party immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party representing
a majority of the total voting power of all outstanding classes of Voting Stock of the surviving Person in substantially the same proportions as their ownership of Voting Stock of such Party immediately prior to such transaction; or 

  
 - 5 - 

			
	Confidential	  	Execution Copy

  

 (c) such Party sells or transfers to any Third Party, in one or more related transactions,
properties or assets representing all or substantially all of such Party’s consolidated total assets to which this Agreement relates; or 

(d) the managing directors, Board of Directors or the holders of capital stock of such Party approve a plan or proposal for the liquidation or
dissolution of such Party. 
 Notwithstanding the foregoing, the occurrence of neither of the following shall, by itself, be considered a Change in Control,
in each case if entered into in the ordinary course of business and not for the purpose or effect of circumventing any other Party’s rights hereunder: (a) the sale of capital stock of such Party in an initial public offering on an
internationally recognized securities exchange, including the NYSE, NASDAQ, London Stock Exchange and Frankfurt Stock Exchange, and (b) the sale of capital stock of such Party to a Financial Party in a capital-raising financing transaction,
e.g. private placement or similar transaction, so long as following such financing transaction no Person other than an existing shareholder of BNT or RNP (as set forth on Schedule 1.42) or a Financial Party (individually or collectively as a
member of any “group”) has the power, directly or indirectly, to elect a majority of the members of the Board of Directors. 
 For the purpose of
this definition of Change in Control, (x) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term “group” includes any
group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the said Act; (y) a “beneficial owner” shall be determined in
accordance with Rule 13d-3 under the aforesaid Act; and (z) the terms “beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial
owner.” 
 1.43 “Change in Control Firewall” has the meaning set forth in Schedule 1.43. 

1.44 [***] 
 1.45
[***] 
 1.46 [***] Change in Control” means any Change in Control that [***] 

1.47 [***] Firewall” has the meaning set forth in Schedule 1.43. 

1.48 “Class of Agents” means all Pharmaceutical Products that [***] 

1.49 “Clinical Data” means with respect to any Collaboration Product and any other drug included in the applicable
Clinical Study, all Information that is generated pursuant to a clinical study under this Agreement [***] 
 1.50 “Clinical
Development Decisions” means all clinical Development decisions [***] 

  
 - 6 - 

			
	Confidential	  	Execution Copy

  

 1.51 “Clinical Facility” has the meaning set forth in the MDSA. 

1.52 “Clinical Manufacture” has the meaning set forth in the MDSA 

1.53 “Clinical Studies” means any and all tests and studies in human subjects that are required by Applicable Law, or
otherwise requested or recommended by the Regulatory Authorities, to obtain or maintain Regulatory Approvals for a Collaboration Product for an Indication, including Post-Approval Commitments and tests or studies that are intended to expand the
Product Labeling for such Collaboration Product with respect to such Indication, together with Marketing Studies. 
 1.54
“CMC” means Chemistry, Manufacturing, and Control. 
 1.55 “CMC Development Costs” has the
meaning set forth in Schedule 1.8. 
 1.56 “CMC Development Plan” has the meaning set forth in the
Manufacturing Development and Supply Agreement. 
 1.57 “Code” means the Internal Revenue Code of 1986, as amended.

 1.58 “Collaboration IP” means Collaboration Patents and Collaboration
Know-How. 
 1.59 “Collaboration
Know-How” means any Know-How that is discovered, generated, conceived or reduced to practice by a Party (or any authorized Third Party acting on a Party’s
behalf) solely or jointly in the course of [***] (other than, in each case [***], Genentech Molecule Clinical Study Data). 
 1.60
“Collaboration Patents” means Patents that claim any Collaboration Know-How. 

1.61 “Collaboration Product” means [***] 

1.62 “Collaboration Product Clinical Study Data” means all Clinical Data that is related to the use in a
Clinical Study of a Collaboration Product alone or in combination with one or more Combination Agents but shall exclude Genentech Molecule Clinical Study Data. 

1.63 “Collaboration Term” means the period from the Effective Date until such time as there is no Collaboration Product
being Developed, Manufactured or Commercialized in the Territory. 
 1.64 “Combination Agent” means a Pharmaceutical
Product that is proposed for Development or being Developed, or has received Regulatory Approval (i.e., under this Agreement) for use in combination with a Collaboration Product, whether or not co-formulated.

 1.65 “Commercial Facility” has the meaning set forth in the MDSA. 

  
 - 7 - 

			
	Confidential	  	Execution Copy

  

 1.66 “Commercial Manufacture” has the meaning set forth in the MDSA.

 1.67 “Commercial Manufacturing Agreement” has the meaning set forth in the MDSA. 

1.68 “Commercial Readiness” means the point in time, prior to [***], at which Genentech seeks to ensure readiness for
market launch of such Collaboration Product [***] in accordance with [***] 
 1.69 “Commercialization” means
any and all activities directed to the preparation for sale of, offering for sale of, or sale of a Collaboration Product, including activities related to marketing, promoting, distributing, and importing such Collaboration Product. When used as a
verb, “to Commercialize” and “Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning. 

1.70 “Commercialization Plan” has the meaning set forth in Section 2.9.2(b). 

1.71 “Commercially Reasonable Efforts” means, with respect to the performance of Development, Commercialization
or Manufacturing activities with respect to a Collaboration Product or the performance of activities with respect to the Research Plan, the carrying out of such activities using efforts and resources comparable to the efforts and resources that such
Party would typically devote [***] 
 1.72 “Commissioning” has the meaning set forth in the MDSA. 

1.73 “Committees” has the meaning set forth in Section 2.1. 

1.74 “Committee Co-Chair” has the meaning set forth in Section 2.2.
 
 1.75 “Competing Program” means any program described in clause (a) or clause (b)(i) of the
definition of [***] 
 1.76 “Competitive Product” means [***] 

1.77 “Competitive Product Infringement” has the meaning set forth in Section 10.5.2(b)(ii). 

1.78 “Compliance Requirements” has the meaning set forth in the MDSA. 

1.79 “Compulsory Sublicense” means a license or sublicense granted to a Third Party (a “Compulsory
Sublicensee”) through the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to Manufacture, use, sell, offer for sale, import or export a Collaboration Product in any country in
the Territory. 
 1.80 “Conduct” means, with respect to any Clinical Study, to (a) sponsor or conduct, directly
or indirectly through an Affiliate or Third Party, such Clinical Study; or (b) provide to an Affiliate or Third Party funding for, or clinical supplies for use in, such Clinical Study. 

  
 - 8 - 

			
	Confidential	  	Execution Copy

  

 1.81 “Confidential Information” has the meaning set forth in
Section 11.1. 
 1.82 “Confidentiality Agreements” means the following agreements: (a) that certain Non-Disclosure Agreement between BNT and Roche, dated June 1, 2014 and (b) that certain Letter between BNT and GNE, dated March 13, 2015, as amended May 7, 2015. 

1.83 “Consensus Clinical Studies” has the meaning set forth in Section 2.7.2. 

1.84 “Control” or “Controlled” means the (a) with respect to Know-How, Patents and Regulatory Documentation or other intellectual property rights, possession by a Party (whether directly or indirectly and whether by ownership, license or otherwise) (other than by operation of
the license and other grants in Article 9) of, (1) with respect to any tangible Know-How, the legal authority or right to physical possession of such tangible
Know-How, with the right to provide such tangible Know-How to the other Party on the terms and conditions set forth herein, or (2) with respect to Patents,
intangible Know-How, Regulatory Documentation or other intellectual property rights, the legal authority or right to grant a license, sublicense, access or right to use (as applicable) (including the right to
reference Regulatory Documentation) under such Patents, intangible Know-How, Regulatory Documentation or other intellectual property rights to the other Party on the terms and conditions set forth herein, in
each case of (1) and (2) without breaching the terms of any agreement with a Third Party, or (b) with respect to any product or agent, the exclusive right (whether by ownership or exclusive license) to develop and commercialize such
product or agent in any Major Market. 
 1.85 “Controlling Litigation Party” has the meaning set forth in
Section 10.5.4. 
 1.86 “Controlling Party” has the meaning set forth in Section 10.3.2. 

1.87 “Co-Promote” or
“Co-Promotion” has the meaning set forth in Section 6.5.4. 
 1.88
“Co-Promotion Agreement” has the meaning set forth in Section 6.5.3. 

1.89 “Co-Promotion Candidate Product” means a GDP Collaboration Product (other
than a GDP Collaboration Product with respect to which a BioNTech Co-Funding Rejection has occurred) for which [***] there are, at the Effective Date, [***] 

1.90 “Co-Promotion Exercise Period” means, with respect to a Co-Promotion Candidate Product [***], the period beginning on [***] and ending [***] in accordance with Section 6.5.2(a). 

1.91 “Co-Promotion Option” has the meaning set forth in Section 6.5.1.

  
 - 9 - 

			
	Confidential	  	Execution Copy

  

 1.92 “Co-Promotion Potential
Territory” means the Major Markets [***] 
 1.93 “Co-Promotion
Product” has the meaning set forth in Section 6.5.2. 
 1.94
“Co-Promotion Territory” has the meaning set forth in Section 6.5.1. 

1.95 “Copyleft Software” has the meaning set forth in Section 12.2.1(k). 

1.96 “Core Facility” has the meaning set forth in the MDSA. 

1.97 “Corporate Names” means the Trademarks and logos identified on Schedule 1.97 and such other names
and logos as BioNTech or Genentech may designate in writing from time to time. 
 1.98 “Course of Therapy” means
[***] 
 1.99 “Covered by” or “Covers,” or the like, means, with respect to a given product
(including a Collaboration Product), that the sale, offer for sale or import of such product (including a Collaboration Product), but for ownership of, or a license granted in this Agreement under, the relevant Patent would infringe a Valid Claim of
such Patent in the country of sale on the date of sale. 
 1.100 “CREATE Act” has the meaning set forth in
Section 10.2.4. 
 1.101 “Declined BioNTech Core Patent” has the meaning set forth in
Section 10.5.2(b)(iv). 
 1.102 “Deemed Opt-Out” has the meaning set
forth in Section 8.5.3. 
 1.103 “Default Notice” has the meaning set forth in Section 14.2.  

1.104 “Defend” or “Defense” has the meaning set forth in Section 10.5.3. 

1.105 “Defending Party” has the meaning set forth in Section 10.5.3. 

1.106 “Deferral Period” has the meaning set forth in Section 8.2.2(a). 

1.107 “Detail” means, with respect to a Co-Promotion Product in the Co-Promotion Territory, a face-to-face sales call in which the sales representative makes a presentation of such Co-Promotion Product to a physician or other medical professional licensed to prescribe drugs, such that the relevant characteristics of such Co-Promotion Product are
described by the sales representative in a fair and balanced manner consistent with the requirements of this Agreement, the Co-Promotion Agreement and Applicable Promotional Law and in a manner that is
customary in the industry for the purpose of promoting a prescription Pharmaceutical Product. When used as a verb, “Detail” means to engage in a Detail. 

  
 - 10 - 

			
	Confidential	  	Execution Copy

  

 1.108 “Development” means all activities related to preclinical and
other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and
validation, quality assurance/quality control, clinical studies (including Clinical Studies), manufacturing (including Manufacturing) in support thereof, statistical analysis and report writing, the preparation and submission of Drug Approval
Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory
Approval for a Collaboration Product. When used as a verb, “Develop” means to engage in Development. 
 1.109
“Development Costs” has the meaning set forth in Schedule 1.8. 
 1.110 “[***] IP”
has the meaning set forth in 10.6.3. 
 1.111 [***] 

1.112 “Disclosing Party” has the meaning set forth in Section 11.1. 

1.113 “Disclosure” has the meaning set forth in Section 11.4. 

1.114 “Dispute” or the like, means any controversy, claim or legal proceeding arising out of or relating to this
Agreement, or the breach, termination or invalidity thereof. Notwithstanding the foregoing, Disputes shall not include any disagreements solely about decisions for which one Party has final decision-making authority under this Agreement, including
under Article 2. 
 1.115 [***] has the meaning set forth in Section 5.3.2(a). 

1.116 “Dollars” or “$” means United States Dollars. 

1.117 “Drug Approval Application” means a New Drug Application or BLA as defined in the FFDCA or PHSA, or any
corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application filed with the EMA pursuant to the centralized approval procedure or with the applicable Regulatory Authority of
a country in Europe with respect to the mutual recognition or any other national approval procedure. 
 1.118 “Effective
Date” has the meaning set forth in Section 14.1.2. 
 1.119 “EMA” means the European
Medicines Agency and any successor agency thereto. 
 1.120 “Enforce” or “Enforcement” has the
meaning set forth in Section 10.5.2(a). 
 1.121 “Engineering Runs” has the meaning set forth in the MDSA. 

1.122 “EUFETS” means EUFETS GmbH. 

  
 - 11 - 

			
	Confidential	  	Execution Copy

  

 1.123 “EUFETS Facility” has the meaning set forth in the MDSA. 

1.124 “EURIBOR” means the Euro Interbank Offered Rate for deposits in Euros having a maturity of one month published by
the European Money Markets Institute, as adjusted from time to time on the first business day of each month. 
 1.125
“European Union” or “EU” means the economic and political union of the countries of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom and any additional countries that may subsequently become members thereof (irrespective of whether
such countries remain in such union). For purposes of this Agreement, Switzerland, Norway and the United Kingdom shall be deemed included within the definition of “European Union.” 

1.126 “Exchange” has the meaning set forth in Section 11.4. 

1.127 “Exclusivity Period” has the meaning set forth in Section 9.7. 

1.128 “Execution Date” has the meaning set forth in the preamble hereto. 

1.129 “Existing BioNTech Product” means a product described in the clinical trial protocols for the Ongoing Clinical
Studies identified in Schedule 4.3.1, as such protocols were provided by BioNTech to Genentech prior to the Execution Date. 

1.130 “Existing [***] Product” has the meaning set forth in Section 15.2.2(b). 

1.131 “Existing Third Party In-License Agreements” has the meaning set forth in
Section 12.2.2(a). 
 1.132 “Existing Third Party In-License Agreement Royalty
Payments” means the royalty payments owed based on the sales of Collaboration Products under the Existing Third Party In-License Agreements set forth in Schedule 1.132. 

1.133 “Exploit” means to make, have made, import, use, sell, or offer for sale a Collaboration Product, including to
research, Develop, Commercialize, register, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, or have sold or otherwise dispose of such Collaboration
Product. 
 1.134 “Exploitation” means the act of Exploiting a Collaboration Product. 

1.135 “Ex-U.S. Territory Activities” has the meaning set forth in
Section 8.13.2. 
 1.136 “Facility” has the meaning set forth in the MDSA. 

  
 - 12 - 

			
	Confidential	  	Execution Copy

  

 1.137 “FDA” means the United States Food and Drug
Administration and any successor agency thereto. 
 1.138 “FFDCA” means the United States Federal Food, Drug,
and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). 

1.139 “Field” means all uses. 

1.140 “Financial Party” means a private equity firm, investment fund, pension fund or venture capital fund that in each
case does not, directly or indirectly, except through a passive investment interest, operate a business other than the investment or portfolio management business including any venture capital arm of a pharmaceutical or biotechnology company or
group provided that such venture capital arm of a pharmaceutical or biotechnology company or group has implemented and continues to maintain and comply with written procedures to prevent disclosure to and use by those parts of the pharmaceutical or
biotechnology company or group which are active in the research, development, manufacture or commercialization of Pharmaceutical Products of: (a) Collaboration Product Clinical Study Data, (b) the GDP (other than a high level summary of
status and results), (c) the Neoepitope Prediction Algorithm, (d) any Confidential Information of Genentech, or (e) Genentech Know-How. 

1.141 “First Commercial Sale” means, with respect to a Collaboration Product or Reversion Product and a country (or the
Territory, as applicable), the first invoiced sale for monetary value for use or consumption by the end user of such Collaboration Product or Reversion Product in such country (or the Territory) after Regulatory Approval for such Collaboration
Product or Reversion Product has been obtained in such country (or the Territory). Sales prior to receipt of Regulatory Approval for such Collaboration Product or Reversion Product, such as so-called
“treatment IND sales,” “named patient sales,” and “compassionate use sales,” shall not be construed as a First Commercial Sale. 

1.142 [***] 
 1.143
[***] 
 1.144 “Frontline Indication” means an Indication for use of a Collaboration Product as a first-line
therapy or component of such therapy. 
 1.145 “FTE” means the equivalent of the work of one (1) employee full
time for one (1) Calendar Year (consisting of at least a total of eighteen hundred (1800) hours per Calendar Year) of work directly related to the applicable activity. 

1.146 “FTE Costs” means, [***] 

1.147 “FTE Rate” means [***] 

  
 - 13 - 

			
	Confidential	  	Execution Copy

  

 1.148 “Fully-Burdened Manufacturing Cost” has the meaning set forth
in Schedule 1.8. 
 1.149 “Future Acquirer” means the Third Party to any Change in Control transaction and
such Third Party’s Affiliates immediately prior to the Change in Control. 
 1.150 “GDP Budget” means the
forecasted annual budget for the Development Activities under the GDP, which budget shall be for informational purposes only, and therefore non-binding on the Parties. The current non-binding estimate of the GDP Budget for 2016 and forecasts for the years from 2017 to 2019 are set forth in Schedule 1.150, for informational purposes only. 

1.151 ”GDP Collaboration Product” means a Collaboration Product Developed under the GDP or with respect to which a
BioNTech Indication Opt-In Fee or a Genentech Indication Co-Funding Fee, as applicable, is due or paid. 

1.152 “GDP Indication” means any Indication that has been, is being or will be Developed under the GDP. 

1.153 “Genentech” has the meaning set forth in the preamble hereto. 

1.154 “Genentech Agent” means any Pharmaceutical Product Controlled by Genentech, an Affiliate of Genentech or a Third
Party Collaborator (to the extent the collaboration by Genentech or its Affiliates with such Third Party Collaborator relates to such Genentech Agent). 

1.155 “Genentech Collaboration Product” has the meaning set forth in Section 2.7.2(c). 

1.156 “Genentech Core Patents” means the Patents listed on Schedule 1.156, and all Patents claiming priority
thereto or claiming priority to a priority document thereof. 
 1.157 “Genentech Indication” has the meaning set
forth in Section 2.7.2(c). 
 1.158 “Genentech Indication Co-Funding
Fee” has the meaning set forth in Section 8.3. 
 1.159 “Genentech IP” means, collectively, Genentech Know-How, Genentech Patents, and Genentech Core Patents. 
 1.160 “Genentech Know-How” means any Neoepitope Prediction Algorithms and any other Know-How, in each case, that is either (a) both (i) Controlled by GNE as of the Execution Date
or at any time thereafter until the end of the Term; and (ii) necessary or useful to research, develop, commercialize, make, have made, use, offer for sale, sell and import Pharmaceutical Products that comprise (A) one or more Neoepitope
RNA(s), but not any Non-Neoepitope RNA(s) or (B) one or more Permitted Hybrid Neoepitope RNA(s), but not any Non-Neoepitope RNA(s) or (b) Controlled by Roche
as of the Effective Date or during the Term and used or disclosed to BioNTech in the performance of the Research Plan, GDP or CMC Development Plan; provided, however, that Genentech Know-How
specifically excludes Collaboration Know-How. 

  
 - 14 - 

			
	Confidential	  	Execution Copy

  

 1.161 “Genentech Marketing Authorization” has the meaning set forth
in Section 5.1. 
 1.162 “Genentech Molecule Clinical Study Data” means all Clinical Data related [***] 

1.163 “Genentech Opt-In Period” has meaning set forth in Section 4.5.5(a).

 1.164 “Genentech Patents” means all Patents that (a) are Controlled by Genentech as of the Execution Date or
at any time thereafter until the end of the Term; (b) [***]; and (c) Cover Genentech Know-How; provided, however, that Genentech Patents specifically exclude Collaboration Patents and
Genentech Core Patents. 
 1.165 “Genentech Reversion IP” means Genentech IP other than Diagnostics IP that both
(a) was actually used or generated by Genentech with respect to a Termination Product, and (b) is necessary to continue Development, Manufacture or Commercialization without unreasonable delay of such Termination Product. 

1.166 “Genentech Study” has the meaning set forth in Section 2.7.2(c). 

1.167 “Genentech Tumor Type” means any of the tumor types set forth on Schedule 1.167, subject to
Section 4.5.3, and subject to any replacement tumor type that Genentech may elect through written notice to BioNTech at any time prior to the Trigger Point (provided that at the time of such replacement notice such replacement tumor type is not
part of a BioNTech Indication), to exchange for any then-current Genentech Tumor Type. 
 1.168 “Global Development
Plan” or “GDP” means a Development plan setting forth in reasonable detail specific Clinical Studies and other Party Development Activities to be performed with respect to GDP Collaboration Product(s), which plan shall
allocate responsibility for such Clinical Studies and Party Development Activities between the Parties. 
 1.169 “Good
Clinical Practices” or “cGCPs” has the meaning set forth in the MDSA. 
 1.170 “Good Laboratory
Practices” or “cGLPs” has the meaning set forth in the MDSA. 
 1.171 “Good Manufacturing
Practices” or “cGMPs” has the meaning set forth in the MDSA. 
 1.172 “Governmental
Authority” means any U.S. federal, state, local, or any non-U.S. government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral
body. 

  
 - 15 - 

			
	Confidential	  	Execution Copy

  

 1.173 “GTT Proposed Study” has the meaning set forth in
Section 4.5.3. 
 1.174 “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

 1.175 “HSR Filing” has the meaning set forth in Section 14.1.1. 

1.176 “[***] 

1.177 “IFRS” means International Financial Reporting Standards. 

1.178 “IND” means (a) in the United States (i) an investigational new drug application filed with the FDA for
authorization to conduct Clinical Studies and (ii) all supplements and amendments that may be filed with respect to the foregoing; and (b) any foreign counterpart of the foregoing. 

1.179 “Indemnification Claim Notice” has the meaning set forth in Section 13.4. 

1.180 “Indemnified Party” has the meaning set forth in Section 13.4. 

1.181 “Independent Facility” has the meaning set forth in the MDSA. 

1.182 “Indication” means the therapeutic indication for use defined in the applicable IND or any Marketing
Authorization for a Collaboration Product. [***] 
 1.183 “Indication Studies” has the meaning set forth in
Section 4.5.1. 
 1.184 “Information” means all technical, scientific, and other
know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs,
drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety,
manufacturing and quality control data and information, including study designs and protocols; Regulatory Authority documentation, correspondence and communications (oral or written); and analytical assays and test methods; in each case (whether or
not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed. 
 1.185
“Infringement” has the meaning set forth in Section 10.5.1(a). 
 1.186 “Initiation” or
“Initiate” means, with respect to a Clinical Study, the first dosing of the first human subject in such Clinical Study. 

1.187 “IVAC 2.0 Process” has the meaning set forth in the MDSA. 

1.188 “IVAC 2.1 Process” has the meaning set forth in the MDSA. 

  
 - 16 - 

			
	Confidential	  	Execution Copy

  

 1.189 “IVAC x.y Process” has the meaning set forth in the MDSA. 

1.190 “IVAC Trademark” means the mark described in Schedule 1.190. 

1.191 “Joint Commercialization Committee” or “JCC” has the meaning set forth in
Section 2.1. 
 1.192 “Joint Confidential Information” has the meaning set forth in Section 11.1. 

1.193 “Joint Development Activities” has the meaning set forth in Section 4.4.1. 

1.194 “Joint Development Committee” or “JDC” has the meaning set forth in
Section 2.1. 
 1.195 “Joint Manufacturing Committee” or “JMC” has the meaning
set forth in Section 2.1. 
 1.196 “Joint Research Committee” or “JRC” has the
meaning set forth in Section 2.1. 
 1.197 “Key Jurisdictions” has the meaning set forth in
Section 10.3.1(c)(i) 
 1.198 “Know-How” means any Information, ideas,
data, inventions, works of authorship, trade secrets, [***], technology, or materials, including formulations [***], molecules (including RNAs), assays, reagents, reference standards, compositions, human or animal tissue, samples or specimens,
techniques, methods, procedures, processes, results, model designs and data bases, test data (including pharmacological, toxicological, immune monitoring, sequencing, pharmacokinetic and preclinical and clinical information and test data, and
statistical analysis) and components thereof. 
 1.199 “Licensure” has the meaning set forth in the MDSA. 

1.200 “Losses” has the meaning set forth in Section 13.1. 

1.201 “Major Markets” means the United States, Germany, the United Kingdom, France, Italy and Spain. 

1.202 “Major Regulatory Filing” has the meaning set forth in Section 5.4.3. 

1.203 “Major Regulatory Jurisdictions” has the meaning set forth in Section 5.4.3. 

1.204 “Manufacture” and “Manufacturing” has the meaning set forth in the MDSA. 

1.205 “Manufacturing Development and Supply Agreement” or “MDSA” has the meaning set forth in
Section 7.1. 

  
 - 17 - 

			
	Confidential	  	Execution Copy

  

 1.206 “Manufacturing Documentation” has the meaning set forth in the
MDSA. 
 1.207 “Manufacturing Network” has the meaning set forth in the MDSA. 

1.208 “Manufacturing Network Plan” has the meaning set forth in the MDSA. 

1.209 “Manufacturing Operations Strategy” has the meaning set forth in the MDSA. 

1.210 “Manufacturing Process” has the meaning set forth in the MDSA. 

1.211 “Marketing Authorization” means regulatory approval (whether a
Non-Accelerated Marketing Authorization or an Accelerated Marketing Authorization) [***] required to sell one or more Collaboration Products for any Indication in accordance with the Applicable Laws of a given
country or territory. [***] 
 1.212 “Marketing Study” means a human clinical study of a Collaboration Product
conducted following Initiation of a Pivotal Study for such Collaboration Product that is not required for receipt of Marketing Authorization (whether such human clinical study is conducted prior to or after receipt of such Marketing Authorization)
and is not a Post-Approval Commitment, but that may be useful in support of the post-Marketing Authorization Exploitation of such Collaboration Product. 

1.213 “Markings” has the meaning set forth in Section 6.4.2. 

1.214 [***] 
 1.215
“Mechanical Completion” has the meaning set forth in the MDSA. 
 1.216 “Medical Affairs
Activities” means, with respect to any country in the Territory, the coordination of medical information requests and field based medical scientific liaisons with respect to Collaboration Products, including activities of medical scientific
liaisons, activities involving key opinion leaders, and the provision of medical information services with respect to a Collaboration Product. 

1.217 “Melanoma Follow-Up Study” has the meaning set forth in
Section 4.3.2(a). 
 1.218 “Neoepitope(s)” means an epitope of a polypeptide arising in a tumor cell, where the
epitope comprises a polypeptide that reflects: (a) a non-inherited DNA mutation, (b) a tumor specific RNA sequence alteration, or (c) an alternative tumor-specific translation start site in the
tumor cell [***] 

  
 - 18 - 

			
	Confidential	  	Execution Copy

  

 1.219 “Neoepitope Prediction Algorithm” means a methodology of
predicting Neoepitopes based on Patient Sequencing, including algorithms, designs, structures, features, functions, processes, and systems, and the underlying software programs (including libraries, databases, scripts, object and source code)
(“Neoepitope Prediction Software”), and any other related Know-How necessary or useful to use, develop, reproduce, prepare derivative works, distribute, display and perform any of the
Neoepitope Prediction Software, and all intellectual property rights other than Patents in any of the foregoing. 
 1.220
“Neoepitope Prediction Software” has the meaning set forth in Section 1.219. 
 1.221 “Neoepitope
RNA(s)” means a single stranded nucleic acid polymer comprising one or more ribose sugars that is capable of being translated into a polypeptide and encoding one or more Neoepitope(s) [***] 

1.222 “Net Profits” and “Net Losses” have the meaning set forth in
Schedule 1.8.  
 1.223 “Net Sales” has the meaning set forth in Schedule
1.8. 
 1.224 “New Partnership Audit Procedures” means the amendments to the Code that were enacted as section
1101 of the Bipartisan Budget Act of 2015, P.L. 114-74. 
 1.225 “Next Generation
Sequencing” or “NGS” means non-Sanger-based whole exome high-throughput nucleic acid sequencing technology to be used in the Manufacturing Process to identify Neoepitopes. 

1.226 “Non-Accelerated Marketing Authorization” means a Marketing Authorization
other than one obtained pursuant to an accelerated approval procedure under 21 C.F.R. part 314, subpart H, 21 C.F.R. part 601, subpart E, or FFDCA section 506 or any foreign equivalents thereof. 

1.227 “Non-Breaching Party” has the meaning set forth in Section 14.2.

 1.228 “Non-Controlling Party” has the meaning set forth in
Section 10.3.2. 
 1.229 [***] 

1.230 [***] 
 1.231
[***] 
 1.232 “Ongoing Clinical Studies” has the meaning set forth in Section 4.3.1. 

1.233 “Ongoing Knowledge Transfer” has the meaning set forth in Section 2.19.2(c). 

1.234 “Operational Readiness” has the meaning set forth in the MDSA. 

1.235 “Opt-In Right” has the meaning set forth in Section 4.5.5(a). 

1.236 “Opt-Out” has the meaning set forth in Section 8.5.1. 

  
 - 19 - 

			
	Confidential	  	Execution Copy

  

 1.237 “Opt-Out Commencement
Date” has the meaning set forth in Section 8.5.1. 
 1.238 “Outside Patent Litigation Counsel” has the
meaning set forth in Section 10.5.4. 
 1.239 “Outside Patent Prosecution Counsel” has the meaning set forth in
Section 10.3.2. 
 1.240 “Party” and “Parties” has the meaning set forth
in the preamble hereto. 
 1.241 “Party Development Activities” means Development activities conducted in support of
obtaining or maintaining Regulatory Approval of a Collaboration Product in a country in the Territory (other than research activities under the Research Plan), including Joint Development Activities, CMC Development Plan activities, Ongoing Clinical
Studies, BioNTech Studies, Genentech Studies and any Post-Approval Commitments and Marketing Studies. 
 1.242
“Patents” means all patents and patent applications in any country in the world, including any continuations, continuations-in-part, divisions,
provisionals or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental protection certificate) of any such patent, and any
confirmation patent or registration patent or patent of addition based on any such patent, and all non-United States counterparts of any of the foregoing. 

1.243 “Patient Sequencing” means the identification of nucleotide or amino acid sequence, including through the use of
Next Generation Sequencing, based upon a Biosample collected from a patient. 
 1.244 “Payee” has the meaning set
forth in Section 8.11.2. 
 1.245 “Payor” has the meaning set forth in Section 8.11.2. 

1.246 [***] 
 1.247
[***] 
 1.248 [***] 

1.249 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency
of a government. 
 1.250 [***] 

  
 - 20 - 

			
	Confidential	  	Execution Copy

  

 1.251 “Pharmaceutical Product” means any medicament that is developed
to treat, cure or prevent a disease in humans and is subject to approval by a Regulatory Authority. 
 1.252
“Pharmacovigilance Agreement” has the meaning set forth in Section 5.8. 
 1.253 “Phase I Clinical
Study” means a Clinical Study, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients or similar Clinical Study prescribed by the Regulatory Authorities, including the trials referred to
in 21 C.F.R. §312.21(a), as amended. 
 1.254 “PHSA” means the United States Public Health Service Act, as
amended from time to time. 
 1.255 “Pilot Facility” has the meaning set forth in the MDSA. 

1.256 “Pivotal Study” means a Clinical Study of a Collaboration Product that is designed to demonstrate, along with
previously conducted studies, substantial evidence of its effectiveness and provide sufficient information to determine whether it is safe, pure and potent for use under conditions prescribed, recommended, or suggested in proposed labeling to obtain
a Marketing Authorization (including an Accelerated Marketing Authorization) of such Collaboration Product, including all tests and studies that are required by the FDA or any other Regulatory Authority from time to time, pursuant to Applicable Law
or otherwise. 
 1.257 “Post-Approval Commitment” means a human Clinical Study for a Collaboration Product conducted
after Marketing Authorization of such Collaboration Product has been obtained from an appropriate Regulatory Authority due to a request or requirement of such Regulatory Authority. 

1.258 “Post-Term License Notice” has the meaning set forth in Section 14.5.4. 

1.259 “Preclinically Developing” means, [***] 

1.260 “Product Labeling” means, with respect to a Collaboration Product in a country in the Territory,
(a) the Regulatory Authority-approved prescribing information for such Collaboration Product for such country, including any required patient information, and (b) all labels and other written,
printed, or graphic matter upon a container, wrapper, or any package insert utilized with or for such Collaboration Product in such country. 

1.261 “Product Trademarks” means the Trademark(s) to be used for the Commercialization of Collaboration Products in the
Territory and any registrations thereof or any pending applications relating thereto in the Territory (excluding, in any event, the Corporate Names and any trademarks, service marks, names or logos that include any corporate name or logo of the
Parties or their Affiliates). 
 1.262 “Proposed Study(ies)” has the meaning set forth in Section 4.5.1. 

  
 - 21 - 

			
	Confidential	  	Execution Copy

  

 1.263 “Prosecution and Maintenance” or “Prosecute and
Maintain,” with respect to a given Patent, means all activities associated with the preparation, filing, prosecution, and maintenance of such Patent, as well as supplemental examinations,
re-examinations, reissues, applications for patent term extensions, calculation and applications for patent term adjustments, supplementary protection certificates, and the like with respect to such Patent. In
addition, Prosecute and Maintain shall include any actions associated with obtaining additional patent protection of the disclosure of a given Patent following a notice of allowance of such Patent or keeping a patent application pending for
strategic reasons (e.g. through the filing of continuation applications, continuation-in-part applications, divisional applications or other substitute applications).
For clarity, Prosecute and Maintain shall not include any such actions with respect to a Patent brought by a Third Party, including any reexaminations, inter partes reviews, and post grant reviews, as well as interferences and derivation
proceedings, oppositions and other similar proceedings brought by a Third Party with respect to such Patent. 
 1.264
“Publication Plan” means a [***] overall scientific communication and publication plan developed each year by the Joint Research Team and the Joint Development Team and approved by the Joint Research Committee and the Joint
Development Committee, that sets forth, for such year, [***] 
 1.265 [***] 

1.266 [***] 
 1.267
“Qualification Batch” has the meaning set forth in the MDSA. 
 1.268 “Quality Agreement” has
the meaning set forth in the MDSA. 
 1.269 “Receiving Party” has the meaning set forth in Section 11.1. 

1.270 “Regulatory Approval” means, with respect to a country in the Territory, any and all approvals (including
Investigational New Drug Applications (“INDs”) or Drug Approval Applications), licenses, registrations, or authorizations of any Regulatory Authority necessary to Manufacture, use, store, import, transport, commercially distribute,
sell, or market in such country a Collaboration Product including, where applicable, (a) pricing or reimbursement approval in such country, (b) post-approval marketing authorizations (including any prerequisite Manufacturing approval or
authorization related thereto), and (c) labeling approval. 
 1.271 “Regulatory Authority” means any applicable
supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities regulating or otherwise exercising authority with respect to the research,
development, manufacture, commercialization, making, having made, use, offering for sale, sale or importation of Collaboration Products. 

1.272 “Regulatory Data” means collectively all non-clinical and Clinical Data,
CMC data and Information and other Information, results, and analyses with respect to any Party Development Activities. 

  
 - 22 - 

			
	Confidential	  	Execution Copy

  

 1.273 “Regulatory Data Exclusivity” means an exclusive right, other
than through the issuance of a patent, lawfully granted by a Governmental Authority, to market, or to rely on certain data in supporting the marketing of, a Collaboration Product or Reversion Product, as applicable, in that country in respect of
which that Governmental Authority has jurisdiction conferred on it by Applicable Law, which exclusive right effectively prohibits reliance on the regulatory submissions made with respect to such product, directly or indirectly and in whole or in
part, in that country for the relevant time period. 
 1.274 “Regulatory Documentation” means all
(a) applications (including all INDs and Drug Approval Applications and other Major Regulatory Filings), registrations, licenses, authorizations, and approvals (including Regulatory Approvals); (b) correspondence and reports submitted to
or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising
and promotion documents, adverse event files, and complaint files; and (c) Regulatory Data contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) relating to a Collaboration Product. 

1.275 “Regulatory Expenses” has the meaning set forth in Schedule 1.8. 

1.276 “Rejects,” and with correlative meaning “Rejected” and “Rejection,” has the
meaning set forth in Section 4.5.2(d). 
 1.277 “Research Plan” has the meaning set forth in Section 3.1.1.

 1.278 “Research Term” means the period commencing on the Effective Date and, unless earlier terminated in
accordance herewith, ending on [***], unless extended by mutual written agreement of GNE and BioNTech. 
 1.279 “Reversion
Product” means any Pharmaceutical Product that [***] 
 1.280 “Right of Reference or Use” means the right to
cross reference, copy, incorporate by reference or rely upon any Regulatory Documentation solely for the purposes of obtaining or maintaining Regulatory Approval or Marketing Authorization for a Collaboration Product, including (1) a
“Right of Reference or Use” as that term is defined in 21 C.F.R. §314.3(b) in the United States, (2) any analogous procedures with respect to biologics or BLAs in the United States and (3) any equivalents thereof outside the
United States. 
 1.281 “ROFN” has the meaning set forth in Section 9.6.3. 

1.282 “ROFN Election Notice” has the meaning set forth in Section 9.6.3. 

1.283 “ROFN Exercise Period” has the meaning set forth in Section 9.6.3. 

1.284 “ROFN Licensable Subject Matter” has the meaning set forth in Section 9.6.3. 

  
 - 23 - 

			
	Confidential	  	Execution Copy

  

 1.285 “ROFN License Agreement” has the meaning set forth in
Section 9.6.3. 
 1.286 “ROFN Notice” has the meaning set forth in Section 9.6.3. 

1.287 “Royalty Product” has the meaning set forth in Schedule 1.8. 

1.288 “Royalty Rate” has the meaning set forth in Section 8.6.1. 

1.289 “Royalty Term” has the meaning set forth in Schedule 1.8. 

1.290 “Sales” has the meaning set forth in Schedule 1.8. 

1.291 “Shared Development Costs” has the meaning set forth in Schedule 1.8. 

1.292 [***]. 
 1.293
[***] 
 1.294 “Signatories” means RNP, BNT, GNE and Roche, each of which is a “Signatory”. 

1.295 “Start-up” has the meaning set forth in the MDSA. 

1.296 “Study Proposal” has the meaning set forth in Section 4.5.1. 

1.297 “Sublicensee” means a Person, other than an Affiliate, that is granted a sublicense by either Party (other
than through a Compulsory Sublicense) as provided in Section 9.3 (other than any sublicense under Section 9.1.2 or Section 9.2.2).  

1.298 [***] 
 1.299
“Team” has the meaning set forth in Section 2.3. 
 1.300 “Team
Co-Leader” has the meaning set forth in Section 2.3. 
 1.301
“TECENTRIQ®” means that certain proprietary product of Genentech having as its active ingredient atezolizumab. 

1.302 “Technology Platform” has the meaning set forth in the MDSA. 

1.303 “Technology Platform Roadmap” has the meaning set forth in the MDSA. 

1.304 “Technology Platform Strategy” has the meaning set forth in the MDSA. 

1.305 “Technology Transfer” has the meaning set forth in the MDSA. 

  
 - 24 - 

			
	Confidential	  	Execution Copy

  

 1.306 “Term” has the meaning set forth in Section 14.1.2. 

1.307 “Termination Product” means a [***] as of the effective date of termination of this Agreement. 

1.308 “Territory” means the entire world. 

1.309 “Third Party” means any Person other than a Party or any of its Affiliates. 

1.310 “Third Party Claims” has the meaning set forth in Section 13.1. 

1.311 “Third Party Collaborator” means a Third Party [***] 

1.312 “Third Party Infringement Claim” has the meaning set forth in Section 10.5.1(b). 

1.313 “Third Party IP” has the meaning set forth in Section 10.6.3. 

1.314 “Third Party IP Payments” has the meaning set forth in Section 10.6.3(b). 

1.315 “Third Party Product” means a product comprising one or more Neoepitope RNA(s) with respect to which [***] 

1.316 “Trademark” means any word, name, symbol, color, designation or device or any combination thereof that
functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol, whether or not registered. 

1.317 [***] 
 1.318
[***] 
 1.319 [***]. 

1.320 [***]. 
 1.321
[***] 
 1.322 [***] 

1.323 “United States” or “U.S.” means the United States of America, its territories and possessions,
Guam and the Commonwealth of Puerto Rico. 
 1.324 [***] 

1.325 “Valid Claim” means [***] 

  
 - 25 - 

			
	Confidential	  	Execution Copy

  

 1.326 “VAT” means within the European Union such Taxes (as defined in
Section 8.11.6) as may be levied in accordance with (but subject to derogation from) Council Directive 2006/112/EC and outside the European Union any Taxes levied by reference to added value or sales. 

1.327 “Voting Stock” has the meaning set forth in the definition of “Change in Control.” 

1.328 “Working Group” has the meaning set forth in Section 2.16. 

1.329 [***] 
 1.330
[***]. 
 ARTICLE 2. 

GOVERNANCE 
 2.1
Establishment of Governance Committees. Within [***] days of the Effective Date, or as otherwise specified below, Genentech and BioNTech shall establish the following committees to have strategic oversight of the joint research,
Development, regulatory, and Manufacturing activities for Collaboration Products: a Joint Research Committee (“JRC”) with responsibility for overseeing, coordinating and expediting the activities under the Research Plan and the
Joint Research Team’s activities related thereto; a Joint Development Committee (“JDC”) with responsibility for overseeing, coordinating and expediting the Global Development Plan and other activities specified below in
Section 2.7.1 and the Joint Development Team’s activities related thereto; a Joint Manufacturing Committee (“JMC”) with responsibility for overseeing, coordinating and expediting all clinical and commercial Manufacturing
activities, including clinical and commercial NGS and Neoepitope prediction, production planning, supply chain management, and activities to scale and improve existing Manufacturing processes; and within [***], a Joint Commercialization Committee
(“JCC”) with responsibility for [***] coordinating any Co-Promotion activities related thereto in accordance with this Agreement and the Co-Promotion
Agreement. Each of the JRC, JDC, JMC and JCC is sometimes referred to individually herein as a “Committee” and collectively as the “Committees.” 

2.2 Committee Membership. Each of the Committees shall be comprised of at least [***] but no more than [***] representatives
designated by each Party (except with respect to the JMC, which shall have no more than [***] representatives per Party) and [***] number of representatives. The representatives shall be appropriate (in terms of their seniority, availability,
function in their respective organizations, training and experience) for the tasks then being undertaken and the stage of Development, Manufacturing or Commercialization of Collaboration Products for which joint activities will be performed. Each
Party shall designate one of its representatives as its primary contact for Committee matters (such Party’s “Committee Co-Chair”). A Party may replace any or all of its representatives
(and designated Committee Co-Chair) at any time by informing the other Party’s Alliance Manager in advance, in writing (which may be by email). The initial members of the Committees are listed in
Schedule 2.2. 

  
 - 26 - 

			
	Confidential	  	Execution Copy

  

 2.3 Team Membership. Each Committee may establish teams from time-to-time, with a defined scope and duration, to carry out the activities of such Committee. Within [***] days of the Effective Date, a Joint Research Team shall be
established to conduct the work being overseen by the JRC, a Joint Development Team shall be established to conduct the work being overseen by the JDC, and a Joint Manufacturing Team shall be established to conduct the work being overseen by the
JMC. Each of the JRT, JDT and JMT is sometimes referred to individually herein as a “Team” and collectively as the “Teams.” Each of the Teams shall be composed of representatives designated by each Party and [***]
number of representatives. The Teams shall include individuals with expertise and responsibilities appropriate (in terms of their seniority, availability, function in their respective organizations, training and experience) for the tasks then being
undertaken and the stage of Development, Manufacturing or Commercialization of Collaboration Products for which joint activities will be performed. Each Party shall designate one of its representatives as its primary contact for Team matters (such
Party’s “Team Co-Leader”). A Party may replace any or all of its representatives (and designated Team Co-Leader) at any time by informing the other
Team Co-Leader in advance, in writing (which may be by email). 
 2.4 Meetings;
Participation. Once established, a Committee or Team shall meet at least [***] (unless otherwise agreed by the Parties) and at such other times as deemed appropriate by the Committee or Team. The presence of at least [***] shall
constitute a quorum at a Committee meeting. The Committee or Team may meet in person or via teleconference, video conference or the like, provided that at least [***] per Calendar Year shall be held in person, unless otherwise agreed by the Parties.
Each Party shall bear the expense of its respective representatives’ participation in Committee or Team meetings. If a Party’s representative is unable to attend a given meeting, such Party may designate a knowledgeable alternate to attend
such meeting and perform the functions of such representative. Each Party may invite a reasonable number of non-voting employees, consultants or scientific advisors to attend Committee or Team meetings,
provided that such invitees are bound by appropriate confidentiality obligations. In addition to formal meetings, the Committee and Team representatives shall communicate as necessary to ensure appropriate progress in their respective areas of
accountability. 
 2.5 Minutes; Other Documentation. Promptly after a Committee or Team is established, it shall hold an
organizational meeting to define such procedures and mechanisms as may be reasonably necessary for its operation to assure the efficient conduct of each Party’s obligations under this Agreement. Genentech shall be responsible for keeping
minutes of Committee and Team meetings that record in writing all decisions made, action items assigned or completed and other appropriate matters. Meeting minutes shall be sent to both Parties promptly after a meeting for review, comment and
approval by each Party. A decision that may be made at a Committee or Team meeting may also be made, without a meeting, if such decision is agreed to in writing (which may be by email) by each Party’s Committee
Co-Chair or Team Co-Leader, as the case may be (or its designee), provided that each Party’s writing clearly indicates that such decision is a formal decision
by such Party’s Committee Co-Chair or Team Co-Leader. Any modifications to the plans and budgets approved at a Committee meeting shall constitute an amendment
to such plan or budget upon approval by both Parties of the meeting minutes related thereto. 

  
 - 27 - 

			
	Confidential	  	Execution Copy

  

 2.6 Joint Research Committee. 

2.6.1 Responsibilities of the JRC. The Joint Research Committee shall be responsible for performing the following functions: 

(a) review progress reported by the Joint Research Team with respect to activities under the approved Research Plan; 

(b) address and coordinate the resolution of issues that may arise relating to the Initial Knowledge Transfer and the Ongoing Knowledge
Transfer in each case to the extent relating to the activities under the approved Research Plan; 
 (c) review and approve amendments to the
Research Plan as proposed by the Joint Research Team as well as any “Non-Clinical GDP Activities” set forth in the GDP; 

(d) together with the Joint Development Committee, review the annual Publication Plan developed by the Joint Research Team together with the
Joint Development Team, and approve the portion of such plan addressed to research publications; 
 (e) review and make recommendations to
the JDC as to [***] 
 (f) ensure that each Party keeps the JRC informed regarding all material activities performed by such Party under
this Agreement that are within the purview of the JRC; and 
 (g) perform such other functions as specified in this Agreement or as agreed
to by the Parties in writing. 
 2.6.2 Decision-Making Authority. With respect to the responsibilities of the JRC, each Party shall
[***], and the Parties shall attempt to make decisions [***]. In the event that agreement on a particular matter cannot be reached by the JRC within [***] Business Days or such longer period as the JRC members agree, after the JRC first meets to
consider such matter, then such matter shall be [***] 
 2.6.3 Term of the JRC Operations. The JRC shall continue to exist until the
first to occur of (a) the mutual agreement of the Parties to disband the JRC, (b) disbandment pursuant to Section 15.2, (c) disbandment pursuant to Section 2.18 or (d) the end of the Research Term. Thereafter, the JRC
shall cease operations and perform no further functions hereunder and any responsibilities which would have been assigned to the JRC shall be responsibilities of the JDC [***]. 

  
 - 28 - 

			
	Confidential	  	Execution Copy

  

 2.7 Joint Development Committee. 

2.7.1 Responsibilities of the JDC. The Joint Development Committee shall be responsible for performing the following functions: 

(a) review progress of Development and regulatory approval of Collaboration Products as reported by the Joint Development Team; 

(b) address and coordinate the resolution of issues that may arise relating to the Initial Knowledge Transfer and the Ongoing Knowledge
Transfer (in each case other than to the extent relating to activities under the Research Plan); 
 (c) review and decide [***] 

(d) review and decide whether to (i) approve amendments to the GDP as proposed by the Joint Development Team or (ii) amend the GDP
to include any additional Clinical Studies proposed by either Party (including Proposed Studies); 
 (e) approve new and amended GDP Budgets
as proposed by the Joint Development Team; 
 (f) review and decide whether to approve any Proposed Studies as BioNTech Studies based upon
the criteria set forth in Section 4.5.2; 
 (g) review and decide whether to approve any GTT Proposed Studies as BioNTech Studies based
upon the criteria set forth in Section 4.5.3; 
 (h) review and decide whether to approve any proposed Melanoma Follow-Up Study based upon the criteria set forth in Section 4.3.2; 
 (i) oversee the Conduct and
modification of Ongoing Clinical Studies (as set forth in Section 4.3.1), any Melanoma Follow-Up Studies (as set forth in Section 4.3.2) and any BioNTech Studies (as set forth in Section 4.5.4),
and to review and decide whether to approve any material deviations from (i) the Ongoing Clinical Studies as such Clinical Studies exist as of the Execution Date (as set forth in Section 4.3.1), (ii) any Melanoma Follow-Up Studies as previously approved by the JDC (as set forth in Section 4.3.2) or (iii) any BioNTech Studies as previously approved by the JDC (as set forth in Section 4.5.4); 

(j) together with the Joint Research Committee, review the annual Publication Plan developed by the Joint Development Team together with the
Joint Research Team, and approve [***] the portion of such plan addressed to Development publications; 
 (k) ensure that each Party keeps
the JDC informed regarding all material activities Conducted or otherwise performed by such Party under this Agreement that are within the purview of the JDC, including status updates of (i) BioNTech’s progress toward Developing BioNTech
Collaboration Products (including Conducting BioNTech Studies) and (ii) Genentech’s progress toward Developing Genentech Collaboration Products (including Conducting Genentech Studies); 

(l) perform such other functions as specified in this Agreement or as agreed to by the Parties in writing; and 

  
 - 29 - 

			
	Confidential	  	Execution Copy

  

 (m) oversee all Clinical Studies, comparator studies or investigator-sponsored studies of
Collaboration Products Conducted by the Parties, regardless of which Party Conducts the studies or has final decision-making authority in matters related to such studies. 

For clarity, all “Non-Clinical GDP Activities” included in the GDP shall not be subject to the
decision-making by the JDC, but shall be controlled by the JRC.  
 2.7.2 Decision-Making Authority. 

(a) With respect to the responsibilities of the JDC, each Party shall [***], and the Parties shall attempt to make decisions [***] 

2.7.3 Term of the JDC Operations. The JDC shall continue to exist until the first to occur of (a) the mutual agreement of the
Parties to disband the JDC, (b) disbandment pursuant to Section 15.2, (c) disbandment pursuant to Section 2.18 or (d) the end of the Term. Thereafter, the JDC shall cease operations and perform no further functions
hereunder. 

  
 - 30 - 

			
	Confidential	  	Execution Copy

  

 2.8 Joint Manufacturing Committee. 

2.8.1 Responsibilities of the JMC. The Joint Manufacturing Committee shall be responsible for performing the following functions: 

(a) coordinate with the JDC and JCC to ensure adequate quantity, quality, and timeliness of supply of Collaboration Products to meet clinical
and commercial needs worldwide; 
 (b) review and approve the initial plans (and any subsequent amendments) specified in the MDSA with
regard to Manufacturing activities for the Collaboration Product, including the CMC Development Plan, Manufacturing Network Plan, Technology Transfer Plans and any other plan recommended by the JMT and approved by the JMC; in all cases, ensuring
that the activities thereunder are performed in accordance with the MDSA, Quality Agreement and JMC-approved performance targets, timelines and budgets; 

(c) review progress of, and provide guidance with respect to, CMC development activities and associated costs as reported by the JMT pursuant
to the approved CMC Development Plan and annual budget; 
 (d) approve and oversee the development and implementation of the Manufacturing
Process for clinical and commercial supply of Collaboration Product in accordance with the MDSA, applicable Quality Agreement, JMC-approved performance targets, timelines and budgets and [***]; 

(e) approve and oversee, with respect to clinical and commercial supply of Collaboration Product, the Technology Platform Strategy and
Manufacturing Operations Strategy; 
 (f) oversee and monitor, with respect to Commercial Facilities within the Manufacturing Network, the
progress of the activities required for construction, Mechanical Completion, Commissioning, Start-up (including Technology Transfer) and Licensure by the applicable Regulatory Authority; 

(g) review and oversee the performance by Third Parties of certain Manufacture or supply obligations in accordance with the MDSA and
applicable Quality Agreement; 
 (h) review and approve business processes for aligning patient demand forecast requirements with
Manufacturing supply planning and scheduling requirements, and assess and resolve gaps between demand, and supply and Capacity plans; 
 (i)
investigate and advise on Manufacturing, supply and quality issues; 
 (j) review, at least semi-annually, the performance under the MDSA by
the Parties; 
 (k) review and recommend for approval by the Parties any changes to the MDSA, applicable Quality Agreement, Commercial
Manufacturing Agreement or other subsequent agreement related to Manufacturing of Collaboration Product, each as proposed by the JMT; 

  
 - 31 - 

			
	Confidential	  	Execution Copy

  

 (l) coordinate and address the resolution of issues that may arise relating to
implementation of the CMC Development Plan Manufacturing and Technology Transfers under the MDSA; and 
 (m) perform such other functions as
specified in this Agreement or the MDSA or as agreed to by the Parties in writing. 
 For clarity, except for reports as provided in Section 2.2.5(c) of
the MDSA, Independent Facilities are outside the scope of the JMC’s responsibilities. 
 2.8.2 Decision-Making Authority. With
respect to the responsibilities of the JMC, each Party shall [***], and the Parties shall attempt to make decisions [***]. In the event that agreement on a particular matter cannot be reached by the JMC within [***] Business Days or such longer
period as the JMC members agree, after the JMC first meets to consider such matter, then such matter shall be [***]  
 [***]

 2.8.3 Term of the JMC Operations. The JMC shall continue to exist until the first to occur of (a) the mutual agreement of the
Parties to disband the JMC, (b) disbandment pursuant to Section 15.2 (if elected by Genentech), (c) disbandment pursuant to Section 2.18 (provided that the JMC shall continue to exist for so long as set forth in Section 2.18) or
(d) the expiration or termination of the MDSA. Thereafter, the JMC shall cease operations and perform no further functions hereunder. For the avoidance of doubt, in the case of survival of the MDSA, as specified herein in Section 7.3,
14.5, or 15.2, (i) the JMC shall continue to exist (until otherwise elected by Genentech), (ii) the JMC shall operate and perform its functions solely for the purpose of and in connection with coordinating and overseeing any remaining CMC
Development Plan and Technology Transfer activities and any remaining Manufacturing and supply services, [***] 

  
 - 32 - 

			
	Confidential	  	Execution Copy

  

 2.9 Joint Commercialization Committee. 

2.9.1 Establishment of the Joint Commercialization Committee. Within [***], the Parties shall establish a Joint Commercialization
Committee with responsibility for [***] coordinating any Co-Promotion activities related thereto. 

2.9.2 Responsibilities of the JCC. Upon establishment, the Joint Commercialization Committee shall be responsible for performing the
following functions: 
 (a) oversight of [***]; 

(b) [***] 
 (c) [***], review
and approve the co-promotion plan for the Co-Promotion Territory as prepared by Genentech; 

(d) [***], serve as a forum for monitoring and coordinating matters relating to Co-Promotion of
Collaboration Products in the Co-Promotion Territory; 
 (e) [***], oversee and coordinate the
Parties’ Detailing activities of GDP Collaboration Products in the Co-Promotion Territory; and 

(f) perform such other functions as specified in this Agreement or as agreed to by the Parties. 

Each Party shall share with the other Party upon request, through the JCC, any marketing and sales information developed by such Party, including market
research, sales force sizing and targeting information, in each case relating solely to GDP Collaboration Products. In addition, each Party shall provide to the JCC on a [***] basis a summary of all Commercialization activities with respect to GDP
Collaboration Products undertaken by such Party. 
 2.9.3 Decision-Making Authority. With respect to the decision-making
responsibilities of the JCC, each Party shall [***], and the Parties shall attempt to make decisions [***]. In the event that agreement on a particular matter cannot be reached in any JCC meeting, Genentech shall have the final decision-making
authority with respect to such matter, which it may exercise following such meeting or at any time thereafter. 
 2.9.4 Term of the JCC
Operations. The JCC shall continue to exist until the first to occur of (a) the mutual agreement of the Parties to disband the JCC, (b) disbandment pursuant to Section 15.2, (c) disbandment pursuant to Section 2.18 or
(d) the end of the Term. Thereafter, the JCC shall cease operations and perform no further functions hereunder. 
 2.10 Joint
Research Team. 
 2.10.1 Establishment of the Joint Research Team. The JRC may establish a Joint Research Team
(“JRT”) to coordinate and implement all activities related to the research activities to be conducted by GNE and BioNTech pursuant to the Research Plan. 

  
 - 33 - 

			
	Confidential	  	Execution Copy

  

 2.10.2 Responsibilities of the JRT. The Joint Research Team shall be responsible for
performing the following functions: 
 (a) implement the Research Plan, ensuring that activities thereunder are performed in accordance with
the approved timelines; 
 (b) prepare draft amendments (as needed) to the Research Plan, and submit such amended Research Plan to
the JRC for approval; 
 (c) ensure that each Party keeps the JRT informed regarding all material activities performed by such Party under
this Agreement that are within the purview of the JRT; 
 (d) develop and implement, in collaboration with the Joint Development Team, the
annual Publication Plan; 
 (e) discuss and attempt to resolve any disputed matters related to the research collaboration before referring
such matters to the JRC; and 
 (f) perform such other functions as agreed to by the JRC or as specified in this Agreement. 

2.10.3 Decision-Making Authority. With respect to the responsibilities of the JRT, each Party shall have [***], and the Parties shall
attempt to make decisions [***]. In the event that agreement on a particular matter cannot be reached by the JRT within [***] Business Days or such longer period as the JRT members agree, after the JRT first meets to consider such matter, the matter
shall be referred to the JRC, which shall resolve such matter in accordance with Section 2.6.2. 
 2.10.4 Term of the JRT
Operations. The Joint Research Team shall continue to exist until the first to occur of (a) the decision of the JRC to disband the JRT or (b) the disbandment of the JRC or JRT otherwise pursuant to this Agreement. Thereafter, the JRT
shall cease operations and perform no further functions hereunder. 
 2.11 Joint Development Team. 

2.11.1 Establishment of the Joint Development Team. The Parties shall establish a Joint Development Team (“JDT”) to
define, coordinate and implement all activities related to the Development of GDP Collaboration Products, including preclinical Development, clinical Development and regulatory filings (but excluding any research activities within the purview of the
JRC (and JRT), any manufacturing activities within the purview of the JMC (and JMT) and any commercial activities within the purview of the JCC). 

  
 - 34 - 

			
	Confidential	  	Execution Copy

  

 2.11.2 Responsibilities of the JDT. The Joint Development Team shall be responsible
for performing the following functions: 
 (a) implement the Global Development Plan, ensuring that activities thereunder are performed in
accordance with the approved timelines; 
 (b) prepare draft amendments (as needed) to the Global Development Plan, and submit such amended
Global Development Plans to the JDC for approval; 
 (c) prepare draft amendments (as needed) to the annual GDP Budget, and submit
such annual GDP Budgets to the JDC for approval; 
 (d) ensure that each Party keeps the JDT informed regarding all material activities
performed by such Party under this Agreement that are within the purview of the JDT; 
 (e) develop and implement, in collaboration with the
Joint Research Team, the annual Publication Plan; 
 (f) discuss and attempt to resolve any disputed matters related to the collaboration
before referring such matters to the JDC; and 
 (g) perform such other functions as agreed to by the JDC or as specified in this Agreement.

 2.11.3 Decision-Making Authority. With respect to the responsibilities of the JDT, each Party shall [***], and the Parties shall
attempt to make decisions [***]. In the event that agreement on a particular matter cannot be reached by the JDT within [***] Business Days or such longer period as the JDT members agree, after the JDT first meets to consider such matter, the matter
shall be referred to the JDC, which shall resolve such matter in accordance with Section 2.7.2. 
 2.11.4 Term of the JDT
Operations. The Joint Development Team shall continue to exist until the first to occur of the decision of the JDC to disband the JDT or the disbandment of the JDC or JDT otherwise pursuant to this Agreement. Thereafter, the JDT shall cease
operations and perform no further functions hereunder. 
 2.12 Joint Manufacturing Team. 

2.12.1 Establishment of the Joint Manufacturing Team. The JMC may establish a Joint Manufacturing Team (“JMT”) to
define, coordinate and implement all activities related to the CMC Development Plan and Manufacture of Collaboration Products. 
 2.12.2
Responsibilities of the JMT. The Joint Manufacturing Team shall be responsible for performing the following functions: 
 (a) coordinate
with the JDT and JCC to ensure adequate quantity and quality of supply of Collaboration Products to meet clinical and commercial needs worldwide; 

  
 - 35 - 

			
	Confidential	  	Execution Copy

  

 (b) keep the JMC informed of all material activities being performed by the JMT; 

(c) prepare and draft the following plans and subsequent amendments (as needed) for submission to the JMC for approval: CMC Development Plan,
Manufacturing Network Plan, Technology Transfer Plans, Technology Platform Strategy and Manufacturing Operations Strategy; 
 (d) implement
the CMC Development Plan and other approved plans and strategies set forth in clause (c) above; in all cases, ensuring that activities thereunder are performed in accordance with the respective plan or strategy, approved timelines and budgets
and guidance provided by the JMC; 
 (e) prepare and draft amendments (as needed) to the annual Manufacturing budget for activities to be
conducted pursuant to the CMC Development Plan and other approved plans and strategies set forth in clause (c) above, and submit such annual budgets to the JMC for approval; 

(f) develop and manage (subject to JMC approval) business processes for aligning patient demand forecast requirements with Manufacturing
supply planning and scheduling requirements; make assessments of and recommendations to the JMC for resolving gaps between demand and supply and Capacity plans; and conduct, on a [***] basis, the activities set forth under Section 6.3.1 of the
MDSA; 
 (g) manage the performance by Third Parties of Manufacture or supply obligations in accordance with the MDSA and Quality Agreement;

 (h) coordinate the activities of the MDSA Parties relating to the Manufacture of the Collaboration Product at a Facility; 

(i) draft and recommend to the JMC for approval any changes to the MDSA, Quality Agreement or other subsequent agreement related to
Manufacturing of Collaboration Product; 
 (j) discuss and attempt to resolve any disputed matters related to the Manufacture of
Collaboration Product before referring such matters to the JMC; and 
 (k) perform such other functions as agreed to by the JMC or as
specified in this Agreement. 
 2.12.3 Decision-Making Authority. With respect to the responsibilities of the JMT, each Party shall
[***], and the Parties shall attempt to make decisions [***]. In the event that agreement on a particular matter cannot be reached by the JMT within [***] Business Days or such longer period as the JMT members agree, after the JMT first meets to
consider such matter, the matter shall be referred to the JMC, which shall resolve such matter in accordance with Section 2.8.2. 

  
 - 36 - 

			
	Confidential	  	Execution Copy

  

 2.12.4 Term of the JMT Operations. The Joint Manufacturing Team shall continue to
exist until the first to occur of the decision of the JMC to disband the JMT or the disbandment of the JMC or JMT otherwise pursuant to this Agreement. Thereafter, the JMT shall cease operations and perform no further functions hereunder. For the
avoidance of doubt, in the case of survival of the MDSA under Section 7.3, 14.5 or 15.2, the JMT shall continue to exist (until otherwise elected by Genentech) and shall operate and perform its functions solely for the purpose of and in
connection with coordinating and overseeing any remaining CMC Development Plan and Technology Transfer activities, and any remaining Manufacturing and supply services. 

2.13 Alliance Managers. Promptly following the Effective Date, each Party shall designate an individual to act as its primary
contact for business matters related to this Agreement (such Party’s “Alliance Manager”), unless another contact is expressly specified in this Agreement or mutually agreed by the Parties. The Alliance Managers shall promote
collaboration between the Parties and attempt to prevent and resolve disputes in a timely manner. Either Party may replace its Alliance Manager at any time by informing the other Party’s Alliance Manager in advance, in writing (which may be by
email). 
 2.14 Limitations on Authority. Each Party shall retain the rights, powers, and discretion granted to it under this
Agreement, and no such rights, powers, or discretion shall be delegated to or vested in a Committee or Team unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. No
Committee or Team shall have the power to amend, modify or waive compliance with this Agreement, which may only be amended or modified, or compliance with which may only be waived, as provided in Section 15.12. 

2.15 Interactions Between Committees, Teams and Internal Teams. The Parties recognize that each Party possesses an internal
structure (including various committees, teams and review boards) that will be involved in administering such Party’s activities under this Agreement. Nothing contained in this Article shall prevent a Party from making routine day-to-day decisions relating to the conduct of those activities for which it has a performance or other obligations hereunder, in each case in a manner consistent with the
then-current applicable plan and the terms and conditions of this Agreement. 
 2.16 Working Groups. From time to time, a
Committee or Team may establish and delegate duties to sub-committees or directed teams (each, a “Working Group”) on an “as-needed” basis to
oversee particular projects or activities (for example, joint finance group, joint regulatory groups or joint medical information group). Each such Working Group shall be constituted and shall operate as the Committee or Team determines; provided
that each Working Group shall have [***], unless otherwise mutually agreed. Working Groups may be established on an ad hoc basis for specific purposes and durations. Each Working Group and its activities shall be subject to the oversight, review and
approval of, and shall report to, the Committee or Team that formed said Working Group. In no event shall the authority of the Working Group exceed that specified for the Committee or Team that formed the Working Group to this Article. All decisions
of a Working Group shall [***]. Any disagreement between the designees of Genentech and BioNTech on a Working Group shall be referred to the Committee or Team that formed the Working Group for resolution. In the event that any Committee or Team is
disbanded, then the Working Groups thereunder shall also automatically be disbanded. 

  
 - 37 - 

			
	Confidential	  	Execution Copy

  

 2.17 Expenses. Each Party shall be responsible for all travel and related costs
and expenses for its members and other representatives to attend meetings of, and otherwise participate on, a Committee, Team or Working Group and such costs and expenses shall not constitute Development Costs or Allowable Expenses. 

2.18 Consequences of BioNTech Opt-Out. In the event that, pursuant to Section 8.5,
BioNTech exercises its Opt-Out to terminate its obligation to co-fund Development (or a Deemed Opt-Out has occurred pursuant to
Section 8.5.3), all Committees or Teams shall automatically be disbanded [***] days (or such longer period as the Parties mutually agree) after the Opt-Out Commencement Date and Genentech shall assume all
decision-making authority previously vested in such Committee(s). Notwithstanding the foregoing, Genentech may request in writing that BioNTech continue its participation on an advisory (non-voting) basis in
any Committee or Team notwithstanding such disbandment, in which case Genentech shall be responsible for the cost and expense of BioNTech’s participation in such Committee or Team based upon BioNTech’s then-current FTE Rate. [***] 

2.19 Technical and Knowledge Transfer. 

2.19.1 Initial Knowledge Transfer. 

(a) In order to enable Genentech to fulfil its obligations as set forth in this Agreement and the Ancillary Agreements, respectively, the
Parties have agreed to an initial knowledge transfer of documents and other Know-How set forth in Schedule 2.19.1(a) attached hereto (“BioNTech Initial Knowledge Transfer Items”).
BioNTech shall, and shall cause its Affiliates to, at BioNTech’s sole cost and expense, disclose such Know-How and transfer true and complete and accurate copies of all documents within the BioNTech
Initial Knowledge Transfer Items to Genentech, within [***] days, as applicable in accordance with Schedule 2.19.1(a), of the Effective Date. BioNTech shall provide the documents and other Know-How
specified in Schedule 2.19.1(a) via a mutually agreed secure document management or project collaboration software platform (e.g., Sharepoint) in an electronic format editable and readable by generally available Third Party software (e.g. PDF
or Microsoft Word documents) or as otherwise reasonably requested by Genentech. [***] 
 (b) In addition to the provision of the BioNTech
Initial Knowledge Transfer Items, BioNTech, at its sole cost and expense, shall provide Genentech with reasonable access to employees and Third Party service providers with relevant subject matter expertise to answer questions and assist Genentech
in understanding the BioNTech Initial Knowledge Transfer Items. Such access and assistance may occur through the Committees and Teams, on-site visits at BioNTech’s or Genentech’s offices or
facilities or telephonic or other meetings with personnel of BioNTech and its Third Party service providers. 

  
 - 38 - 

			
	Confidential	  	Execution Copy

  

 (c) GNE shall at Genentech’s sole cost and expense, disclose to BioNTech the Genentech Know-How set forth on Schedule 2.19.1(c). GNE shall provide such Genentech Know-How via a mutually agreed secure document management or project collaboration software
platform (e.g., Sharepoint) in an electronic format editable and readable by generally available Third Party software (e.g., PDF or Microsoft Word documents) or as otherwise reasonably requested by BioNTech. In addition, Genentech, at its sole cost
and expense, shall provide BioNTech with reasonable access to employees with relevant subject matter expertise to answer questions and assist BioNTech in understanding such Genentech Know-How. Such access and
assistance may occur through the Committees and Teams, on-site visits at BioNTech’s or Genentech’s offices or facilities or telephonic or other meetings with personnel of Genentech. 

2.19.2 Ongoing Transfer of Technical Information. 

(a) Until [***] or such other date as mutually agreed by the Parties, on a [***] basis, or such other frequency as mutually agreed by the
Parties through the applicable Committee, BioNTech shall provide to such Committee or Joint Research Team, Joint Development Team, Joint Manufacturing Team or such other team or working group appointed by a Committee, the following:
(i) BioNTech Know-How, to the extent not previously disclosed, Genentech requires to perform its obligations under this Agreement or the Ancillary Agreements and (ii) Collaboration Know-How made or developed by or on behalf of BioNTech pursuant to this Agreement or the Ancillary Agreements. BioNTech shall respond to subsequent requests for such Know-How
and make appropriate personnel available to Genentech at reasonable times and places and upon reasonable prior notice for the purpose of assisting Genentech to understand and use the BioNTech Know-How and
Collaboration Know-How in connection with the Research Plan, CMC Development Plan, GDP or other plan as requested and approved by the respective Committee. 

(b) Until [***] or such other date as mutually agreed by the Parties, on a [***] basis, or such other frequency as mutually agreed by the
Parties through the applicable Committee, Genentech shall provide to such Committee or Joint Research Team, Joint Development Team, Joint Manufacturing Team or such other team or working group appointed by a Committee, the following:
(i) Genentech Know-How described in clause (a) of the definition of Genentech Know-How, to the extent not previously disclosed, that BioNTech requires to
perform its obligations under this Agreement or the Ancillary Agreements, (ii) Genentech Know-How described in clause (b) of the definition of Genentech
Know-How upon Genentech’s decision to include such Genentech Know-How in the performance of the Research Plan, GDP or CMC Development Plan and
(iii) Collaboration Know-How made or developed by or on behalf of Genentech pursuant to this Agreement or the Ancillary Agreements. Genentech shall respond to subsequent requests for such Know-How and make appropriate personnel available to BioNTech at reasonable times and places and upon reasonable prior notice for the purpose of providing reasonable assistance to BioNTech to understand and use such
Genentech Know-How and Collaboration Know-How in connection with performing the activities for which BioNTech is responsible under the Research Plan, CMC Development
Plan, GDP or other plan as requested and approved by the respective Committee.  

  
 - 39 - 

			
	Confidential	  	Execution Copy

  

 (c) The ongoing knowledge transfer obligation described in clause (a) above for
BioNTech and the ongoing knowledge transfer obligation described in clause (b) above for Genentech shall each be referenced herein as the (“Ongoing Knowledge Transfer”). 

2.19.3 Transfer of Materials. Without limiting any specific transfer of materials set forth in the MDSA, BioNTech shall provide
Genentech with sufficient quantities of the physical specimens and materials set forth in Schedule 2.19.3 within [***] days of the Effective Date as specified in Schedule 2.19.3 or as otherwise may be extended as mutually agreed upon
by the Parties pursuant to Section 10.9. In addition, BioNTech shall provide Genentech with sufficient quantities of any other materials deemed appropriate by the applicable Committee or as set forth in the CMC Development Plan, solely for the
purposes of enabling Genentech to fulfill its obligations under this Agreement and the Ancillary Agreements. BioNTech represents and warrants that it, to its’ and its Affiliates’ knowledge, has sufficient rights to transfer such materials
to Genentech and to grant Genentech and its Affiliates and Sublicensees the right to use such materials in the exercise of its rights or performance of its obligations under this Agreement and the Ancillary Agreements (including use of such
materials in or for the Exploitation of Collaboration Products) without restriction or payment. Notwithstanding the foregoing, each Party shall otherwise be responsible for procuring any materials required for it to conduct its activities under the
Research Plan. 
 2.20 [***] Activities 

2.20.1 Subject to the provisions of this Section 2.20, and notwithstanding any other provisions of subcontracting under this
Agreement or any of the Ancillary Agreements, BioNTech may use [***] as a subcontractor to perform activities on its behalf, including under the Research Plan, under this Agreement or the Ancillary Agreements but only pursuant to the terms of the
[***] Agreement, [***] Agreement and the [***] Agreement (collectively, the “[***] Agreements”); provided that (a) BioNTech shall negotiate in good faith with [***], in consultation with Genentech, and enter into an amendment
to the [***] Agreement or similar agreement to obtain rights to any [***] developed by [***], and any such amendment or agreement shall be reviewed and approved by Genentech prior to execution, and (b) during the Term, BioNTech shall not enter
into any amendments to the [***] Agreements and shall not terminate any of the [***] Agreements without Genentech’s prior written consent. If BioNTech has not entered into an amendment to the [***] Agreement or similar agreement to obtain
rights to improvements to the [***] by January 1, 2017, then, at Genentech’s discretion and written notice, BioNTech shall cease using, and thereafter may no longer use, [***] as a subcontractor to perform activities on its behalf under
this Agreement or any Ancillary Agreement. BioNTech shall be responsible for ensuring that [***] performs any activities subcontracted to [***] hereunder in a timely manner and in accordance with the terms of this Agreement applicable to the
performance by BioNTech of such activities. In no event shall BioNTech permit [***] to subcontract any of its activities to be performed on behalf of BioNTech without the prior written consent of Genentech. [***]. 

2.20.2 [***] 

  
 - 40 - 

			
	Confidential	  	Execution Copy

  

 ARTICLE 3. 

RESEARCH PROGRAM 
 3.1
Research Plan and Activities. 
 3.1.1 Research Program. During the Research Term, GNE and BioNTech shall conduct a research
collaboration oriented to improving the Technology Platform relating to the Collaboration Products, pursuant to a research plan, which shall set forth each of Genentech’s and BioNTech’s respective activities under the plan, and the number
of FTEs (which may be a range) to be devoted by each Party, [***] (“Research Plan”). Each Party shall be responsible for funding its own FTEs and
out-of-pocket costs and expenses under the Research Plan. 

3.1.2 Initial Research Plan and Activities. Attached hereto as Schedule 3.1.2 is the initial Research Plan,
which plan assigns responsibility for research activities between the Parties. Each Party shall use Commercially Reasonable Efforts to perform the activities assigned to it under the Research Plan. Each Party shall conduct its activities under the
Research Plan in accordance with the terms and conditions of this Agreement. Each Party shall use Commercially Reasonable Efforts to devote to its activities under the Research Plan those FTEs specified in the Research Plan.

3.1.3 Amendments. During the Research Term, the JRC shall review the Research Plan from time to time as necessary for the
purpose of considering appropriate amendments thereto. In addition, either Party, through its representatives on the JRC, may propose amendments to the Research Plan at any time. In connection with amending the Research Plan, the Parties shall
determine the FTEs and other resources and out-of-pocket expenditures required for implementation of the Research Plan for the applicable Calendar Year and for each
Calendar Quarter within such Calendar Year. 
 3.2 Subcontracting. 

3.2.1 Genentech shall have the right to subcontract any of its activities under the Research Plan to a Third Party. Genentech shall
keep the JRC informed of such subcontracting activities. 
 3.2.2 Each Party shall be responsible (and liable) to the other Party for
the performance of its subcontractors and for any failure by its subcontractors to comply with the restrictions, limitations and obligations set forth in this Agreement as if such performance or failure of such subcontractors were the performance or
failure of the subcontracting Party under this Agreement. 
 3.2.3 Subject to Section 2.20, any subcontracting by either Party
of any of its activities under the Research Plan shall be conducted pursuant to a written subcontract specifying the work to be subcontracted, and containing provisions that are compliant with the applicable terms and conditions of this Agreement
and any Ancillary Agreements, including provisions with respect to intellectual property and confidential information, and that as between the subcontracting Party or its Affiliates and its subcontractor, any intellectual property arising out of the
performance of such activities shall be Controlled by the subcontracting Party or its Affiliates. [***]. 

  
 - 41 - 

			
	Confidential	  	Execution Copy

  

 3.2.4 Subject to Section 2.20, BioNTech shall have the right to subcontract any
of its activities under the Research Plan to a Third Party; provided that [***] 
 3.3 Records and Results. 

3.3.1 Without limiting Section 10.1, each Party shall use reasonable efforts to keep the other Party informed of its activities
under the Research Plan and [***] per Calendar Year, at mutually agreed meetings of the JRC, shall provide to the JRC a reasonably detailed written report, in English, describing activities performed and results obtained under the Research Plan
since the prior written report, in a form determined by the JRC. In the event that either Party requests further information regarding any such report, including a request for data or other primary research results, the Parties shall cooperate to
achieve such data exchange in a timely and efficient manner. Neither Party shall be required to generate additional data or prepare additional reports to comply with the foregoing obligation. Notwithstanding the foregoing, the JRC may determine what
reports shall be generated in respect of Research Plan activities, including the content and timing thereof, including by authorizing or requiring reports other than as provided in this Section 3.3.1. The Parties shall promptly share all such
reports with the JRC.
 3.3.2 In addition to Section 3.3.1, in the event a Party identifies, as part of the Research Plan or
otherwise in connection with its activities with respect to the Collaboration Products, an improvement [***], then such Party shall provide to the JRC, if such results have not already been so provided under Section 3.3.1, a reasonably detailed
written report, in English, describing the activities performed and results obtained and [***] The JRC shall review such report, and may request further information regarding any such report, including a request for data or other primary research
results, that may be reasonably useful to evaluate [***]; provided that such Party shall not be required to generate additional data or prepare additional reports to comply with the foregoing obligation. Within [***] days of the receipt of such
report, the JRC shall [***] 
 3.3.3 Each Party shall, and shall ensure that any Third Parties contracted pursuant to
Section 3.2, maintain records in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, and in compliance with Applicable Law, which shall be complete and accurate and shall properly reflect all work
done and results achieved in the performance of its designated activities under a Research Plan and which shall record only such activities and shall not include or be commingled with records of activities other than those conducted pursuant to the
Research Plan. Such records shall be retained by the applicable Party for the longer of (a) ten (10) years from its creation or (b) such period as may be required by Applicable Law. 

  
 - 42 - 

			
	Confidential	  	Execution Copy

  

 ARTICLE 4. 

DEVELOPMENT 
 4.1
Generally. The Parties shall use Commercially Reasonable Efforts to Develop one or more Collaboration Products for Commercialization in the Major Markets.  

4.2 GDP. Genentech and BioNTech shall pursue the Global Development Plan as set forth herein. Except as set forth in this Article
4, neither Party nor its Affiliates shall (a) Conduct any Clinical Studies of a Collaboration Product that is not set forth in the GDP or (b) use any BioNTech IP, that does not fall within any of the exceptions under Section 11.1.4
and is disclosed to Genentech under this Agreement or the Ancillary Agreements, to conduct any clinical studies of any Pharmaceutical Product that (i) comprises one or more Neoepitope RNA(s), but not any
Non-Neoepitope RNA(s) or (ii) one or more Permitted Hybrid Neoepitope RNA(s), [***] that is not set forth in the GDP. 

4.3 BioNTech Ongoing Clinical Studies and Related Follow-Up Studies. 

4.3.1 Conduct of Ongoing Clinical Studies. Notwithstanding [***], BioNTech may complete its ongoing Clinical Study in triple negative
breast cancer along with its ongoing Clinical Study in melanoma, each as described in, and in accordance with, the protocols identified in Schedule 4.3.1, as such protocols were provided by BioNTech to Genentech prior to the Execution Date
(“Ongoing Clinical Studies”), including, upon notification to the JDC, reasonable amendments thereto within the ordinary course of business that are not material deviations. Any amendments proposed by BioNTech to such protocols that
are material deviations shall require the approval of the JDC. 
 4.3.2 Other Clinical Studies in Melanoma. 

(a) If, in BioNTech’s reasonable judgment, the results of BioNTech’s Ongoing Clinical Study in melanoma demonstrate sufficient
evidence of activity to warrant a subsequent Clinical Study, then prior to [***], BioNTech may propose to the JDC one non-registrational subsequent Clinical Study in melanoma that BioNTech would conduct at its
sole cost and expense under a BioNTech IND (“Melanoma Follow-Up Study”). In connection with such proposal, BioNTech shall provide to the JDC the draft protocol for the proposed study. The JDC
shall approve such Melanoma Follow-Up Study if [***]. If the JDC approves such Melanoma Follow-Up Study, BioNTech may Conduct such Melanoma Follow-Up Study, at BioNTech’s sole cost and expense, provided that BioNTech provides updates to the JDC regarding the status of such Melanoma Follow-Up Study and obtains
the prior written approval of the JDC for any modifications to the protocol to such Melanoma Follow-Up Study that would (individually or collectively) constitute material deviations from the protocol that was
presented to the JDC at the time of its initial approval. The JDC shall approve such material deviations from the protocol if the criteria for approval of the Melanoma Follow-Up Study set forth in this
Section 4.3.2(a) continue to be fulfilled. 
 (b) Any additional clinical Development by BioNTech shall be solely as permitted under
Sections 4.4 and 4.5. 

  
 - 43 - 

			
	Confidential	  	Execution Copy

  

 4.3.3 Genentech’s Use of Ongoing Clinical Study Data. Genentech may access and
use any data generated in connection with the Ongoing Clinical Studies and, if applicable, the Melanoma Follow-Up Study. [***] 

4.4 Development Under the Global Development Plan. 

4.4.1 GDP. The initial GDP for the Development of the Collaboration Products hereunder, which assigns responsibility for Party
Development Activities between the Parties in relation to GDP Collaboration Products (such activities, “Joint Development Activities”), is attached hereto as Schedule 4.4.1. Each Party shall Conduct
Joint Development Activities assigned to it with reasonable care and diligence and in accordance with the terms and conditions of this Agreement and the GDP. Except as otherwise expressly provided in the GDP, the CMC Development Plan or otherwise
specified herein, all Development under the GDP shall be conducted by Genentech. 
 4.4.2 Amendments. The JDC shall review the GDP
from time to time as necessary for the purpose of considering appropriate amendments thereto. In addition, either Party, through its representatives on the JDT, may propose amendments to the GDP for Joint Development Activities at any time.
Following [***], if Genentech proposes to amend the GDP to include a Clinical Study for Development of a Collaboration Product in an Indication that is not then included in the GDP, it shall provide the JDC with a written clinical Development plan
from proof of concept through Regulatory Approval for such Indication consisting of [***] As part of the process of amending the GDP, the Parties shall determine the internal personnel and other resources and out-of-pocket expenditures required for the Joint Development Activities for the applicable Calendar Year and for each Calendar Quarter within such Calendar Year, to be reflected in the GDP Budget. 

4.4.3 Conduct of Clinical Studies Under the GDP. Except as otherwise agreed by the Parties in writing, Genentech shall Conduct all
Clinical Studies prior to [***] under the GDP, and thereafter all Clinical Studies under the GDP with respect to which Genentech has final decision-making authority as set forth in Section 2.7.2(g)(i). [***]. Except as otherwise agreed by the
Parties in writing, BioNTech shall Conduct all Clinical Studies with respect to which BioNTech has [***]; provided that (a) BioNTech shall Conduct any applicable Clinical Studies under the GDP in a timely, effective and cost-efficient
manner according to Applicable Law (including Compliance Requirements), and (b) BioNTech may only Conduct a Clinical Study under the GDP if BioNTech possesses safety reporting and other applicable infrastructure and personnel adequate to
support such Clinical Study and share safety data with Genentech in a manner that enables Genentech’s compliance with any Regulatory Authority reporting requirements per Genentech’s standard processes [***] 

4.4.4 Subcontracting. 

(a) Genentech shall have the right to subcontract any of its activities under the GDP or in connection with a Genentech Study to a Third
Party. Genentech shall keep the JDC informed of such subcontracting activities. 

  
 - 44 - 

			
	Confidential	  	Execution Copy

  

 (b) BioNTech shall have the right to subcontract any of its activities under the GDP or in
connection with an Ongoing Clinical Study, Melanoma Follow-Up Study or BioNTech Study to a Third Party; provided that [***] 

(c) Subject to Section 2.20, any subcontracting by either Party of any of its activities under the GDP or in connection with an Ongoing
Clinical Study, Melanoma Follow-Up Study, Genentech Study or BioNTech Study shall be conducted pursuant to a written subcontract specifying the work to be subcontracted, and containing provisions that are
compliant with the applicable terms and conditions of this Agreement and any Ancillary Agreements, including provisions with respect to intellectual property and confidential information, and that as between the subcontracting Party or its
Affiliates and its subcontractor, any intellectual property arising out of the performance of such activities by such subcontractor shall be Controlled by the subcontracting Party or its Affiliates. In the event that such intellectual property
would, if it were made by a Party, be Collaboration IP, then such intellectual property shall be Collaboration IP and in the event that such intellectual property would, if it were made by a Party, be BioNTech IP or Genentech IP, then such
intellectual property is hereby licensed to the other Party subject to Section 9.1 or 9.2, as applicable. 
 (d) Each Party shall be
responsible (and liable) to the other Party for the performance of its subcontractors and for any failure by its subcontractors to comply with the restrictions, limitations and obligations set forth in this Agreement as if such performance or
failure of such subcontractors were the performance or failure of the subcontracting Party under this Agreement. 
 4.5 BioNTech Proposed
New Indications; BioNTech Studies. 
 4.5.1 Proposed Additional Indication. BioNTech may, at any time during the Term, based upon
sound scientific rationale, provide the JDC with a written proposal meeting the requirements of this Section 4.5.1 (“Study Proposal”) to amend the GDP to include a Clinical Study (“Proposed Study”) for
Development of a Collaboration Product in an Indication that is not then included in the GDP.    Each such Study Proposal shall include [***]. BioNTech shall present such Study Proposal to the JDC at its next regularly scheduled
meeting. The JDC shall decide whether to approve such Proposed Study and whether to add the relevant Indication to the GDP, which decision shall be reflected in the minutes of the JDC. Each Study Proposal shall contain reasonably sufficient detail
to enable the JDC to assess whether to approve such Proposed Study and whether to add the relevant Indication to the GDP. If the JDC decides to add the Indication covered by the Study Proposal to the GDP, the GDP shall be amended to include the
Proposed Study (together with any modifications agreed upon by the JDC), such Indication shall become a GDP Indication, and the Conduct of such Proposed Study (as modified by the JDC) and any additional Clinical Studies in such Indication shall be a
Joint Development Activity, pursuant to Section 4.4. In the event that the JDC declines to add a new Indication presented by BioNTech to the GDP pursuant to this Section 4.5.1, then BioNTech may have the right to Conduct the Proposed Study
to the extent permitted pursuant to Section 4.5.2 as a “BioNTech Study”, and upon Initiation by BioNTech of the Proposed Study and subject to Section 4.5.5(c), such Indication, shall be a “BioNTech
Indication” and such Collaboration Product shall be a “BioNTech Collaboration Product”. 

  
 - 45 - 

			
	Confidential	  	Execution Copy

  

 4.5.2 BioNTech’s Right to Conduct a BioNTech Study. Subject to
Section 4.5.5, BioNTech shall have the rights set forth in this Section 4.5.2 to Conduct a Proposed Study that the JDC declines to include in the GDP solely if [***], the “BioNTech Study Conduct Requirements”), and
(5) the applicable conditions in subsections (a)-(d) below are satisfied. In the event that BioNTech fails to Initiate a Proposed Study that the JDC has declined to include in the GDP within [***] of the JDC decision to not include the study in
the GDP, then if BioNTech wishes to Conduct the study at a later time, it must re-submit the Study Proposal for such study to the JDC for consideration in accordance with Section 4.5.1 as if the study
were a new Proposed Study. 
 [***] 

4.5.3 Preservation of Genentech Tumor Types. Following [***], if at a given time, the then-current GDP does not provide for a Clinical
Study for a tumor type listed on Schedule 1.167 as Genentech Tumor Types, then BioNTech may propose a Clinical Study in such tumor type (a “GTT Proposed Study”) by presenting a Study Proposal to the JDC pursuant to
Section 4.5.1; provided that a GTT Proposed Study may not be in a Genentech Indication. The JDC shall decide whether to add such GTT Proposed Study to the GDP with Genentech having the right to cast the deciding vote. In the event that the JDC
determines to add the GTT Proposed Study to the GDP, the applicable tumor type shall remain a Genentech Tumor Type and the applicable Indication shall become a GDP Indication. In the event the JDC determines not to add such GTT Proposed Study to the
GDP, then BioNTech may pursue the GTT Proposed Study in accordance with the Study Proposal if all of the following conditions are met: [***]. In such case, upon BioNTech’s timely (within the [***] timeframe described in the preceding sentence)
Initiation of the GTT Proposed Study and so long as BioNTech is using Commercially Reasonable Efforts to Conduct such GTT Proposed Study, the GTT Proposed Study will be a BioNTech Study, the proposed Indication will be a BioNTech Indication and the
applicable tumor type will cease to be a Genentech Tumor Type. 

  
 - 46 - 

			
	Confidential	  	Execution Copy

  

 4.5.4 BioNTech’s Conduct of BioNTech Studies. For any BioNTech
Study (including [***] Conducted by BioNTech), the following shall apply: 
 (a) Each BioNTech Study shall be Conducted by BioNTech at
BioNTech’s sole cost and expense, which costs and expenses shall not be included in Shared Development Costs, unless otherwise agreed by the Parties. Notwithstanding the foregoing, in the event the JMC determines that the Manufacture and supply
of Collaboration Product for such BioNTech Study can be supported within the Manufacturing Network in accordance with patient demand forecasting pursuant to the MDSA, the cost for Manufacturing the Collaboration Product at Commercial Facilities of
Genentech within the Manufacturing Network will be charged to BioNTech [***]. BioNTech may contract with a contract research organization to conduct such study, provided that the terms of Section 4.4.4 shall also apply with respect to
BioNTech’s Conduct of BioNTech Studies. 
 (b) BioNTech shall not Initiate any BioNTech Study until after execution of the
Pharmacovigilance Agreement by both Parties. BioNTech shall Conduct any BioNTech Clinical Study under [***] in accordance with Section 5.3. For clarity, subject to Genentech’s rights and BioNTech’s obligations as set forth in this
Section 4.5, BioNTech may conduct a subsequent Clinical Study, including a Pivotal Study to the extent permitted under Section 4.5.2(b) or Section 4.5.2(c). 

(c) All BioNTech Studies will be subject to oversight by the JDC and BioNTech shall (i) provide regular updates on the status and results
of each such BioNTech Study to the JDC, including reporting the achievement of key Clinical Study and Development milestones to be determined by the JDC, and (ii) inform the JDC of any changes to the Study Proposal (including study designs and
protocols) for each BioNTech Study. Genentech, through the JDC, shall be permitted to provide BioNTech with comments on the Development plans for BioNTech Studies and on the conduct of the BioNTech Studies, and BioNTech shall [***]. Notwithstanding
the foregoing, any modifications to the protocol for a BioNTech Study that would (individually or collectively) constitute material deviations from the protocol in the Study Proposal originally presented to the JDC shall require the prior approval
of the JDC, [***]. 
 (d) BioNTech will use Commercially Reasonable Efforts to ensure careful and diligent execution of the Development
program for each BioNTech Indication reflected in the initial Study Proposal therefor, and shall Conduct each BioNTech Study according to Applicable Law including Compliance Requirements. BioNTech shall fully and adequately fund and be responsible
for any BioNTech Studies permitted pursuant to Section 4.5.2 (including Manufacturing at BioNTech’s cost and expense adequate supply of Collaboration Product for such studies, which supply shall not prejudice the supply of Collaboration
Product for activities under the Research Plan or the GDP or activities relating to Genentech Indications). 
 (e) In the event a BioNTech
Study is in a Genentech Tumor Type, Genentech shall [***], in accordance with Section 2.7.2(g)(i). For clarity, (i) such [***] shall not apply in relation to Ongoing Clinical Studies or the Melanoma
Follow-up Study and (ii) BioNTech shall [***] regarding any BioNTech Study that was proposed as a GTT Proposed Study in accordance with Section 4.5.3. 

  
 - 47 - 

			
	Confidential	  	Execution Copy

  

 (f) Unless otherwise agreed by the Parties, a BioNTech Study may only involve [***] 

(g) [***] 
 4.5.5
Genentech’s Opt-In Right for BioNTech Studies. 
 (a) For each BioNTech Study (including
[***] that has been or is being conducted by BioNTech in a particular Indication, Genentech shall have the option (“Opt-In Right”), exercisable at any time prior to the first filing for the
first application for Marketing Authorization for such Indication (“Genentech Opt-In Period”), to convert the Indication to a GDP Indication by providing written notice to BioNTech and paying
the BioNTech Indication Opt-In Fee pursuant to Section 8.3. Upon written request of Genentech, BioNTech shall inform Genentech (in writing within [***] days of Genentech’s written request) in
reasonable detail of all Development Costs incurred for such BioNTech Indication which would form the basis for the calculation of the BioNTech Indication Opt-In Fee pursuant to Section 8.3. Any disputes
in relation to such Development Costs shall be settled in accordance with Sections 8.16 and 8.17. 
 (b) In the event that the Genentech Opt-In Period expires with respect to a BioNTech Indication without exercise by Genentech of its Opt-In Right, and BioNTech’s [***], the Parties may amend this Agreement
to address further details of the transition including with respect to Product Trademarks, branding, NDC numbers and commercial launch activities. 

(c) Following Genentech’s exercise of its Opt-In Right with respect to a BioNTech Study [***],
(i) the relevant Indication shall become a GDP Indication, and (ii) the relevant Collaboration Product shall cease to be a BioNTech Collaboration Product and shall become a GDP Collaboration Product. In addition, following Genentech’s
exercise of its Opt-In Right [***] with respect to a BioNTech Study (A) BioNTech shall complete any applicable Clinical Study (if such Clinical Study is still ongoing) under the GDP unless otherwise
agreed by the Parties, (B) all Development Costs for such study incurred thereafter shall constitute Shared Development Costs and (C) BioNTech shall [***]. If, at the time of Genentech’s exercise of its
Opt-In Right [***], BioNTech has incurred costs or entered into non-cancellable financial commitments, in each case, relating to the construction, Commissioning,
licensing, operation and/or maintenance of an Independent Facility, the Parties shall enter into good faith negotiations to determine whether it is feasible to continue to have such Independent Facility support the Manufacturing of such
Collaboration Product or to find alternative ways to compensate BioNTech for the investments already made to the extent that such costs and non-cancellable financial commitments were specific to the
Manufacture of the relevant BioNTech Collaboration Product and cannot be used for other purposes by BioNTech. 

  
 - 48 - 

			
	Confidential	  	Execution Copy

  

 (d) In the event that the Genentech Opt-In Period
with respect to a BioNTech Indication expires without exercise by Genentech of its Opt-In Right, then BioNTech shall notify Genentech [***]. 

4.6 Genentech’s Conduct of Genentech Studies; [***] for Genentech Collaboration Products. In the
event that BioNTech exercises its BioNTech Co-Funding Rejection right pursuant to Section 2.7.2(c), the following shall apply: 

4.6.1 Each Genentech Study shall be Conducted by Genentech at Genentech’s sole cost and expense, which costs and expenses shall
not be included in Shared Development Costs, unless otherwise agreed by the Parties. The cost for Manufacturing the Collaboration Product at Clinical Facilities will be charged to Genentech [***]. 

4.6.2 In the event that a Regulatory Authority accepts a Drug Approval Application for a Genentech Collaboration Product in a Genentech
Indication, then upon the first such acceptance by a Regulatory Authority, BioNTech shall be required to pay the Genentech Indication Co-Funding Fee (as set forth in Section 8.3.2) with respect to the
applicable Genentech Indication. Following the first acceptance by a Regulatory Authority of an application for Marketing Authorization of a Genentech Collaboration Product, (a) the relevant Indication shall become a GDP Indication, and
(b) the relevant Collaboration Product shall cease to be a Genentech Collaboration Product and shall become a GDP Collaboration Product. 

4.7 [***] 
 4.8 Records
and Reports; Study Data. 
 4.8.1 Each Party shall, and shall ensure that any of its Affiliates, subcontractors and Sublicensees
performing Development activities with respect to the Collaboration Products and any Third Parties contracted pursuant to Section 4.4.4, maintain records in sufficient detail and in good scientific manner appropriate for patent and regulatory
purposes, and in compliance with Applicable Law, which shall be complete and accurate and shall properly reflect all work done and results achieved in the performance of its designated Party Development Activities which shall record only such
activities and shall not include or be commingled with records of activities other than Party Development Activities. Such records shall be retained by the applicable Party for the longer of (a) ten (10) years from its creation or (b) such
period as may be required by Applicable Law. 
 4.8.2 Without limiting Sections 5.8 or 10.1, each Party shall use reasonable efforts
to keep the other Party informed of its Party Development Activities and [***] per Calendar Year, at mutually agreed meetings of the JDC, shall provide to the JDC a reasonably detailed written report, in English, describing Party Development
Activities performed and results obtained since the prior written report, in a form determined by the JDC. In the event that either Party requests further information regarding any such report, 

  
 - 49 - 

			
	Confidential	  	Execution Copy

  

 
including a request for Clinical Data, the Parties shall cooperate to achieve such data exchange in a thorough, timely and efficient manner. Neither Party shall be required to generate additional
data or prepare additional reports to comply with the foregoing obligation. Notwithstanding the foregoing, the JDC may determine what reports shall be generated in respect of Party Development Activities, including the content and timing thereof,
including by authorizing or requiring reports other than as provided in this Section 4.8.2. The Parties shall promptly share all such reports with the JDC. 

4.8.3 Genentech shall own all right, title and interest in and to Genentech Molecule Clinical Study Data; provided that BioNTech shall
have the right to use such Genentech Molecule Clinical Study Data, subject to Section 11.1, solely to perform its obligations under this Agreement. 

4.9 Investigator-Sponsored Studies. Investigator-sponsored studies of the Collaboration Product with respect to which a Party or
its Affiliate or its Sublicensee is providing funding or clinical supplies of Collaboration Product shall be treated as a Clinical Study Conducted by such Party for all purposes (including JDC review and approval, cost allocation and intellectual
property). [***]. 
 4.10 Compliance. Each Party shall perform or cause to be performed, any and all of its Party Development
Activities in good scientific manner and in compliance with all Applicable Laws, including Compliance Requirements. 
 ARTICLE 5. 

REGULATORY 
 5.1
General. For the purposes of this Agreement, the Parties agree that all GDP Indications for all Collaboration Products in a given jurisdiction will be governed by one or more Marketing Authorization(s) owned by Genentech or its Affiliate
or Sublicensee (such Marketing Authorization(s) and any additional Marketing Authorizations owned by Genentech or its Affiliate or Sublicensee, each hereinafter a “Genentech Marketing Authorization”). 

5.2 Lead Regulatory Parties. “Lead Regulatory Party” means the Party so assigned pursuant to this
Section 5.2, with the rights and responsibilities set forth under Section 5.4. The Party that is not the Lead Regulatory Party shall be the “Supporting Regulatory Party”. Genentech shall be the Lead Regulatory Party with
respect to all Collaboration Products for all Indications, other than with respect to (a) the Ongoing Clinical Studies, any Melanoma Follow-Up Study permitted pursuant to Section 4.3.2(a), and
(b) any BioNTech Study Conducted under [***] 
 5.3 BioNTech Study under [***] 

5.3.1 If the JDC declines to include a Proposed Study from BioNTech in the GDP after [***] (or at such earlier time permitted pursuant
to Section 4.5.2), and BioNTech has right to Conduct such Proposed Study pursuant to Section 4.5.2, then BioNTech may Conduct such Proposed Study as a BioNTech Study under [***]. 

  
 - 50 - 

			
	Confidential	  	Execution Copy

  

 5.3.2 Subject to Genentech’s rights and BioNTech’s obligations as set forth
in Section 4.5 and provided that [***] 
 5.3.3 BioNTech shall prioritize Development and Manufacturing activities it is
conducting in support of the GDP and GDP Collaboration Products and any Genentech Indications and Genentech Products over any development and manufacturing activities it is conducting in support of [***]. In particular, BioNTech agrees that: 

(a) In any communications and interactions with a Regulatory Authority that are undertaken [***] 

(b) BioNTech shall ensure that BioNTech Development and [***] Activities do not distract or divert resources from activities conducted under
or in support of the GDP or GDP Collaboration Products or any Genentech Indications or Genentech Collaboration Products; and 
 (c) [***]

 5.3.4 The Parties acknowledge and agree that this Agreement has been drafted primarily in view of the Genentech Marketing
Authorization for GDP Collaboration Products. No later than [***] days following the request of Genentech, and in any event prior to [***], the Parties agree to amend this Agreement to reflect [***]. 

5.4 Regulatory Activities. 

5.4.1 As between the Parties, the Lead Regulatory Party shall have the sole right and responsibility to prepare and submit Regulatory
Documentation and to file for, obtain, and maintain Regulatory Approvals (including the setting of the overall regulatory strategy therefor). With respect to GDP Collaboration Products and Genentech Collaboration Products, the Supporting Regulatory
Party shall support the Lead Regulatory Party, as may be reasonably necessary, in obtaining such Regulatory Approvals for the Collaboration Products, and in the activities in support thereof, including providing information, documents or other
materials required by Applicable Law for inclusion in or in support of Regulatory Documentation, in each case in accordance with the terms and conditions of this Agreement and the GDP. 

5.4.2 All Regulatory Documentation (including all Regulatory Approvals and Product Labeling) (except for Clinical Data which shall be
owned pursuant to Section 4.8.3 or Section 11.1) relating to the Collaboration Products with respect to the Territory shall be owned by, and shall be the sole property and held in the name of, the Lead Regulatory Party or its designated
Affiliate, Sublicensee or designee. 

  
 - 51 - 

			
	Confidential	  	Execution Copy

  

 5.4.3 The Lead Regulatory Party pursuant to Section 5.2 with respect to [***]
shall provide the other Party with an opportunity to review and comment on [***] The Lead Regulatory Party shall provide the Supporting Regulatory Party access to [***] 

5.4.4 The Lead Regulatory Party pursuant to Section 5.2 [***] shall provide the Supporting Regulatory Party with prior written
notice, to the extent the Lead Regulatory Party has advance knowledge, of any material scheduled meeting, conference, or discussion (including any advisory committee meeting) with a Regulatory Authority [***] 

5.4.5 The Lead Regulatory Party shall make every reasonable effort to notify the Supporting Regulatory Party promptly following its
determination that any event, incident, or circumstance has occurred that may result in the need for a recall, market suspension, or market withdrawal of a Collaboration Product in the Territory, and shall include in such notice the reasoning behind
such determination, and any supporting facts. The Lead Regulatory Party shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension, or market withdrawal in the Territory. If a recall,
market suspension, or market withdrawal is mandated by a Regulatory Authority in the Territory, the Lead Regulatory Party shall initiate such a recall, market suspension, or market withdrawal in compliance with Applicable Law. For all recalls,
market suspensions or market withdrawals undertaken pursuant to this Section 5.4.5, the Lead Regulatory Party responsible for the recall, market suspension, or market withdrawal shall be solely responsible for the execution thereof, and the
Supporting Regulatory Party shall reasonably cooperate in all such recall efforts. [***]
 5.5 CMC Regulatory Support. 

5.5.1 For Clinical Manufacture and Commercial Manufacture of GDP Collaboration Products and Genentech Collaboration Products, BioNTech
shall consult with Genentech, and provide to Genentech all CMC-related documents and input as required by Genentech (or its Affiliate) or any applicable Regulatory Authority in connection with any
Regulatory Documentation to be submitted to any applicable Regulatory Authority by Genentech (or its Affiliate) in order to obtain any required Regulatory Approvals in the Territory. In addition, for clinical supply of GDP Collaboration
Products and Genentech Collaboration Products, BioNTech shall provide Genentech in a timely manner with a copy of any BioNTech Manufacturing and control records for Existing BioNTech Product and Collaboration Product which may be required for any
Regulatory Documentation to be submitted by Genentech with respect to Collaboration Product, which records shall be in BioNTech’s standard formats unless otherwise agreed upon by the Parties. 

5.5.2 For GDP Collaboration Products and Genentech Collaboration Products that will be Manufactured by Genentech, BioNTech shall
(a) consult with and otherwise provide support to Genentech on CMC-related regulatory matters, as requested by Genentech and (b) assist Genentech (or its Affiliate) in responding to requests and
inquiries from Regulatory Authorities prior to, during and after regulatory review periods, and attending meetings with Regulatory Authorities to the extent Genentech requests BioNTech to participate given its unique knowledge or its status as
manufacturer of the Collaboration Product for clinical supply. 

  
 - 52 - 

			
	Confidential	  	Execution Copy

  

 5.6 Regulatory Correspondence. 

5.6.1 Each Party shall immediately and within [***] notify the other Party in writing of, and shall provide the other Party with copies
of, any correspondence and other documentation received or prepared by such Party in connection with any of the following events: (a) receipt of a regulatory letter, warning letter, Form 483 (Inspectional Observations) or similar item, from the
FDA or any other Regulatory Authority directed to the Manufacture or distribution of Collaboration Product by BioNTech or in connection with any general cGMP inspections applicable to the Facility; (b) any recall, market withdrawal or
correction of any Collaboration Product Manufactured, tested, packaged, stored or distributed hereunder, where the recall, market withdrawal or correction is attributable to any Manufacturing or distribution activities by or on behalf of BioNTech;
and (c) receipt of a regulatory letter, warning letter or similar item from the FDA or any other Regulatory Authority directed to or any regulatory comments related to Collaboration Product Manufactured or distributed hereunder where the
comments relate or are attributable to any Manufacturing, testing, packaging, storage or distribution activities by or on behalf of BioNTech. 

5.6.2 In the event Genentech receives any regulatory letter or comments from any Regulatory Authority in the Territory related to the
Manufacture of Collaboration Product, including receipt of a Form 483 (Inspectional Observations) or a warning letter, BioNTech will, to the extent within its control or possession, promptly provide Genentech with relevant data or information
related to the Manufacture of Collaboration Product sufficient for Genentech to prepare any response related to the Manufacture or distribution of Collaboration Product and will cooperate fully with Genentech in preparing such response. Genentech
shall provide BioNTech with a copy of each such response (redacted to remove information not related to the Manufacture or distribution of Collaboration Product or Genentech’s obligations under this Agreement) for BioNTech’s review and
comment prior to Genentech’s submission of its detailed written response. Genentech shall give all due consideration to any BioNTech comments to each such proposed Genentech response provided that BioNTech conveys its comments to Genentech in a
timely manner. 
 5.6.3 In the event BioNTech receives any regulatory letter or comments from any Regulatory Authority in the
Territory directed to its Manufacture or distribution of Collaboration Product, including receipt of a Form 483 (Inspectional Observations) or a warning letter, Genentech will, to the extent within its control or possession, promptly provide
BioNTech with all Information related to the Manufacture of Collaboration Product sufficient for BioNTech to prepare any response related to the Manufacture or distribution of Collaboration Product and will cooperate fully with BioNTech in preparing
such response. BioNTech shall provide Genentech with a copy of each such response (redacted to remove information not related to the Manufacture or distribution of Collaboration Product or BioNTech’s obligations under this Agreement) for
Genentech’s review and comment prior to BioNTech’s submission of its detailed written response. BioNTech shall give all due consideration to any Genentech comments to each such proposed BioNTech response provided that Genentech conveys its
comments to BioNTech in a timely manner. 

  
 - 53 - 

			
	Confidential	  	Execution Copy

  

 5.7 Regulatory Data; Annual Report. 

5.7.1 Each Party shall promptly provide to the other Party summaries of [***] 

5.7.2 BioNTech shall support Genentech, as may be reasonably necessary or appropriate, in obtaining Regulatory Approval for the
Collaboration Products, including providing necessary documents or other materials required by Applicable Law to obtain Regulatory Approvals, in each case in accordance with the terms and conditions of this Agreement and the GDP. 

5.7.3 BioNTech shall provide Genentech within [***] days after the end of each annual reporting period for each applicable
Collaboration Product (as calculated consistent with appropriate regulations and guidelines) with such information as is reasonably requested in writing by Genentech for the preparation of the annual report with respect to the Manufacturing and
control of such Collaboration Product for such annual reporting period. Thereafter, Genentech shall provide to BioNTech at least [***] Business Days prior to Genentech’s filing with the respective Regulatory Authorities a copy of such Genentech
annual report, and Genentech shall take into consideration any BioNTech comments to such annual report with respect to the Manufacture of Collaboration Product. 

5.8 Pharmacovigilance. Prior to [***], the Parties shall execute a separate pharmacovigilance agreement setting forth the
Parties’ responsibilities and obligations with respect to the procedures and timeframes for compliance with Applicable Law pertaining to safety reporting of the Collaboration Products (“Pharmacovigilance Agreement”). 

5.9 BioNTech Platform Product. During the Term and to the extent permissible under relevant agreements concluded with Third
Parties, BioNTech shall provide a high level safety report in connection with the development of BioNTech Platform Products in order for Genentech to determine whether such development could impact the Development of Collaboration Products and
whether a Regulatory Authority may require the reporting of certain safety data and related Information for such applicable BioNTech Platform Products. The contents and frequency of such report shall be determined by the JDC. In the event that
Genentech determines that it may need to inform or report certain safety data and related Information for one or more BioNTech Platform Products, the Parties, through the JDC, shall discuss in good faith a path for providing such safety data and
related Information for such BioNTech Platform Products to a Regulatory Authority and BioNTech shall provide reasonable assistance to Genentech in order for Genentech to report such safety data and related Information. In the event that BioNTech may
not disclose such safety data and related Information to Genentech under relevant agreements concluded with Third Parties, BioNTech shall use reasonable efforts to enable Genentech to comply with its obligations under Applicable Law (e.g., if
requested by Genentech, through a direct communication with the Regulatory Authority requesting such safety data and related Information or by obtaining the consent from the relevant Third Party, if possible). Genentech shall provide to BioNTech
copies of all correspondence submitted to or received from any Regulatory Authority to the extent related to such safety data or related Information provided to Genentech under this Section 5.9. 

  
 - 54 - 

			
	Confidential	  	Execution Copy

  

 ARTICLE 6. 

COMMERCIALIZATION AND MEDICAL AFFAIRS 

6.1 Generally. 
 6.1.1
Commercialization of GDP Collaboration Products, Royalty Products and BioNTech Collaboration Products. Except as otherwise provided in this Agreement or any Co-Promotion Agreement, Genentech (itself
or through its Affiliates or Sublicensees) shall have the sole right to Commercialize each GDP Collaboration Product (including any Royalty Product) in the Territory and shall use Commercially Reasonable Efforts to Commercialize each GDP
Collaboration Product (including any Royalty Product) in the Major Markets and in each other market in the Territory in which it has obtained Marketing Authorization for such GDP Collaboration Product. Except as otherwise provided in this Agreement,
BioNTech shall have the right to Commercialize any BioNTech Collaboration Product under [***] Authorization, provided that [***] 
 6.1.2
Marketing of BioNTech Collaboration Products under [***]. In the event BioNTech has the right to Commercialize a BioNTech Collaboration Product under [***] in accordance with Section 5.1 and Section 6.1.1, BioNTech shall
have the sole right to conduct, at its sole cost and expense, marketing activities in connection with such Commercialization, as addressed further in Schedule 5.3. 

6.1.3 Value Creation. [***] 

6.2 Booking of Sales; Distribution. Genentech shall have the sole right to (a) invoice and book sales, establish all terms
of sale (including pricing and discounts), warehouse, and distribute GDP Collaboration Products (including Royalty Products) in the Territory and to perform or cause to be performed all related services and other Commercialization activities,
(b) handle all order processing, invoicing, collection, distribution, reimbursement services, and inventory management with respect to such GDP Collaboration Products (including Royalty Products) in the Territory, (c) handle all returns,
recalls, or withdrawals with respect to any GDP Collaboration Product (including any Royalty Product) in the Territory, (d) handle all payer/distributor account management with respect to any GDP Collaboration Product (including any Royalty
Product) in the Territory, and (e) manage all aspects of contracting with providers, distributors, managed care vendors or payers with respect to any GDP Collaboration Product (including any Royalty Product) in the Territory. BioNTech shall
have the sole right to do any of the above in relation to BioNTech Collaboration Products. 

  
 - 55 - 

			
	Confidential	  	Execution Copy

  

 6.3 Product Trademarks. Genentech shall have the sole right and responsibility
to determine the Product Trademarks to be used with respect to the Exploitation of the GDP Collaboration Products (including Royalty Products) on a worldwide basis, and to own any such Product Trademarks other than (in the event that Genentech
determines that the IVAC Trademark shall be a Product Trademark) the IVAC Trademark. BioNTech shall not, and shall not permit its Affiliates to (a) use in their respective businesses, any Trademark that is confusingly similar to, misleading or
deceptive with respect to or that dilutes any (or any part) of the Product Trademarks, or (b) do any act which endangers, destroys, or similarly affects, in any material respect, the value of the goodwill pertaining to the Product Trademarks.
BioNTech agrees, and shall cause its Affiliates, to conform (x) to the customary industry standards for the protection of Product Trademarks for Pharmaceutical Products and such guidelines of Genentech with respect to manner of use (as provided
in writing by Genentech) of the Product Trademarks, and (y) to maintain the quality standards of Genentech with respect to the goods sold and services provided in connection with such Product Trademarks. BioNTech shall not do any act which
endangers, destroys, or similarly affects, in any material respect, the value of the goodwill pertaining to the Product Trademarks. BioNTech shall not, and shall not permit its Affiliates to, attack, dispute, or contest the validity of or ownership
of such Product Trademark anywhere in the Territory or any registrations issued or issuing with respect thereto. The JCC shall approve any Product Trademarks to be used by BioNTech in connection with BioNTech Collaboration Products Commercialized
under [***] pursuant to Section 6.1.1, and shall decline to approve any such Product Trademarks that the JCC determines may be confusingly similar to the Product Trademarks being used to Commercialize GDP Collaboration Products. 

6.4 Product Labeling; Markings and Co-Branding. 

6.4.1 Genentech shall own and be responsible for all Product Labeling for all GDP Collaboration Products (including Royalty Products),
and BioNTech shall be responsible for all Product Labeling for all BioNTech Collaboration Products under [***] 
 6.4.2 To the extent
permitted and appropriate, and except as otherwise required by Applicable Law, and subject to obtaining necessary Regulatory Approvals in a country in the Territory, the packaging, and Product Labeling for any GDP Collaboration Product
(including any Royalty Product) and any promotional materials dedicated solely to a GDP Collaboration Product (including a Royalty Product) used by either Party or its Affiliates in connection with any GDP Collaboration Product (including any
Royalty Product) in such country shall contain, [***] (collectively, the “Markings”). The manner in which the Markings are to be presented on such promotional materials, packaging, and Product Labeling for GDP Collaboration Products
(including Royalty Products) shall be [***], subject to Sections 9.4 and 10.7. [***] 
 6.5
Co-Promotion Option. 
 6.5.1 Option. For each
Co-Promotion Candidate Product, [***], during the applicable Co-Promotion Exercise Period, subject to the requirements of this Section 6.5, BioNTech shall have the
right to assume [***] of the total sales force [***] measured in terms of FTEs (at a percentage within such range to be determined by Genentech), [***] in the Co-Promotion Potential Territory, [***], the
“Co-Promotion Territory”) (the “Co-Promotion Option”). 

  
 - 56 - 

			
	Confidential	  	Execution Copy

  

 6.5.2 Notice and Exercise. 

(a) No later than [***], BioNTech shall notify Genentech that BioNTech has an interest in exercising its
Co-Promotion Option [***]. Following receipt of such notice, Genentech shall (i) conduct a sales force sizing analysis for the applicable Co-Promotion Candidate
Product [***], and (ii) provide the results of such analysis, as soon as reasonably practicable, but in any event no later than [***] months before the anticipated date of Commercial Readiness, to BioNTech for review and comment along with the
percentage of such sales force for which BioNTech may exercise its Co-Promotion Option; provided that, following the first such BioNTech notice to Genentech that specifies countries other than or in addition
to the U.S., Genentech shall provide the results of such sales force sizing analysis for any such countries that are European Union countries no later than [***] months before the anticipated date of Commercial Readiness. 

(b) To exercise the Co-Promotion Option, BioNTech must provide Genentech with written notice of its
election to exercise the Co-Promotion Option for the offered percentage with respect to the applicable Co-Promotion Candidate Product (thereafter, a “Co-Promotion Product), [***] within [***] days following receipt of Genentech’s sales force analysis and percentage pursuant to Section 6.5.2(a). 

(c) Notwithstanding the foregoing, if after the end of the Co-Promotion Exercise Period, Genentech
exercises its Opt-In Right or a [***] occurs pursuant to Section 4.5.5, BioNTech shall automatically be deemed to have exercised its Co-Promotion Option with
respect to the applicable GDP Collaboration Products [***] in all of the countries in the Co-Promotion Potential Territory unless and to the extent BioNTech rejects such deemed exercise in writing within [***]
days of Genentech’s payment of the applicable BioNTech Indication Opt-In Fee. Any such deemed exercise of BioNTech’s Co-Promotion Option shall become effective
upon the earlier of the expiration of the [***]-day rejection period or BioNTech’s written notice to Genentech confirming its acceptance of such deemed exercise. 

(d) Except as set forth in subsection (c) above, if BioNTech does not provide the election notice described in subsection (b) prior
to expiration of the applicable Co-Promotion Exercise Period, BioNTech shall be deemed to have irrevocably waived its right to Co-Promote such Co-Promotion Candidate Product [***] 
 6.5.3 Co-Promotion
Agreement. Promptly after BioNTech’s first exercise of its Co-Promotion Option (or the effective date of a deemed exercise of BioNTech’s Co-Promotion
Option), the Parties shall commence negotiations in good faith and enter into a separate co-promotion agreement (the “Co-Promotion Agreement”) setting
forth the terms of BioNTech’s and Genentech’s Co-Promotion rights and obligations in accordance with the terms and conditions in this Section 6.5 and those set forth in
Schedule 6.5.3 attached hereto. The Parties shall negotiate with such diligence as is required to enter into and execute the Co-Promotion Agreement within [***] months
following BioNTech’s first exercise (including any deemed exercise) of its Co-Promotion Option, or such other date as the Parties may agree in writing. The Parties shall promptly amend the Co-Promotion Agreement upon each subsequent exercise or deemed exercise by BioNTech of its Co-Promotion Option (e.g., [***]. 

  
 - 57 - 

			
	Confidential	  	Execution Copy

  

 6.5.4 General Requirements for Co-Promotion
Activities. BioNTech shall not engage in any Detailing until the Co-Promotion Agreement has been executed. BioNTech may not use a contract sales force to fulfill its
Co-Promote obligations. Any BioNTech sales representatives involved in promoting a Co-Promotion Product shall devote [***] Under the
Co-Promotion Agreement, Genentech shall have the sole right to control all decisions with respect to the co-promotion arrangement, including the call plans and assigned
territories of BioNTech’s sales representatives, the promotional materials to be used, the training and testing applicable to such sales representatives, and restrictions with respect to the ability of such sales representatives to Detail other
products; provided that [***] “Co-Promote” or “Co-Promotion” means the Detailing and such other activities assigned to BioNTech in the Co-Promotion Agreement, and shall not include any Medical Affairs Activities, sale or distribution of such Co-Promotion Product [***] by BioNTech or its Affiliates. At least
[***] months prior to the anticipated launch of each Co-Promotion Candidate Product, BioNTech must have a qualified sales force in place (representing the percentage of the total sales force assigned to
BioNTech pursuant to Section 6.5.2(a)) with prior experience promoting products to prescribing oncologists in each relevant country. If BioNTech cannot demonstrate that it has such a qualified internal sales force [***] at least [***] months
prior to the launch of the applicable Co-Promotion Candidate Product [***], BioNTech shall be deemed to have irrevocably waived its right to Co-Promote such Co-Promotion Candidate Product in such Indications in such country(ies). 
 6.5.5 Effect of Opt-Out. BioNTech’s rights and obligations under this Section 6.5, including its Co-Promotion Option and any
Co-Promotion Agreement, shall terminate immediately upon exercise of BioNTech’s Opt-Out. 

6.6 Medical Affairs. 

6.6.1 General. Medical Affairs Activities are not intended to market or promote Collaboration Products. 

6.6.2 GDP Collaboration Products. Genentech shall have the sole right and responsibility to conduct and make decisions regarding
Medical Affairs Activities with respect to any GDP Collaboration Product. For clarity, Genentech shall retain such sole right and responsibility in the event that BioNTech exercises its Co-Promotion Option,
including under the Co-Promotion Agreement. 
 6.6.3 BioNTech Indications. For each BioNTech
Indication under [***], BioNTech shall have the sole right and obligation to conduct Medical Affairs Activities in relation to such BioNTech Indication, at BioNTech’s sole cost and expense. 

  
 - 58 - 

			
	Confidential	  	Execution Copy

  

 ARTICLE 7. 

MANUFACTURING 
 7.1
Manufacturing Development and Supply Agreement. That certain Manufacturing Development and Supply Agreement entered into by and among RNP, BNT, GNE and Roche as of even date herewith and effective as of the Effective Date (the
“Manufacturing Development and Supply Agreement”) shall govern the Parties’ respective responsibilities for and obligations with respect to Development of the Manufacturing Process and Technology Platform for Collaboration
Product, Clinical Manufacture and Commercial Manufacture and supply of Collaboration Product and the Manufacturing Network for Collaboration Product, including Clinical Facilities and Commercial Facilities and the Manufacturing Operations Strategy;
all of which shall be conducted under the oversight of the JMC. 
 7.2 Conflicts Between MDSA and Current Agreement. In the
event of a conflict between this Agreement and the MDSA, the following principles shall apply: (a) this Agreement controls with respect to governance, decision-making and financial matters, and (b) the MDSA governs with regard to matters
not falling within the categories specified in clause (a). 
 7.3 Effect of
Opt-Out. In the event BioNTech exercises its Opt-Out right, or a Deemed Opt-Out occurs pursuant to Section 8.5.3,
the following provisions shall apply upon the Opt-Out Commencement Date in respect of Development of the Manufacturing Process and Technology Platform and Manufacture of Collaboration Product. 

7.3.1 Development Services. During a transitional period until the earlier of (i) [***] and (ii) [***], BioNTech shall continue to
(a) develop the Manufacturing Process and the Technology Platform in accordance with the Technology Platform Strategy and Technology Platform Roadmap, each as may be amended from time to time; (b) conduct and support respective Technology
Transfers to the Facilities of Genentech and (c) provide technical support for the Manufacturing Process in the Facilities of Genentech. In addition, and without limiting the foregoing, Genentech may request that BioNTech (including EUFETS)
perform, to the extent not already completed and to enable Genentech to continue to develop the Manufacturing Process and Technology Platform, a Technology Transfer of the Manufacturing Process from the Clinical Facilities or the Pilot Facility to
Genentech, including the Development of the Manufacturing Process, Manufacturing Documentation and BioNTech Know-How and any other reasonable activities, including any such activities that may be on-going in support of the Technology Platform Strategy and Technology Platform Roadmap. The following shall apply in respect of any activities performed by BioNTech (including EUFETS) under this Section 7.3.1:

 (a) Genentech shall compensate BioNTech for the performance of such Development and Technology Transfer services at a rate equal to
BioNTech’s FTE Costs and consumables multiplied by one hundred fifteen percent (115%). 
 (b) Genentech may, at any time after the Opt-Out Commencement Date, terminate such Development and Technology Transfer services under this Section 7.3.1 upon [***] days’ written notice. 

(c) BioNTech shall perform the Development and Technology Transfer services in accordance with the requirements of the MDSA and the Quality
Agreement. 

  
 - 59 - 

			
	Confidential	  	Execution Copy

  

 7.3.2 Clinical Manufacture and Supply. During a transitional period until the earlier
of (i) [***] or (ii) [***], BioNTech shall perform Clinical Manufacture and supply the quantities of Collaboration Products for Clinical Studies contemplated by the GDP (as amended until the Opt-Out
Commencement Date) or for Genentech Studies pursuant to the patient demand forecasting provisions of the MDSA. The following shall apply in respect of any activities performed by BioNTech (including EUFETS) under this Section 7.3.2: 

(a) Genentech shall pay BioNTech a supply price for Collaboration Product equal to [***] 

(b) Genentech may at any time after the Opt-Out Commencement Date, terminate the clinical supply of
Collaboration Products under this Section 7.3.2 upon [***] written notice. 
 (c) During such time as BioNTech is obligated to provide
clinical supply of Collaboration Products, it shall perform the Clinical Manufacture of Collaboration Product in accordance with the requirements of the MDSA (including for the avoidance of doubt with respect to Capacities and forecasting) and the
Quality Agreement. 
 7.3.3 BioNTech Rights to Build Manufacturing Facilities and JMC Decision-Making Rights. BioNTech’s rights
to build any Commercial Facilities for inclusion in the Manufacturing Network pursuant to Section 2.2.2 of the MDSA and any Independent Facilities outside of the Manufacturing Network (including the Manufacture of BioNTech Indications under
[***]) pursuant to Section 2.2.5 of the MDSA, respectively, shall terminate upon the Opt-Out Commencement Date. In addition, BioNTech’s JMC decision-making rights as set forth in Section 2.8.2
shall terminate and become Genentech decision-making rights upon the Opt-Out Commencement Date. Notwithstanding the foregoing, in the event that BioNTech has completed Commissioning or obtained Licensure for a
BioNTech Commercial Facility(ies) upon the Opt-Out Commencement Date, then [***] 
 7.3.4
Survival. The MDSA, the Commercial Manufacturing Agreement and the respective Quality Agreement(s) shall survive solely to the extent that, and as long as, BioNTech provides Development services or Manufacturing and supply services under this
Section 7.3, and shall terminate thereafter except for those provisions specified in the MDSA, the Commercial Manufacturing Agreement and the respective Quality Agreement(s) which expressly survive termination. 

ARTICLE 8. 
 PAYMENTS AND
RECORDS 
 8.1 Upfront Payments. No later than [***] days following the Effective Date, Genentech shall pay BioNTech an
irrevocable upfront amount equal to [***] of which: 
 [***] 

  
 - 60 - 

			
	Confidential	  	Execution Copy

  

 Upon completion of the transfer of all documents, Know-How and
materials set forth on Schedule 2.19.1(a) and Schedule 2.19.3 in accordance with the terms of Sections 2.19.1(a) and 2.19.3, BioNTech shall provide written notice to Genentech of such completion. No later than [***] Business Days from
such notice, Genentech shall request any missing or incomplete documents, Know-How or materials set forth on Schedule 2.19.1(a) or Schedule 2.19.3. Subject to Section 10.9, no later than
[***] days following (a) Genentech’s confirmation that such transfer is complete and the transferred items are reasonably acceptable to Genentech in terms of content that would be reasonably expected for a transfer of this type, or
(b) the expiration of such [***] Business Day period without any Genentech request for missing or incomplete documents, Know-How or materials, Genentech shall pay BioNTech an additional amount equal to
[***]. In the initial BioNTech press release permitted under Section 11.4.2, BioNTech may describe the two payments under this Section 8.1 as “$310,000,000 in upfront and near term milestone payments”. [***]. 

8.2 Development Costs. 

8.2.1 Development Costs Relating to Ongoing Clinical Studies. BioNTech shall be solely responsible for and shall bear all Development
Costs incurred by it and its Affiliates in connection with the performance of the Ongoing Clinical Studies and any Melanoma Follow-Up Study conducted pursuant to Section 4.3.2.

8.2.2 Development Costs Relating to Joint Development Activities (i.e., Shared Development Costs). Except as otherwise provided herein,
each Party shall bear fifty percent (50%) of all Shared Development Costs. 
 (a) [***] 

(b) [***] 
 (c) Genentech shall
be solely responsible for and bear 100% of all Shared Development Costs incurred after the Opt-Out Commencement Date in the event of an Opt-Out by BioNTech or a Deemed Opt-Out pursuant to Section 8.5.3. 
 8.2.3 Forecasting of Development Costs. 

(a) Genentech shall provide to BioNTech consolidated non-binding forecasts of Shared Development Costs
in accordance with its regular internal forecasting processes for informational purposes only. This shall include forecasting of the GDP Budget for a given Calendar Year, regular variance updates to the then current Calendar Year forecast, and
multi-year outlooks. The forecasting process shall commence with the first forecast cycle at Genentech following the Effective Date and shall continue as long as there are forecasted Shared Development Costs. Genentech shall provide notice to
BioNTech [***] days prior to each forecast to request BioNTech’s forecast of Shared Development Costs that BioNTech expects to incur in connection with Joint Development Activities assigned to BioNTech in accordance with the relevant forecast
period. BioNTech will provide the appropriate data within [***] days of receipt of any such notice. 

  
 - 61 - 

			
	Confidential	  	Execution Copy

  

 (b) In addition, BioNTech shall inform Genentech if it determines that the Development Costs
relating to any BioNTech Study or any Ongoing Clinical Study which are expected to be incurred by BioNTech will likely exceed, in each case, the originally forecasted BioNTech budget by more than [***]. 

8.2.4 Shared Development Cost Overruns. [***] 

8.2.5 Development Costs Relating to BioNTech Studies. BioNTech shall bear one hundred percent (100%) of all Development Costs incurred
in connection with the performance of BioNTech Studies, subject to Section 4.5.5. In the event that Genentech incurs Development Costs in connection with a BioNTech Study, then such costs shall be reported to BioNTech within [***] days after
the end of each Calendar Quarter and reimbursed by BioNTech with [***] days after the end of such Calendar Quarter, and Genentech may offset the amounts of any such unpaid invoices from any payments due to BioNTech pursuant to Sections 8.2.7, 8.4.1,
and 8.7. The preceding sentence shall apply mutatis mutandis if BioNTech incurs Development Costs in connection with any Genentech Study. 

8.2.6 Development Costs and Reconciliation. Each Party shall report to the other Party, within [***] days after the end of each
Calendar Quarter, the Development Costs incurred by such Party during such Calendar Quarter for Joint Development Activities (unless the other Party has no obligation to reimburse such Development Costs). Such report shall specify in reasonable
detail all amounts included in such Development Costs during such Calendar Quarter (broken down by activity), and any FTE Costs and out-of-pocket costs shall be
allocated to the extent possible to a specific activity in the applicable GDP. Each such report shall enable the receiving Party to compare the reported Development Costs against the applicable GDP Budget previously approved by the JDC, on both a
quarterly basis and a cumulative basis for each activity. With respect to Shared Development Costs under the GDP (other than those following the effective date of an Opt-Out by BioNTech), the Parties shall
seek to resolve any questions related to such accounting statements within [***] days following receipt by each Party of the other Party’s report hereunder. Following such resolution, Genentech shall prepare a reconciliation report for the
Shared Development Costs under the GDP for such Calendar Quarter and shall either (a) deliver an invoice to BioNTech for any amounts due to Genentech as a result of reconciliation or (b) notify BioNTech that it should issue an invoice to
Genentech, if BioNTech is assigned activities under the GDP and its Shared Development Costs under the GDP exceed Genentech’s Shared Development Costs under the GDP for such Calendar Quarter. 

8.2.7 Shared Development Cost Reconciliation Payments. Shared Development Costs shall initially be borne by the Party (or its
Affiliates) incurring the cost or expense and thereafter shall be subject to reimbursement, if applicable, in accordance with Section 8.2.2, Section 8.2.6 and this Section 8.2.7. Within [***] days after the end of each Calendar
Quarter, following receipt of an invoice therefor from the other Party, the Party that has paid less than its share of Shared Development Costs during such Calendar Quarter shall make a reconciling payment to the other Party to achieve the
appropriate allocation of Shared Development Costs provided in Section 8.2.2. 

  
 - 62 - 

			
	Confidential	  	Execution Copy

  

 8.3 BioNTech Indication Opt-In Fee; Genentech
Indication Co-Funding Fee. 
 8.3.1 BioNTech Indication
Opt-In Fee. Upon Genentech’s exercise of its Opt-In Right or occurrence of a [***] with respect to a BioNTech Indication pursuant to Section 4.5.5,
BioNTech shall submit a written invoice to Genentech for the BioNTech Indication Opt-In Fee which shall set forth in reasonable detail all Development Costs incurred by BioNTech prior to the date of the
invoice for such BioNTech Indication. Genentech shall pay such invoice within [***] days following receipt thereof except in the event of a dispute regarding the invoiced amount, in which case the dispute shall be resolved pursuant to Sections 8.16
and 8.17, and Genentech shall pay such invoice within [***] days following the resolution of such dispute. The opt-in fee for a given BioNTech Indication shall be a
one-time fee equal to [***] (such amount, a “BioNTech Indication Opt-In Fee”). Following Genentech’s exercise of its Opt-In Right with respect to a BioNTech Indication, any future Development Costs for such Indication shall be considered Shared Development Costs and the applicable Collaboration Product shall thereafter be deemed a
GDP Collaboration Product (and no longer a BioNTech Collaboration Product).  
 8.3.2 Genentech Indication Co-Funding Fee. In the event BioNTech is required pursuant to Section 4.6.2 to pay a Genentech Indication Co-Funding Fee, then Genentech shall submit a written
invoice to BioNTech for such fee which shall set forth in reasonable detail all Development Costs incurred by Genentech prior to the date of the invoice for such Genentech Indication as to which BioNTech exercised the BioNTech Co-Funding Rejection plus [***] (“Genentech Indication Co-Funding Fee”). BioNTech shall pay such invoice within [***] days following receipt thereof except in
the event of a dispute regarding the invoiced amount, in which case the dispute shall be resolved pursuant to Sections 8.16 and 8.17, and BioNTech shall pay such invoice within [***] days following the resolution of such dispute. After the date of
such invoice, any future Development Costs for such Indication shall be considered Shared Development Costs. 
 8.4 Profit or Loss
Share. Commencing as of the First Commercial Sale in the Territory of a GDP Collaboration Product, in the event that BioNTech has not exercised its Opt-Out pursuant to Section 8.5, the terms
and conditions of this Section 8.4 shall govern each Party’s rights and obligations with respect to Net Profits and Net Losses relating to GDP Collaboration Products. Subject to this Section 8.4, (a) BioNTech shall receive fifty
percent (50%) of all Net Profits, and bear fifty percent (50%) of all Net Losses, as applicable, with respect to GDP Collaboration Products and (b) Genentech shall receive fifty percent (50%) of all Net Profits, and bear fifty percent (50%) of
all Net Losses. An example of a calculation of Net Profit/Loss and related settlement calculations is set forth on Schedule 8.4. This example is for illustration only and reflects only one possible scenario. 

8.4.1 Profit/Loss Split Reports and Payments. In the event that this Section 8.4 applies, each Party shall report to the other
Party within [***] days after the end of each Calendar Quarter commencing with the Calendar Quarter in which the First Commercial Sale in the Territory of a GDP Collaboration Product occurs, the elements of the Net Profit/Net Loss calculation,
including Net Sales and Allowable Expenses (including Fully-Burdened Manufacturing Cost) incurred by such Party during such Calendar Quarter. 

  
 - 63 - 

			
	Confidential	  	Execution Copy

  

 
Such report shall specify in reasonable detail all deductions allowed and taken in the calculation of Net Sales and all expenses included in Allowable Expenses. [***]. Within [***] days after
receipt of such reports, Genentech shall provide a consolidated financial statement setting forth the Net Profit or Net Loss for the Calendar Quarter. The following remittances shall be paid within [***] days after Genentech has provided the
consolidated financial statement: 
 (a) If there is a Net Profit for such Calendar Quarter, then Genentech shall pay to BioNTech an amount
equal to (i) fifty percent (50%) of the Net Profit for such Calendar Quarter, plus (ii) the Allowable Expense, if any, incurred by BioNTech in such Calendar Quarter; or 

(b) Subject to Section 8.4.1(d) below, if there is a Net Loss for such Calendar Quarter, then the Party that has borne less than fifty
percent (50%) of the Net Losses in in such Calendar Quarter shall make a reconciling payment to the other Party so that each Party bears a fifty percent (50%) share of the Net Losses during such Calendar Quarter. 

(c) [***] 
 (d) [***] 

(e) [***] 
 8.4.2 FTE Records
and Calculations. Each Party shall record and account for its FTE effort to the extent that such FTE efforts are included in Development Costs or Allowable Expenses that are, or may in the future be, shared (or the basis for determining a
BioNTech Indication Opt-In Fee or a Genentech Indication Co-Funding Fee) under this Agreement. Each Party shall calculate and maintain records of FTE effort incurred by
it in the same manner as used for other products Developed by such Party, unless other procedures are set forth in the Co-Promotion Agreement, in which case such other procedures shall be applied equally to
both Parties to the extent set forth in the Co-Promotion Agreement. 
 8.5 BioNTech Opt-Out Right. 
 8.5.1 Exercise of Opt-Out by BioNTech.
During the BioNTech Opt-Out Period, by written notice to Genentech, BioNTech shall have the right to opt-out of its obligation to pay fifty percent (50%) of all
future Shared Development Costs (“Opt-Out”) incurred after the Opt-Out commencement date set forth in the table below, or such later date in the table
below as may be specified in BioNTech’s notice (“Opt-Out Commencement Date”). In no event shall BioNTech shall have the right to Opt-Out if a
notice of termination of this Agreement has been delivered by either Party. For clarity, BioNTech shall continue to co-fund the GDP during the period between the exercise of its
Opt-Out and the Opt-Out Commencement Date. 

  
 - 64 - 

			
	Confidential	  	Execution Copy

  

 [***] 

8.5.2 Consequences of Opt-Out. In the event BioNTech exercises its Opt-Out (or a Deemed Opt-Out occurs pursuant to Section 8.5.3), then starting with the Opt-Out Commencement Date, (a) Net
Profits/Net Losses shall no longer be shared by the Parties pursuant to Section 8.4, and (b) Shared Development Costs shall no longer be shared by the Parties pursuant to Section 8.2.2, Section 8.2.6 and Section 8.2.7.
Instead, BioNTech shall receive as its sole future financial consideration, royalty payments on Net Sales of Royalty Products pursuant to Section 8.6. In addition, effective as of the Opt-Out Commencement
Date, the consequences set forth in Sections 2.18, 6.5.5 and 7.3 shall become effective immediately, and BioNTech shall become solely responsible for any Existing Third Party In-License Agreement Royalty
Payments, and, unless otherwise agreed in writing between the Parties, BioNTech shall cease all its activities under the Research Plan and all its Party Development Activities (to the extent permitted by Applicable Law) and transfer to Genentech all
data and other Know-How created in connection with the Party Development Activities and activities under the Research Plan or the CMC Development Plan in BioNTech’s possession and not previously
transferred to Genentech pursuant to Section 2.19. 
 8.5.3 Deemed Opt-Out. At
any time during the Term, if BioNTech is either (i) unable to pay or is late in paying (by [***] days or more with respect to any invoice) BioNTech’s portion of its Development Costs shared under Section 8.2.2 [***], Genentech may
provide BioNTech with written notice that an Opt-Out by BioNTech has been deemed to have occurred (“Deemed Opt-Out”), which notice shall state the
applicable Opt-Out Commencement Date, which shall be the first day of the Calendar Quarter following such default in payment. 

8.6 Royalties. 
 8.6.1
Royalty Rates. In lieu of sharing Net Profit/Net Loss, in the event of an Opt-Out by BioNTech pursuant to Section 8.5 or a Deemed Opt-Out pursuant to
Section 8.5.3, during the Royalty Term, and subject to Section 8.6.3, Genentech shall pay to BioNTech [***] (the “Royalty Rate”) on annual worldwide Net Sales of each Royalty Product which, at the time of sale, is Covered
by a Valid Claim included in the [***] 
 8.6.2 Royalty Term. Genentech shall have no obligation to pay any royalty with respect to
Net Sales of any Royalty Product in any country after the Royalty Term for such Royalty Product in such country has expired. Upon expiry of Genentech’s payment obligation under this Section 8.6 with respect to a Royalty Product in a
country, the license in Section 9.1.1 shall be fully paid-up, royalty-free and irrevocable in respect of that Royalty Product in that country. 

  
 - 65 - 

			
	Confidential	  	Execution Copy

  

 8.6.3 Reductions. Notwithstanding the foregoing: 

(a) in the event that [***] during the Royalty Term for a Royalty Product, one or more Competitive Products are sold [***], then the Royalty
Rate applicable to Net Sales of Royalty Products [***] shall be reduced to [***] for the remainder of the Royalty Term, [***]; 
 (b) in the
event that Genentech obtains rights or licenses from a Third Party under Third Party IP pursuant to Section 10.6, Genentech shall be entitled to deduct [***]; 

(c) [***]; and 
 (d) at
Genentech’s election, Genentech shall have the right to offset from future royalties under this Section 8.6 any unpaid deferred Development Costs that have come due under Section 8.2.2. 

8.7 Royalty Payments and Reports. Genentech shall calculate all amounts payable to BioNTech pursuant to Section 8.6 at the
end of each Calendar Quarter, which amounts shall be converted to Dollars, in accordance with Section 8.9. Genentech shall pay to BioNTech the royalty amounts due with respect to a given Calendar Quarter within [***] days after the end of such
Calendar Quarter. Each payment of royalties due to BioNTech shall be accompanied by a statement of the amount of Net Sales of each Royalty Product in the Territory during the applicable Calendar Quarter converted to Dollars and a calculation of the
amount of royalty payment due on such Net Sales for such Calendar Quarter. Without limiting the generality of the foregoing, Genentech shall require its Affiliates and Sublicensees to account for their Net Sales and to provide such reports with
respect thereto as if such sales were made by Genentech. 
 8.8 Apportionment of Compulsory Sublicensee Consideration. 

[***]. 
 8.9 Mode of Payment;
Offsets. All payments to either Party under this Agreement shall be made by deposit of Dollars in the requisite amount to such bank account as the receiving Party may from time to time designate by notice to the paying Party. As of
the Execution Date, that applicable bank account for payments to each Party is set forth in Schedule 8.9. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of
Net Sales expressed in currencies other than Dollars), a Party shall convert any amount expressed in a foreign currency into Dollar equivalents using the then-current internal foreign currency translation method actually used by such Party on a
consistent basis in preparing its audited financial statements. Either Party shall have the right to offset any expense that is owed by the other Party but not paid against any payments owed by either Party, if any, under this Agreement. 

  
 - 66 - 

			
	Confidential	  	Execution Copy

  

 8.10 Accounting Procedures. For purposes of determining Development Costs and
Allowable Expenses, any expense allocated by either Party to a particular expense category of Development Costs or Allowable Expenses shall not also be allocated to another category under Development Costs or Allowable Expenses. Each Party shall
determine Development Costs and Allowable Expenses using its standard accounting procedures, consistently applied, to the maximum extent practicable as if the Collaboration Product were a solely-owned product of the Party (provided that the
application of such procedures results, on balance, in outcomes that are fair and equitable to both Parties taking into consideration the interests of both Parties as reflected in this Agreement). The Parties also recognize that such procedures may
change from time to time and that any such changes may affect the calculation of Development Costs, Allowable Expenses, and such other expenses. Where the change is or would be material to the other Party, the Party proposing to make the change
shall provide the other Party with an explanation of the proposed change and an estimation of the effect of the change on the relevant cost or expense category. The Parties shall use good faith efforts to negotiate any resulting changes to this
Agreement so as to preserve as closely as reasonably possible the Parties’ respective economic interests under this Agreement. Transfers between a Party and its Affiliates (or between such Affiliates) shall not have any effect for purposes of
calculating Development Costs, Allowable Expenses, or other payments or expenses under this Agreement. 
 8.11 Taxes. 

8.11.1 Each Party will make all payments to the other Party under this Agreement without deduction or withholding for Taxes except to
the extent that any such deduction or withholding is required by law in effect at the time of payment. 
 8.11.2 Any Tax required to
be withheld on amounts payable under this Agreement will promptly be paid by the Party making the payment (the “Payor”) on behalf of the Party receiving the payment (the “Payee”) to the appropriate
Governmental Authority, and Payor will furnish Payee with proof of payment of such Tax. 
 8.11.3 Each Party agrees to use
commercially reasonable efforts to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or any similar agreement or treaty from time to time in force and in minimizing the amount required to be so
withheld or deducted.  
 8.11.4 All amounts payable under or provided for in this Agreement shall be exclusive of any
amount in respect of VAT. If VAT is applicable on any amount payable under this Agreement and the reverse charge procedure does not apply, then the Payor shall pay an additional amount equal to VAT on that amount; provided it has first received a
valid invoice for the supply, save when the reverse charge procedure applies. Valid invoices must include all relevant information as stated in any applicable guideline or as defined by other local rules and regulations as the case may be.
 
 8.11.5 To the extent the activities of the Parties under this Agreement result in the recognition of a partnership for non-U.S. Tax purposes, the Parties agree that any non-U.S. Tax imposed at the level of the partnership on its profit (not including Tax required to be withheld to satisfy a
Party’s own income tax obligation) shall be allocated and borne by the Parties according to the partnership profit allocation under the respective applicable tax law. 

  
 - 67 - 

			
	Confidential	  	Execution Copy

  

 8.11.6 In the event of a conflict between this Agreement and any Ancillary Agreement,
this Agreement shall control with respect to Tax matters. Solely for purposes of this Section 8.11, “Tax” or “Taxes” means any present or future taxes, levies, imposts duties, charges, assessments or
fees of any nature (including interest, penalties and additions thereto). 
 8.12 Interest on Late Payments. If any
payment due to either Party under this Agreement is not paid when due, then such paying Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of [***], such interest to run
from the date on which payment of such sum became due until payment thereof in full together with such interest. 
 8.13 Tax Returns.

 [***] 
 8.14 Financial
Records. Each Party shall, and shall cause its Affiliates to, keep complete and accurate books and records pertaining to Development Costs, Net Sales, Fully-Burdened Manufacturing Costs, Allowable Expenses and, with limiting the
foregoing, elements in the calculation of Net Profits/Net Losses, as applicable, and Development of Collaboration Products in sufficient detail to calculate all amounts payable hereunder and to verify compliance with its obligations under this
Agreement. Such books and records shall be retained by such Party and its Affiliates until the later of (a) [***] after the end of the period to which such books and records pertain, and (b) the expiration of the applicable tax statute of
limitations (or any extensions thereof), or for such longer period as may be required by Applicable Law. 
 8.15 Invoices. Each
invoice issued pursuant to this Article 8 shall refer to this Agreement and identify the trigger for the payment obligation. Unless otherwise requested by Genentech in writing, BioNTech shall send invoices to Genentech at the address for GNE in the
preamble of this Agreement, to the attention of [***]. With respect to invoices issued by Genentech, Genentech shall send invoices to BioNTech at: 

Biontech RNA Pharmaceuticals GmbH 

Attn: [***] 
 An der Goldgrube
12 
 55131 Mainz, Germany. 

  
 - 68 - 

			
	Confidential	  	Execution Copy

  

 8.16 Audit. At the request of the other Party, each Party shall, and
shall cause its Affiliates to, permit an independent auditor designated by the other Party and reasonably acceptable to the audited Party, at reasonable times and upon reasonable notice, to audit the books and records maintained pursuant to
Section 8.14 to ensure the accuracy of all reports and payments made hereunder. Such examinations may not (a) be conducted for any Calendar Quarter more than [***] after the end of such quarter, (b) [***] or (c) [***]. Except as
provided below, the cost of this audit shall be borne by the auditing Party, unless the audit reveals a variance of more than [***] from the reported amounts, in which case the audited Party shall bear the cost of the audit. Unless disputed pursuant
to Section 8.17 below, if such audit concludes that (i) additional amounts were owed by the audited Party, the audited Party shall pay the additional amounts, with interest from the date originally due as provided in Section 8.12, or
(ii) excess payments were made by the audited Party, the auditing Party shall reimburse such excess payments, in either case ((i) or (ii)), within [***] days after the date on which such audit is completed by the auditing Party. 

8.17 Audit Dispute. In the event of a dispute with respect to any audit under Section 8.16, BioNTech and Genentech
shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days, either Party may submit the dispute for resolution to a certified public accounting firm
jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Arbitrator”). The decision of the Arbitrator shall be final and the costs of such arbitration as
well as the initial audit shall be borne between the Parties in such manner as the Arbitrator shall determine. Not later than [***] days after such decision and in accordance with such decision, the audited Party shall pay the additional
amounts, with interest from the date originally due as provided in Section 8.12, or the auditing Party shall reimburse the excess payments, as applicable. 

8.18 Confidentiality. The receiving Party shall treat all information subject to review under this Article 8 in accordance
with the confidentiality provisions of Article 11 and the Parties shall cause the Arbitrator to enter into a reasonably acceptable confidentiality agreement with the audited Party obligating such firm to retain all such financial information in
confidence pursuant to such confidentiality agreement. 
 ARTICLE 9. 

GRANT OF RIGHTS 
 9.1
Licenses to Genentech.  
 9.1.1 Exclusive License. BioNTech hereby grants to Genentech an
exclusive (subject to [***], non-transferable (other than in connection with a permitted assignment of this Agreement), sublicensable (only in accordance with Section 9.3) license, under the
BioNTech IP (including the Know-How and Patents related to the Manufacturing Process which includes the IVAC 2.0 Process, the IVAC 2.1 Process, any IVAC x.y Process and the Commercial Manufacturing
Process) and BioNTech’s interest in the Collaboration IP (subject in the case of [***] subject to [***], to (a) research, develop, make, have made, use, offer for sale, sell and import Pharmaceutical Products that comprise
(i) one or more Neoepitope RNA(s), [***] in the Field in the Territory and (b) otherwise perform its obligations under this Agreement and the Ancillary Agreements, provided that [***] 

  
 - 69 - 

			
	Confidential	  	Execution Copy

  

 9.1.2 Non-Exclusive License. [***] 

9.1.3 No License. Notwithstanding the license granted in Section 9.1.1, nothing in this Agreement shall be deemed to grant to
Genentech any license or other rights under the BioNTech IP to [***]  
 9.1.4 Notice Rights. [***] 

9.2 Licenses to BioNTech. 

9.2.1 License; Grant Back License. 

(a) Genentech hereby grants to BioNTech an exclusive (subject to Genentech’s rights under Section 4.5.5 and Genentech’s
obligations under MDSA), non-transferable (other than in connection with a permitted assignment of this Agreement), sublicensable (only in accordance with Section 9.3) license, under the
Genentech IP, the BioNTech IP (to the extent exclusively licensed to Genentech under Section 9.1.1) and Genentech’s interest in the Collaboration IP (to the extent exclusively licensed to Genentech under Section 9.1.1) (in
the case of Collaboration Product Clinical Study Data, subject to Section 11.6), to (a) research, develop, make, have made, use, and import BioNTech Collaboration Products solely in connection with the Conduct of the BioNTech Studies and
(b) Conduct the Ongoing Clinical Studies in accordance with Section 4.3.1 and any related follow-up clinical study to the extent permitted under and in accordance with Section 4.3.2; provided
that, [***]. 
 (b) Genentech hereby grants to BioNTech a non-exclusive, non-transferable (other than in connection with a permitted assignment of this Agreement), sublicensable (only in accordance with Section 9.3) license, under the Genentech IP (excluding any Neoepitope
Prediction Algorithm within the Genentech IP which is the subject of the license set forth in Section 9.2.2), the BioNTech IP (to the extent licensed to Genentech under Section 9.1.1) and the Collaboration IP (but in the case of
Collaboration Product Clinical Study Data, subject to Section 11.6) (i) to perform its obligations under this Agreement and the Ancillary Agreements (including any Co-Promotion Agreement) and (ii) to
construct and use Commercial Facilities as set forth in Section 2.2.4 of the MDSA. 
 (c) Subject to, and effective only upon
expiration of, Genentech’s Opt-In Rights and [***] pursuant to Section 4.5.5, Genentech hereby grants to BioNTech an exclusive, non-transferable (other than in
connection with a permitted assignment of this Agreement), sublicensable (only in accordance with Section 9.3) license, under the Genentech IP, the BioNTech IP (to the extent exclusively licensed to Genentech under Section 9.1.1) and
Genentech’s interest in the Collaboration IP (to the extent exclusively licensed to Genentech under Section 9.1.1) (in the case of Collaboration Product Clinical Study Data, subject to Section 11.6), to offer for sale, sell or
import BioNTech Collaboration Products. 

  
 - 70 - 

			
	Confidential	  	Execution Copy

  

 9.2.2 Non-Exclusive License. [***].
 
 9.2.3 No License. Notwithstanding the licenses granted in Section 9.2.1, nothing in this Agreement shall be deemed
to grant to BioNTech any license or other rights under the Genentech IP to [***]. 
 9.3 Sublicenses; Exercise of Licensed Rights by Third
Parties or Affiliates. Either Party may sublicense the rights under the licenses granted to it under Sections 9.1.1, 9.2.1, 9.4 and 9.5 to its permitted subcontractors hereunder (subject to Sections 3.2 and 4.4.4) or under any Ancillary
Agreement (or in the case of Genentech, [***] without the other Party’s consent, provided that such Party (1) shall remain directly responsible for all of its obligations under this Agreement that have been, so subcontracted or
sublicensed and (2) shall ensure that such subcontractors and sublicensees comply with the terms and conditions of this Agreement, including the intellectual property provisions and confidentiality provisions of this Agreement. Subject to
Sections 3.2 and 4.4.4, the rights under the licenses granted in Sections 9.1.1 and 9.1.2 and Sections 9.2.1 and 9.2.2 may be exercised by a Third Party on behalf of a Party (or a permitted sublicensee) without the grant of a sublicense of such
rights. Either Party may exercise its rights and perform its obligations under this Agreement by itself or through the engagement of any of its Affiliates. Any other sublicensing under Section 9.1.1 or 9.2.1 shall require the other Party’s
prior written consent. For the avoidance of doubt, any sublicenses granted hereunder shall terminate automatically upon the termination of the relevant main license granted hereunder. As between the sublicensing Party and its Sublicensee, any
intellectual property made as a result of the performance of such activities by such Sublicensee shall be Controlled by the sublicensing Party. In the event that such intellectual property would, if it were made by a Party, be Collaboration IP, then
such intellectual property shall be Collaboration IP. In the event that such intellectual property would, if it were made by a Party, be BioNTech IP or Genentech IP, then such intellectual property is hereby licensed to the other Party subject to
Section 9.1 or 9.2, as applicable. 
 9.4 Trademark and Corporate Names Licenses. BioNTech hereby grants to Genentech a
worldwide, fully-paid, non-exclusive license, with the right to grant sublicenses solely as provided in Section 9.3 and subject to Section 10.7.1, to use the Corporate Names of BioNTech, solely in
connection with the exercise of Genentech’s rights and fulfillment of Genentech’s obligations under Section 6.4. BioNTech hereby grants to Genentech a worldwide, fully-paid, exclusive license, with the right to grant sublicenses
solely as provided in Section 9.3, and subject to Section 10.7, to use the IVAC Trademark as a Product Trademark in connection with the exercise of Genentech’s rights and obligations under this Agreement if Genentech sees fit to also
use the IVAC Trademark as a Product Trademark. In the event that the Parties enter into a Co-Promotion Agreement, Genentech shall grant to BioNTech a non-exclusive
license to use the Corporate Names of Genentech and any Product Trademarks in connection with BioNTech’s activities under such agreement. 

  
 - 71 - 

			
	Confidential	  	Execution Copy

  

 9.5 Rights of Reference or Use. 

9.5.1 In the event that BioNTech [***] pursuant to Sections 4.5 and 5.3, effective as of the date of filing, Genentech hereby grants
(and shall cause its Affiliates and Sublicensees under the license granted in Section 9.1.1 to grant) to BioNTech during the Term a non-exclusive, non-transferable
(other than in connection with a permitted assignment of this Agreement but not in connection with a Change in Control except as otherwise provided in Section 15.2) Right of Reference or Use (with the right to grant further rights of reference
to Affiliates, Sublicensees and any exclusive distributor in any country in which BioNTech uses an exclusive distributor for its products) to [***] Genentech will provide a letter to FDA or the applicable Regulatory Authority confirming such Right
of Reference or Use in support of a [***]. For clarity, notwithstanding any grant to BioNTech of a Right of Reference or Use pursuant to this Section 9.5, BioNTech shall have no rights to any Genentech Molecule Clinical Trial Data, any
Genentech IP (except as licensed pursuant to Section 9.2) or any other intellectual property Controlled by Genentech or any of its Affiliates or sublicensees. 

9.5.2 BioNTech hereby grants (and shall cause its Affiliates and Sublicensees under the license granted in Section 9.2.1 to grant)
to Genentech during the Term a non-exclusive, non-transferable Right of Reference or Use to [***] BioNTech will provide a letter to FDA or the applicable Regulatory
Authority confirming such Right of Reference or Use in support of a Genentech IND or Genentech Marketing Authorization. For clarity, notwithstanding any grant to Genentech of a Right of Reference or Use pursuant to this Section 9.5, Genentech
shall have no rights to any Clinical Data or other intellectual property, in both cases, that is solely related to any Combination Agent Controlled by BioNTech or any of its Affiliates or sublicensees. 

9.6 Genentech Rights of First Negotiation. Genentech shall have rights to engage in exclusive negotiations with BioNTech
and certain other related rights as set forth in this Section 9.6. 
 9.6.1 [***] 

9.6.2 [***] 
 9.6.3
ROFN Procedures. “ROFN Licensable Subject Matter” means each combination of products under Section 9.6.1 or each [***] under Section 9.6.2, as with respect to which Genentech has a right of first negotiation under such
Section. “ROFN” means, with respect to each ROFN Licensable Subject Matter, Genentech’s right to engage in exclusive negotiations for such ROFN Licensable Subject Matter before BioNTech licenses, grants, or otherwise transfers,
including by option or sale, to any Third Party any rights to develop manufacture, commercialize, make, have made, use, offer for sale, sell and import (or any exclusive rights to research), in whole or in part, such ROFN Licensable Subject Matter
in the Field in the Territory as set forth in this Section 9.6. 
 (a) Notice. At any time during the Term (with respect to ROFN
Licensable Subject Matter under Section 9.6.1) prior to [***] or at any time during the Term prior to the [***] (with respect to ROFN Licensable Subject Matter under Section 9.6.2), in the event that BioNTech intends to license, grant, or
otherwise transfer, including by option or sale, to any Third Party any rights to develop, manufacture, commercialize, make, have made, use, offer for sale, sell and import (or any exclusive rights to research), in whole or in part, any ROFN
Licensable Subject Matter, BioNTech shall so notify Genentech in writing and [***] “ROFN Notice”). 

  
 - 72 - 

			
	Confidential	  	Execution Copy

  

 (b) ROFN Exercise. Genentech may exercise a ROFN with respect to a ROFN
Licensable Subject Matter by providing written notice to BioNTech (a “ROFN Election Notice”) at any time during the period commencing on the first date on which Genentech has received the ROFN Notice and ending [***] days thereafter
(the “ROFN Exercise Period”) with respect to such ROFN. 
 (c) ROFN License Agreement. If Genentech
exercises a ROFN with respect to a ROFN Licensable Subject Matter during the ROFN Exercise Period, then during the period beginning on the date Genentech provides the ROFN Election Notice to BioNTech and ending [***] thereafter (or such later date
as may be mutually agreed by the Parties) (the “ROFN Negotiation Period”), the Parties shall negotiate in good faith the terms and conditions of an agreement pursuant to which Genentech or an Affiliate of Genentech would obtain the
exclusive rights to develop, manufacture, commercialize, make, have made, use, offer for sale, sell and import (and the non-exclusive right to research) such ROFN Licensable Subject Matter in the Field in the
Territory (a “ROFN License Agreement”). 
 (d) Genentech Failure to Exercise. If (i) Genentech does not
deliver a ROFN Election Notice to BioNTech with respect to the applicable ROFN Licensable Subject Matter during the applicable ROFN Exercise Period or (ii) Genentech and BioNTech do not agree on the terms of a ROFN License Agreement despite
good faith negotiations with respect to the applicable ROFN Licensable Subject Matter during the applicable ROFN Negotiation Period, then, in either case (i) or (ii), BioNTech shall be free to grant to a Third Party rights to research, develop,
manufacture, commercialize, make, have made, use, offer for sale, sell and import, in whole or in part, such ROFN Licensable Subject Matter in the Field in the Territory; provided that, in the case of (ii) above, during the [***],
BioNTech shall not grant to a Third Party rights to research, develop, manufacture, commercialize, make, have made, use, offer for sale, sell and import, in whole or in part, such ROFN Licensable Subject Matter in the Field in the Territory on terms
and conditions [***] 
 9.7 Exclusivity. For a period of [***] years after the Effective Date (such period, the
“Exclusivity Period”), none of (a) [***], and (b) BioNTech and its Affiliates shall carry out, conduct or engage in any activity, by itself or with or through any Third Party, directly or indirectly, to research, develop,
manufacture, commercialize, make, have made, use, offer for sale, sell and import any Pharmaceutical Products comprising one or more Neoepitope RNA(s) in the Field other than pursuant to and in accordance with this Agreement; provided,
however that such restriction does not restrict any of the foregoing Persons from conducting internal research and preclinical development for benchmarking purposes on Pharmaceutical Products comprising one or more Neoepitope RNA(s) that are
Third Party Products at the time of such research or preclinical development. [***] 

  
 - 73 - 

			
	Confidential	  	Execution Copy

  

 ARTICLE 10. 

INTELLECTUAL PROPERTY 

10.1 Disclosure. During the Term, without limiting Section 2.19.2, each Party shall promptly disclose to the other Party
[***] 
 10.2 Ownership; Assignment and Cooperation; Inventorship. 

10.2.1 Ownership of Intellectual Property. As between the Parties: 

(a) BNT or RNP (as applicable) shall solely own the BioNTech IP, 

(b) [***] 
 (c) [***] 

10.2.2 Assignment and Cooperation. The assignments necessary to accomplish the ownership provisions set forth in this Article 10 are
hereby made, and each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and cooperation to implement the provisions of this Article 10. Accordingly, each Party
(“Assignor”) hereby irrevocably assigns to the other Party (“Assignee”) an equal, undivided interest in and to all right, title, and interest in and to Collaboration IP. Assignor agrees to execute such documents,
render such assistance, and take such other action as an Assignee may reasonably request, to apply for, register, perfect, confirm, and protect Assignee’s rights in all Collaboration IP. Each Party shall require, to the extent legally possible
under relevant national or local laws, all of its employees, Affiliates and any Third Parties working pursuant to this Agreement on its behalf, to assign (or otherwise convey rights) to such Party its right, title and interests in any Patents and Know-How conceived, reduced to practice, created or otherwise made by such employee, Affiliate or Third Party, and to cooperate with such Party in connection with obtaining patent protection therefor. 

10.2.3 Inventorship and Authorship. Inventorship and authorship shall be determined in accordance with the Applicable Laws of the
United States regarding patents and copyrights, respectively; provided, however, that in the event that determining inventorship or authorship in accordance with such Applicable Laws would be in violation of the Applicable Laws of the country
or jurisdiction in which such invention or creation was made or created, inventorship or authorship, as applicable, shall be determined in accordance with the Applicable Laws of such country or jurisdiction. 

10.2.4 CREATE Act. This Agreement shall be deemed a joint research agreement under the Cooperative Research and Technology Enhancement
Act of 2004, 35 U.S.C. §102(c) (the “CREATE Act”), and any foreign counterparts thereto, entered into for the purpose of researching, identifying and developing products comprising one or more Neoepitope RNA(s) including
Collaboration Products and under the terms set forth herein. 

  
 - 74 - 

			
	Confidential	  	Execution Copy

  

 10.3 Patent Prosecution and Maintenance. 

10.3.1 Patent Prosecution and Maintenance Control. As between the Parties: 

[***] 
 10.3.2 Patent
Prosecution and Maintenance Cooperation. Solely with respect to the rights and obligations described in this Section 10.3, the Party that has the right to Prosecute and Maintain the BioNTech Patents, BioNTech Core Patents, Genentech
Patents, Genentech Core Patents or Collaboration Patents, as applicable, will be referred to as the “Controlling Party” and the other Party will be referred to as the “Non-Controlling
Party”. During the Term, the Parties agree to cooperate fully in the preparation, filing, prosecution, and maintenance of the BioNTech Patents, BioNTech Core Patents, Genentech Patents, Genentech Core Patents and Collaboration Patents in
the Territory. Notwithstanding which Party is the Controlling Party, the Parties shall agree, on a country by country basis, on preferably the same outside patent counsel firms to be responsible for the Prosecution and Maintenance of the BioNTech
Core Patents, Genentech Core Patents and Collaboration Patents on behalf of each Party as the Controlling Party (each, an “Outside Patent Prosecution Counsel”); [***] Cooperation shall include: 

(a) The Non-Controlling Party shall, at the Controlling Party’s reasonable request, assist and
cooperate in the Prosecution and Maintenance of the BioNTech Patents, BioNTech Core Patents, Genentech Patents, Genentech Core Patents or Collaboration Patents, including making its relevant scientists and scientific records reasonably available to
the Controlling Party, executing all papers and instruments (including assignment of invention agreements and powers of attorney) and requiring its employees or contractors to execute such papers and instruments. 

(b) [***] 
 (c) [***] 

  
 - 75 - 

			
	Confidential	  	Execution Copy

  

 (d) [***] 

10.4 [***] 
 10.5
Enforcement and Defense of Patents; Defense of Claims by Third Parties . 
 10.5.1 Notice. Each Party shall promptly notify, in
writing, the other Party upon learning of: 
 (a) any actual, alleged, or suspected infringement, misappropriation or misuse by a Third
Party of a BioNTech Core Patent, Genentech Core Patent, Collaboration Patent or any Know-How or Patent related to the Neoepitope Prediction Algorithm (within the BioNTech IP, Genentech IP or Collaboration IP)
or any reexaminations, inter partes reviews, and post grant reviews as well as interferences and derivation proceedings, oppositions and other similar proceedings or claim of declaratory judgment brought by a Third Party alleging the invalidity,
unpatentability, unenforceability, or non-infringement of any such BioNTech Core Patent, Genentech Core Patent or Collaboration Patent (including receipt of a copy or knowledge of a Biosimilar Application
under Section 351(l)(1)(B)(iii) or Section 351(l)(8)(A) of the PHSA (or other Applicable Law in the relevant jurisdiction) or alleging misappropriation or misuse of any Know-How or Patent related to
the Neoepitope Prediction Algorithm (within the BioNTech IP, Genentech IP or Collaboration IP)) (each an “Infringement”), and 

(b) any notice, allegation, suit, or other proceeding against BioNTech or Genentech, or any of their respective Affiliates or licensees or
customers, of infringement, misappropriation or misuse of any intellectual property rights as a result of the Exploitation of any Collaboration Product or any Neoepitope Prediction Algorithm (“Third Party Infringement Claim”). 

In each case ((a) or (b)), the Party providing notice shall promptly notify the other Party and use commercially reasonable efforts to provide all evidence in
its possession pertaining to the Infringement, claim or suit that it can disclose without breach of pre-existing obligations to a Third Party or waiver of privilege. [***] 

10.5.2 Enforcement and Defense Actions Against Infringements. 

(a) [***] 
 (b) [***] 

  
 - 76 - 

			
	Confidential	  	Execution Copy

  

 (c) [***] 

(d) [***] Collaboration Patents in the Territory or to Enforce against any misappropriation or misuse of any
Know-How or Patent related to the Neoepitope Prediction Algorithm within the Collaboration IP (including any Genentech IP or BioNTech IP (other than BioNTech Core Patents) incorporated therein). If Genentech
declines to Enforce against an Infringement that constitutes a substantial risk to the overall value of such Collaboration Patent in the applicable country within the Territory or any misappropriation or misuse of any
Know-How or Patent related to the Neoepitope Prediction Algorithm within the Collaboration IP, then: (i) Genentech shall provide BioNTech with reasonable advanced written notice of such decision [***]

 10.5.3 Third Party Infringement Defense Actions. Notwithstanding Section 13.5, for any Third Party Infringement Claim,
Genentech (with respect to any Third Party Infringement Claim as to (a) GDP Collaboration Product(s) or Genentech Collaboration Product(s) alone, (b) at least one GDP Collaboration Product or Genentech Collaboration Product, on the one
hand, and at least one BioNTech Collaboration Product, on the other hand, or (c) as to any Know-How or Patent related to the Neoepitope Prediction Algorithm within the Collaboration IP (including any
Genentech IP or BioNTech IP incorporated therein) and BioNTech (with respect to any Third Party Infringement Claim that does not include any GDP Collaboration Product or Genentech Collaboration Product but includes a BioNTech Collaboration Product)
shall have the right, but not the obligation, to defend and control the defense of any such Third Party Infringement Claim, including directing all aspects, stages, motions, and proceedings of litigation (“Defend” or
“Defense”). In the event the Party with the right to defend against a Third Party Infringement Claim under this Section 10.5.3 does not elect to assume the defense of such Third Party Infringement Claim (“Non-Defending Party”) and the other Party (“Defending Party”) has the obligation to assume the defense of such Third Party Infringement Claim under Section 13.5 or the other Party is
the defendant against which the Third Party Infringement Claim was made, then the Non-Defending Party shall provide to the Defending Party with reasonable advanced written notice of such decision so as to
permit the Defending Party to take appropriate action in accordance with this Agreement, [***] 
 10.5.4 Cooperation. Solely with
respect to the rights and obligations described in this Section 10.4, the Party that has the right to Enforce against the Infringement or Defend against the Third Party Infringement Claim, will be referred to as the “Controlling
Litigation Party” and the other Party will be referred to as the “Non-Controlling Litigation Party”. Notwithstanding which Party is the Controlling Litigation Party, the Parties shall
agree on an outside patent counsel firm to be responsible for the Enforcement against an Infringement and Defense of a Third Party Infringement Claim on behalf of the Controlling Litigation Party (“Outside Patent Litigation
Counsel”). Cooperation shall include: 

  
 - 77 - 

			
	Confidential	  	Execution Copy

  

 (a) The Non-Controlling Litigation Party shall
cooperate with the Controlling Litigation Party in any such action to Enforce against any Infringement or Defend against any Third Party Infringement Claim or raising of any counter claim in connection with the Enforcement or Defense as described in
this Section 10.4, including, if necessary, by being joined as a party, provided the Non-Controlling Litigation Party shall have the right to be represented by their own counsel at their own expense
(notwithstanding any other cost allocation provision of this Agreement). The Outside Patent Litigation Counsel shall lead the Enforcement against the Infringement or Defense against the Third Party Infringement Claim with respect to any other
counsel participation in the Enforcement or Defense. 
 (b) The Controlling Litigation Party shall, through Outside Patent Litigation
Counsel, keep the other Party reasonably informed of all material developments in connection with any such Infringement or Third Party Infringement Claim, including providing the other Party with copies of draft and filed filings, motions, pleadings
and other material submissions and communications (including oral communications) with the relevant judicial authority relating to such Infringement or Third Party Infringement Claim, sufficiently in advance, where reasonable, for the Non-Controlling Litigation Party to comment, through Outside Patent Litigation Counsel, on the Enforcement against or Defense of such Infringement or Third Party Infringement Claim. The Controlling Litigation Party
shall give due consideration to the Non-Controlling Litigation Party’s comments with respect to the Enforcement against or Defense of such Infringement or Third Party Infringement Claim under this
Section 10.4. Notwithstanding the foregoing, BioNTech shall Enforce against or Defend of such Infringement or Third Party Infringement Claim consistent with Genentech’s comments as required under this Section 10.4. 

(c) Settlement. The Controlling Litigation Party shall, at its sole discretion, have the right to settle such claim; provided that the
Controlling Litigation Party may not settle or consent to an adverse judgment without the expressed written consent of the Non-Controlling Party (such consent not to be unreasonably withheld or delayed). 

(d) Third Party Payments. [***] 

(e) Recoveries. Any recovery realized as a result of any action described in this Section 10.4 (whether by way of settlement or
otherwise) shall be [***] 
 10.6 Third Party Licenses. Existing Third Party
In-License Agreement Royalty Payments for any GDP Collaboration Product shall be shared equally by the Parties as an “Allowable Expense” in the Net Profit/Net Loss calculation pursuant to
Section 8.4 or in the case of a Royalty Product, shall be borne solely by BioNTech in accordance with the terms and conditions of this Agreement, including Section 12.2.2(d). For all other payments or other consideration payable to any
Third Party for rights or licenses under BioNTech IP or Genentech IP or intellectual property rights that are reasonably necessary for the Exploitation of any Collaboration Product, the following shall apply: 

  
 - 78 - 

			
	Confidential	  	Execution Copy

  

 10.6.1 BioNTech IP. BioNTech shall be responsible for and bear the following: 

(a) all costs for any payments or other consideration payable to any Third Party (i) for the rights and licenses (including the right to
grant sublicenses) under the BioNTech IP as such BioNTech IP exists as of the Effective Date; (ii) for the rights and licenses (including the right to grant sublicenses) under [***]; or (iii) as a result of the Exploitation of
Collaboration Products under any agreement between BioNTech or its Affiliates and a Third Party existing as of the Effective Date, including any Existing Third Party In-License Agreements (except for Existing
Third Party In-License Agreement Royalty Payments which shall be allocated as described above in Section 10.6); 

(b) any compensation payable by BioNTech or its Affiliates under statute, contract or otherwise to inventors that have contributed or will
contribute to BioNTech IP or (subject to any sharing as an Allowable Expense) any Collaboration IP created, conceived or reduced to practice by or on behalf of BioNTech; and 

(c) any costs for any payments or other consideration payable to any Third Party for the rights or licenses under intellectual property rights
necessary or reasonably useful for BioNTech to perform its research activities in relation to the Neoepitope Prediction Algorithm under the Research Plan, including any such rights or licenses under the software disclosed in Schedule
12.2.1(i) and Schedule 12.3.1(h). 
 For clarity, except for Existing Third Party In-License Agreement
Royalty Payments which shall be allocated as described above in Section 10.6, BioNTech shall be responsible for and bear the costs for any payments or other consideration to a Third Party as listed under Schedule 12.2.1(a).
Notwithstanding the foregoing, any additional rights or licenses that may be obtained for the Exploitation of Collaboration Products (other than for research activities under the Research Plan) under any agreement with a Third Party existing as of
the Effective Date shall be considered “Third Party IP” as defined under Section 10.6.3 and the Parties shall [***] 

10.6.2 Genentech IP. Other than in connection with (a) an amendment of this Agreement pursuant to Section 5.3.4 or
(b) grant of a post-termination license to BioNTech pursuant to Section 14.5.4, Genentech shall be responsible and bear the following: 

(a) all costs for any payments or other consideration due to any Third Party (i) for the rights and licenses (including the right to
grant sublicenses) under the Genentech IP as such Genentech IP exists as of the Effective Date or (ii) as a result of the Exploitation of Collaboration Products under any agreement of Genentech or its Affiliates with a Third Party existing as
of the Effective Date; 

  
 - 79 - 

			
	Confidential	  	Execution Copy

  

 (b) any compensation payable by Genentech or its Affiliates under statute, contract or
otherwise to inventors that have contributed or will contribute to Genentech IP (subject to any sharing as an Allowable Expense); and 
 (c)
any costs for any payments or other consideration payable to any Third Party for the rights or licenses under intellectual property rights necessary or reasonably useful for Genentech to perform its research activities in relation to the Neoepitope
Prediction Algorithm under the Research Plan, including any such rights or licenses under the software disclosed in Schedule 12.2.1(i) and Schedule 12.3.1(h). 

Notwithstanding the foregoing, any additional rights or licenses that may be obtained for the Exploitation of Collaboration Products (other than for research
activities under the Research Plan) under any agreement with a Third Party existing as of the Effective Date shall be considered “Third Party IP” as defined under Section 10.6.3 and the Parties shall [***] 

10.6.3 Other Third Party IP. With respect to (a) all intellectual property rights owned or controlled by a Third Party (including
any improvements by the inventors that have contributed to the BioNTech IP) and that are reasonably necessary for the Exploitation of any Collaboration Product (other than for research activities under the Research Plan), including the clinical
Development of the Neoepitope Prediction Algorithm for such Collaboration Product (“Third Party IP”) or [***] 
 (a) [***]

 (b) [***] 
 (c) In all
other cases [***], Genentech shall have the first right to negotiate and obtain rights or licenses under any Third Party IP [***] that is reasonably necessary for the Exploitation of the Collaboration Products. [***] 

10.7 Corporate Names and Product Trademarks. 

10.7.1 Ownership of Corporate Names. Subject to Section 9.4, as between the Parties, BioNTech shall retain all right, title and
interest in and to its Corporate Names, and Genentech shall retain all right, title and interest in and to its Corporate Names. 
 10.7.2
Ownership and Prosecution of Product Trademarks. Subject to Section 9.4, Genentech shall own all right, title, and interest to the Product Trademarks (other than the IVAC Trademark) in the Territory for use with GDP Collaboration
Product(s) or Genentech Collaboration Product(s), and shall be responsible for the registration, prosecution, and maintenance thereof. BioNTech shall provide all assistance and documents reasonably requested by Genentech in support of its
prosecution, registration, and maintenance of the Product Trademarks. BioNTech shall own the IVAC Trademark and any Product Trademarks exclusively used in connection with BioNTech Collaboration Products, and the terms of this Section 10.7.2
shall apply with respect to the IVAC Trademark and such Product Trademarks exclusively used in connection with BioNTech Collaboration Products, mutatis mutandis. 

  
 - 80 - 

			
	Confidential	  	Execution Copy

  

 10.7.3 Enforcement of Product Trademarks. Genentech shall have the sole right and
responsibility for taking such action as Genentech, after consultation with BioNTech, deems necessary against a Third Party based on any alleged, threatened, or actual infringement, dilution, misappropriation, or other violation of, or unfair trade
practices or any other like offense relating to, the Product Trademarks by a Third Party in the Territory. All costs of enforcing the Product Trademarks shall be shared equally (50%:50%) by the Parties. 

10.7.4 [***] 
 10.7.5
Notice and Cooperation. Each Party shall provide to the other Party prompt written notice of any actual or threatened infringement of the Product Trademarks in the Territory and of any actual or threatened claim that the use of the Product
Trademarks in the Territory violates the rights of any Third Party. Each Party agrees to cooperate fully with the other Party with respect to any enforcement action or defense commenced pursuant to this Section 10.7. 

10.8 [***] 
 10.9
[***] 
 10.10 Attorney-Client Privilege. Neither Party is waiving, nor shall be deemed to have waived or diminished, any
of its attorney work product protections, attorney-client privileges or similar protections and privileges or the like as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential
Information related to pending or threatened litigation) to the receiving Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (a) share a common legal
and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend
that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the disclosing Party’s Confidential Information covered by such protections and privileges relates; and
(d) intend that after the Effective Date both the receiving Party and the disclosing Party shall have the right to assert such protections and privileges. 

ARTICLE 11. 

CONFIDENTIALITY AND NON-DISCLOSURE 

11.1 Disclosure and Use of Confidential Information. 

11.1.1 Continuing Obligation. This Article 11 shall survive the expiration or termination of this Agreement for a period of
[***] years, except for [***] 
 11.1.2 Rights and Obligations. Except to the extent expressly authorized by this Agreement, each
Party (in context, the “Receiving Party”) in possession of the Confidential Information of the other Party (in context, the “Disclosing Party”) or Joint Confidential Information agrees to: (a) hold in
confidence and not disclose the Disclosing 

  
 - 81 - 

			
	Confidential	  	Execution Copy

  

 
Party’s Confidential Information or Joint Confidential Information to any Affiliate or Third Party (other than, subject to Section 15.2, by a Party to an Affiliate under an obligation
of confidentiality), (b) use commercially reasonable efforts to protect the Confidential Information of the other Party or Joint Confidential Information (including commercially reasonable efforts a Party employs with respect to its own confidential
information of a similar nature and commercially reasonable efforts to assure that no unauthorized use or disclosure is made by others to whom access to the Confidential Information of the other Party (or Joint Confidential Information) is granted)
and (c) only use (or permit the use of) the Disclosing Party’s Confidential Information or Joint Confidential Information in connection with activities contemplated by, the exercise of rights permitted by, or in order to further the
purposes of, this Agreement. [***] 
 11.1.3 “Confidential Information” means any and all Information
(a) provided by or on behalf of one Party to the other Party in connection with this Agreement, whether prior to, on, or after the Effective Date and (b) owned solely by a Party or jointly by the Parties; in all cases, including
information relating to the following: [***] Notwithstanding the foregoing, the following shall be deemed to be “Joint Confidential Information” for purposes of this Article 11: [***] 

11.1.4 Exceptions. The obligations of the Receiving Party set forth in Section 11.1.2, shall not apply to the Disclosing
Party’s Confidential Information or Joint Confidential Information to the extent that such Confidential Information: 
 (a) can be
demonstrated by documentation or other competent proof to have been in the Receiving Party’s possession prior to disclosure by the Disclosing Party without any obligation of confidentiality with respect to such information; provided that
the foregoing exception shall not apply with respect to Joint Confidential Information; 
 (b) is subsequently received by the Receiving
Party from a Third Party which is not bound by any obligation of confidentiality with respect to such information; 
 (c) has been published
by a Third Party or otherwise enters the public domain through no fault of the Receiving Party in breach of this Agreement; 
 (d) can be
demonstrated by documentation or other competent evidence to have been independently developed by or for the Receiving Party without reference to the Disclosing Party’s Confidential Information; provided that the foregoing exception
shall not apply with respect to Joint Confidential Information; or 
 (e) is no longer subject to the provisions of this Section 11.1
by the prior written consent of the Disclosing Party. 
 Specific aspects or details of Confidential Information shall not be deemed to be within the public
domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential
Information shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the
combination and its principles are in the public domain or in the possession of the Receiving Party. 

  
 - 82 - 

			
	Confidential	  	Execution Copy

  

 11.2 Permitted Disclosures. 

11.2.1 Legal Compliance. A Party may disclose the other Party’s Confidential Information or Joint Confidential Information if such
disclosure is required by law, rule or regulation (including to comply with the order of a court or governmental regulations), but only to the extent such disclosure is reasonably necessary for such compliance; provided, however, except for
disclosures otherwise permitted under Section 11.2, or as otherwise required or necessitated by law, such Party shall provide prompt notice of such disclosure requirement to the other Party and provide reasonable assistance to enable such other
Party to seek a protective order or otherwise prevent such disclosure. 
 11.2.2 Regulatory Authorities. A Party may disclose the
other Party’s Confidential Information or Joint Confidential Information to the extent such disclosure is required to comply with applicable governmental regulations, to conduct preclinical or Clinical Studies related to Collaboration Products
in accordance with the terms of this Agreement, or, with respect to any Lead Regulatory Party, to obtain Regulatory Approval of Collaboration Products in accordance with the terms of this Agreement. 

11.2.3 Patent Prosecution. A Party may disclose the other Party’s Confidential Information or Joint Confidential Information to
the extent such disclosure is reasonably necessary for the filing, publication or Prosecution and Maintenance of any patent application or patent on inventions, subject to the provisions of Section 10.3. 

11.2.4 Permitted Third Parties. Subject to Sections 4.8.3, 11.6 and 11.7, the Receiving Party may disclose and grant use of particular
Confidential Information of the Disclosing Party or Joint Confidential Information to the Receiving Party’s permitted sublicensees, agents, consultants, clinical investigators, or subcontractors as the Receiving Party reasonably determines is
necessary to fulfill its obligations or exercise its rights under this Agreement; provided, however, that (a) any such permitted sublicensees, agents, consultants, clinical investigators or subcontractors must be contractually bound in writing
by obligations substantially similar to those set forth in Section 11.1 and (b) in no event may BioNTech disclose or grant use of any such Information to any Class A Competitor or an Affiliate thereof (or an employee or consultant of
such Class A Competitor or Affiliate thereof) without Genentech’s prior written consent. [***] 
 11.2.5 Scientific
Publications. The Receiving Party may disclose the Disclosing Party’s Confidential Information or Joint Confidential Information as expressly permitted pursuant to Section 11.5. 

11.2.6 Genentech Molecule Clinical Trial Data. Genentech Molecule Clinical Trial Data is the Confidential Information of Genentech.
Notwithstanding any other provision of this Section 11.2, BioNTech may not disclose Genentech Molecule Clinical Trial Data without Genentech’s prior written consent, other than pursuant to Section 11.2.1. 

  
 - 83 - 

			
	Confidential	  	Execution Copy

  

 11.3 Use of Name. Except as expressly provided herein, neither Party shall (and
no right, express or implied, is granted to) mention or otherwise use the name, logo, or Trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional
material or other form of publicity, or in any other manner in connection with the performance of this Agreement, without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 11.3 shall not
prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law. 
 11.4 Press Releases
and Other Public Disclosures. 
 11.4.1 Generally. For purposes of Section 11.4 a “Disclosure” means a
press release or other public disclosure concerning this Agreement or the subject matter hereof, including (a) the existence and terms and conditions of this Agreement; (b) information arising from the conduct of activities under this
Agreement; and (c) Collaboration Products, and any information specifically related to such Collaboration Products (including any Collaboration Product Clinical Study Data). Disclosures include public communications that contain previously
disclosed information. The provisions of Section 11.4 are in addition to the other provisions of Article 11. 
 11.4.2 Disclosures.
If one Party desires to make a Disclosure, it shall obtain the other Party’s prior written approval for the proposed Disclosure, which approval shall not unreasonably be withheld or delayed. Each Party hereby agrees that the other Party may
issue the applicable press release set forth in Schedule 11.4.2, following the Execution Date by both Parties. 
 11.4.3
Disclosure Required by Law. In the event that one Party reasonably concludes that a Disclosure is required by law, rule or regulation (including the disclosure requirements of the Securities and Exchange Commission or the securities exchange or
other stock market on which such Party’s securities are traded (for purposes of Section 11.4, collectively, an “Exchange”)), it shall notify the other Party at least [***] Business Days in advance and if the other Party
notifies the disclosing Party that it would prefer not to make such Disclosure, the Party seeking such Disclosure shall either (a) limit such Disclosure to address the concerns of the other Party or (b) provide a written opinion from
counsel stating that such limited Disclosure is not sufficient to comply with the applicable law, rule or regulation before making such Disclosure. Each Party agrees that it shall obtain its own legal advice with regard to its compliance with
securities laws, rules and regulations, and will not rely on any statements made by the other Party relating to such securities laws, rules and regulations. 

11.4.4 Filing of Agreement. Without limiting Section 11.4.3, with respect to complying with the disclosure requirements of an
Exchange, in connection with any required filing of this Agreement with such Exchange, the filing Party shall, at the request of the other Party, seek confidential treatment for portions of this Agreement from such

  
 - 84 - 

			
	Confidential	  	Execution Copy

  

 
Exchange and shall provide such other Party with the opportunity, for no less than [***] Business Days (before the date of the proposed filing), to review and comment on any such proposed filing,
and shall thereafter provide reasonable advance notice and opportunity for comment on any subsequent changes to such filing. BioNTech shall, whether or not requested by Genentech, redact and request confidential treatment for [***], and the
information in the Schedules to this Agreement. 
 11.5 Scientific Publications. Notwithstanding Section 11.4, in the
event a Party wishes to publish in a peer review journal or present at a scientific conference (a) Information relating to or arising from this Agreement (including relating to or arising from activities performed by a Third Party subcontractor
on behalf of a Party, [***]) consistent with the then-current Publication Plan, if any, or if no Publication Plan is in effect, as otherwise approved by the JRC, with respect to research publications, or the JDC, with respect to Development
publications, or (b) Information solely made, collected or otherwise generated by or on behalf of it or its Affiliates [***] prior to the Effective Date, such Party shall provide to the other Party the proposed publication or presentation
(including, without limitation, abstracts and manuscripts) at least [***] days ([***] days for posters, slides and written descriptions of oral presentations only) for publications under clause (a) and [***] days for publications under clause
(b) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The other Party shall review such submitted materials and respond to the submitting Party as soon as
reasonably possible, but in any case (i) within [***] days for the proposed publication or presentation (including but not limited to abstracts and manuscripts) and [***] days for posters, slides and written descriptions or oral presentations
only, of receipt thereof for publications under clause (a) and (ii) within [***] days for the proposed publications under clause (b). At the option of the reviewing Party, the submitting Party shall (1) take into due consideration any
comments made by the reviewing Party, (2) delete from such proposed publication or presentation any Confidential Information of the reviewing Party and [***]; and (3) delay the date of such submission for publication or the date of such
presentation for a period of time sufficiently long (but in no event longer than [***] days for publications under clause (a) and [***] days for publications under clause (b)) to permit the reviewing Party to seek appropriate patent protection.
In the event the reviewing Party does not respond within the period specified above, the submitting Party will be free to make such proposed publication or presentation. 

11.6 Restriction on Disclosure of [***] 

11.7 Restriction on Disclosure of [***] 

ARTICLE 12. 

REPRESENTATIONS AND WARRANTIES 

12.1 Mutual Representations and Warranties. As a condition and an inducement to the Parties to enter into this Agreement, each
of RNP and BNT on the one hand, and GNE and Roche on the other, represents and warrants to the other, as of the Execution Date, and covenants, as follows: 

  
 - 85 - 

			
	Confidential	  	Execution Copy

  

 12.1.1 Organization. It is duly organized, validly existing, and in good standing
under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement and the Ancillary Agreements. 

12.1.2 Authorization. The execution and delivery of this Agreement and the Ancillary Agreements and the performance of this Agreement
and the Ancillary Agreements by it have been duly authorized by all necessary corporate action, and do not and will not (a) conflict with such Signatory’s charter documents, bylaws, or other organizational documents, (b) conflict
with, or result in a breach or constitute default under, or give rise to any payment obligations or right of termination, cancellation, modification or acceleration of any obligation or loss of any benefit under any agreement, instrument, or
contractual obligation to which such Signatory is bound, (c) violate any requirement of any Applicable Law, or (d) violate any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently
in effect applicable to such Signatory. 
 12.1.3 Binding Agreement. This Agreement is a legal, valid, and binding obligation of such
Signatory enforceable against it in accordance with its terms and conditions. It is not under any obligation to any Person, contractual or otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or any
Ancillary Agreement or that would impede the diligent and complete fulfillment of its obligations of this Agreement or any Ancillary Agreement. 

12.2 Additional Representations and Warranties of BioNTech. BioNTech further represents and warrants to Genentech, as of the
Execution Date, and covenants, as follows: 
 12.2.1 Intellectual Property. 

(a) Title. All Patents Controlled by BioNTech or its Affiliates that are to the knowledge of BioNTech and its Affiliates necessary to
research, develop, manufacture, commercialize, make, have made, use, offer for sale, sell and import Pharmaceutical Products that comprise (i) one or more Neoepitope RNA(s), [***] are listed on Schedule 1.20. BioNTech is (a) the
sole and exclusive owner of the entire right, title and interest in the BioNTech Core Patents listed on Schedule 1.20 as “Owned BioNTech Core Patents”; (b) the sole and exclusive licensee of the BioNTech Core Patents indicated
on Schedule 1.20 as “In-Licensed BioNTech Core Patents”; and (c) entitled to grant the rights and licenses (or sublicenses) specified in this Agreement and the Ancillary Agreements,
including the rights of Prosecution and Maintenance specified in this Agreement, in each case of (a), (b), and (c), free of any encumbrance, lien, or claim of ownership by any Third Party or Affiliate and except as disclosed in Schedule
12.2.1(a), without payment of any royalties, license fees or other amounts to any Person. 
 (b) Valid and Enforceable. To the
knowledge of BioNTech and its Affiliates, all BioNTech Core Patents are subsisting, and all necessary Prosecution and Maintenance fees in connection with such BioNTech Core Patents have been paid, and all necessary documents and certificates in
connection with such BioNTech Core 

  
 - 86 - 

			
	Confidential	  	Execution Copy

  

 
Patents have been filed with the relevant Governmental Authorities for the purposes of Prosecuting and Maintaining such BioNTech Core Patents and BioNTech has complied with its duty to disclose
material information to the U.S. Patent and Trademark Office and other foreign patent authorities in connection with such BioNTech Core Patents. To the knowledge of BioNTech and its Affiliates and except as may be disclosed from BioNTech to
Genentech or Genentech to BioNTech through their respective outside counsel, the BioNTech Core Patents are not invalid or unenforceable. 

(c) Rights of Prosecution and Enforcement. To the knowledge of BioNTech and its Affiliates and except as otherwise disclosed on
Schedule 12.2.1(c), neither BioNTech nor any of its Affiliates has (i) granted any Person the right to control the Prosecution and Maintenance of any of the BioNTech Core Patents, (ii) granted any Person the right to bring
infringement actions with respect to, or otherwise to enforce rights with respect to, any of the BioNTech Core Patents, or (iii) expressly agreed not to sue or to indemnify any Person against any charge of infringement of any of BioNTech Core
Patents. 
 (d) No Infringement of BioNTech IP. To the knowledge of BioNTech and its Affiliates, no Person is infringing or
threatening to infringe or misappropriating or threatening to misappropriate the BioNTech Core Patents (including pending applications and registrations therefor as if such applications or registrations were to issue or become registered), any
Neoepitope Prediction Algorithm within the BioNTech IP or the Regulatory Documentation. 
 (e) No Infringement of Third Party IP. To
the knowledge of BioNTech and its Affiliates and except as may be disclosed from BioNTech to Genentech or Genentech to BioNTech through their respective outside counsel, (i) the conception, reduction to practice or creation of the BioNTech Core
Patents, any Neoepitope Prediction Algorithm within the BioNTech IP and Regulatory Documentation and the Exploitation of Collaboration Products based upon the BioNTech Core Patents, any Neoepitope Prediction Algorithm within the BioNTech IP and
Regulatory Documentation do not and will not infringe or misappropriate any intellectual property right (including pending applications and registrations therefor as if such applications or registrations were to issue or become registered) of any
Person, or otherwise violate any intellectual property right of any Person under the Applicable Laws of any jurisdiction, and (ii) the BioNTech Core Patents are not dominated by any Patent (including pending applications and registrations
therefor as if such applications or registrations were to issue or become registered) of any Person and not Controlled by BioNTech. 
 (f)
German Employees’ Inventions Act. In accordance with the German Employees’ Inventions Act, BioNTech agrees to claim the unlimited use of any Invention conceived, reduced to practice, developed, made or created in the performance of,
or as a result of the Research Plan, CMC Development Plan or Joint Development Activities by employees of any German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the obligations towards their employees under the
German Employee’s Inventions Act. 

  
 - 87 - 

			
	Confidential	  	Execution Copy

  

 (g) Assignments. To the extent the assignment of inventions to BioNTech or its
Affiliates is not effected by statutory law (e.g. the German Employees’ Inventions Act), all current and former officers, employees, agents and consultants of BioNTech or any of its Affiliates or, to the knowledge of BioNTech and its
Affiliates, their respective subcontractors [***] who are inventors of or have otherwise contributed in a material manner to the creation or development of any BioNTech IP have, directly or indirectly, agreed to protect such BioNTech IP as
proprietary information and assign any and all rights in and to such BioNTech IP to BioNTech or such Affiliate or such subcontractor (as applicable), by execution and delivery to BioNTech or such Affiliate or subcontractor of an assignment or other
agreement or otherwise. To the knowledge of BioNTech and its Affiliates, no current officer, employee, agent, or consultant of BioNTech or any of its Affiliates or their respective subcontractors [***] is in violation of any term of any assignment
or other agreement regarding the protection of Patents or other intellectual property or proprietary information of BioNTech or such Affiliate or of any employment contract or any other contractual obligation relating to the relationship of any such
Person with BioNTech. To the knowledge of BioNTech, all inventions relating to any Pharmaceutical Products that comprise (i) one or more Neoepitope RNA(s), [***] made as of the Effective Date by inventors who are employed by or in any other way
legally related to BioNTech or its Affiliates have been disclosed by such inventors to BioNTech or its Affiliates, as applicable.  

(h) Confidentiality of BioNTech Know-How. Except as disclosed in scientific publications made
generally available to the public, BioNTech and its Affiliates have maintained the BioNTech Know-How at all times as confidential and only disclosed the BioNTech
Know-How to Third Parties, [***] under obligations of confidentiality. To the knowledge of BioNTech and its Affiliates, no such Third Party has used or disclosed BioNTech
Know-How in breach of its confidentiality obligations. 
 (i) Neoepitope Prediction
Algorithm. To the knowledge of BioNTech and its Affiliates [***] (i) BioNTech owns or has sufficient rights in any Neoepitope Prediction Algorithm within the BioNTech IP as of the Execution Date to transfer such Neoepitope Prediction Algorithm
and grant the rights and licenses (and sublicenses) to Genentech under this Agreement, free of any encumbrance, lien, or claim of ownership by any Third Party or Affiliate and without payment of any royalties, license fees or other amounts to any
Person, and (ii) the use and other exploitation of such Neoepitope Prediction Algorithm in the Exploitation of Collaboration Products will not depend on the acquisition of rights from any Third Party. 

(j) No Viruses. To the knowledge of BioNTech and its Affiliates, any Neoepitope Prediction Algorithm within the BioNTech IP as of the
Execution Date does not contain or incorporate any code, lock, authorization key, disabling code, or similar device or code that is intended to impair, disable or otherwise impede the operation of software or hardware or any “back door,”
“time bomb,” “Trojan horse,” “drop-dead device,” “virus” or other software routines or code or hardware components designed to permit unauthorized access, to send information to any Third Party without the
user’s consent, to disable or erase software, hardware or data, or to contaminate, corrupt, or damage information technology systems or architecture or to perform any other similar actions. 

  
 - 88 - 

			
	Confidential	  	Execution Copy

  

 (k) No Copyleft. To the knowledge of BioNTech and its Affiliates, any Neoepitope
Prediction Algorithm within the BioNTech IP and the Neoepitope Prediction Software used by BioNTech in its Neoepitope Prediction Algorithm as of the Execution Date are not, do not contain or incorporate, and are not bundled, combined, or linked
with, any software or other materials in a form or manner which creates, or purports to create, obligations (i) for a licensee to license its own intellectual property rights, including Patents, to any Third Parties or (ii) that a
licensee’s software or other materials must: (A) be disclosed or distributed in source code form; (B) be licensed for the purpose of making derivative works; or (C) be redistributable at no charge (such software or other
materials collectively, “Copyleft Software”). Without limiting the foregoing: 
 (i) To the knowledge of BioNTech and its
Affiliates and to the extent that, at any time prior to the Execution Date, any mechanism was used to facilitate communication between (x) the Neoepitope Prediction Software owned by BioNTech within the BioNTech IP and (y) any Copyleft
Software, or other software disclosed on Schedule 12.2.1(i), the mechanism that was used was a command line argument and the semantics of the communication did not involve the exchange of complex data structures. 

(ii) To the knowledge of BioNTech and its Affiliates, the Neoepitope Prediction Software used by BioNTech in its Neoepitope Prediction
Algorithm as of the Execution Date has not [***] 
 (iii) In the development of the Neoepitope Prediction Software used by BioNTech in its
Neoepitope Prediction Algorithm as of the Execution Date, BioNTech has followed standard operating procedures with respect to software development that control and document the use of Copyleft Software. During the Term, BioNTech will maintain and
enforce standard operating procedures with respect to the use of Copyleft Software in association with the development of the Neoepitope Prediction Software used in the development of Collaboration Products under this Agreement. Such standard
operating procedures shall require that the Committee Co-Chairs of the JRC and the JDC be notified of any anticipated use or transfer of Copyleft Software and that to the extent that any communication
mechanism is implemented between (x) the Neoepitope Prediction Software owned by BioNTech within the BioNTech IP and (y) any Copyleft Software, including any software disclosed on Schedule 12.2.1(i), that mechanism shall be a
command line argument and the semantics of the communication shall not involve the exchange of complex data structures. Any variation from these standard operating procedures must be approved in writing by the JRC and the JDC. 

(l) No Other Claims. To the knowledge of BioNTech and its Affiliates, there are no claims, judgments, or settlements against, or
amounts with respect thereto owed by, BioNTech or any of its Affiliates relating to (i) the BioNTech Core Patents, any Neoepitope Prediction Algorithm within the BioNTech IP or the Regulatory Documentation or (ii) the research,
development, manufacture, commercialization, making, having made, using, offering for sale, selling and importing Pharmaceutical Products that comprise (i) one or more Neoepitope RNA(s), [***]. 

  
 - 89 - 

			
	Confidential	  	Execution Copy

  

 12.2.2 Existing Third Party In-License
Agreements. 
 (a) Disclosure. Except for those agreements listed on Schedule 12.2.2(a) (collectively,
“Existing Third Party In-License Agreements”), there are no agreements between BioNTech or any of its Affiliates with any Third Parties (i) pursuant to which BioNTech or its Affiliate has
obtained, or has a right to obtain, a license under or rights to use BioNTech Core Patents (other than any Neoepitope Prediction Algorithm) that is relevant to this Agreement or the Ancillary Agreements or (ii) pursuant to which BioNTech or its
Affiliate otherwise owes, or would otherwise owe, payments to a Third Party as a result of the Exploitation of Collaboration Products based upon the BioNTech Core Patents (other than any Neoepitope Prediction Algorithm) or other activities conducted
hereunder or under any Ancillary Agreement (whether by BioNTech or Genentech or their respective (sub)licensees), including the grant of rights and licenses under the BioNTech Core Patents (other than any Neoepitope Prediction Algorithm) to
Genentech; 
 (b) Existing Third Party In-License Agreements. (i) BioNTech has provided
Genentech true and complete and accurate copies of the Existing Third Party In-License Agreements (as may be redacted to remove confidential information) as the same is in effect; (ii) each Existing Third
Party In-License Agreement is in full force and effect and BioNTech has the rights under each such Existing Third Party In-License Agreement to disclose and provide the
BioNTech IP to Genentech and to grant Genentech the licenses under, and right to use, such BioNTech IP (other than any Neoepitope Prediction Algorithm) in the Exploitation of the Collaboration Products without restriction in accordance with the
terms of this Agreement; (iii) BioNTech shall maintain each Existing Third Party In-License Agreement in full force and effect during the Term, in each case in accordance with its terms and conditions,
but subject to BioNTech’s rights to terminate, amend, waive or otherwise modify any such agreement as provided in Section 12.2.2(c) below; (iv) no written notice of default or termination has been received or given by BioNTech or any
of its Affiliates under any Existing Third Party In-License Agreement; and (v) to BioNTech’s and its Affiliates’ knowledge, there is no act or omission by BioNTech or any of its Affiliates that
would give the counterparty thereto a right to terminate any Existing Third Party In-License Agreement; 

(c) Maintenance of Existing Third Party In-License Agreements. During the Term, neither
BioNTech nor any of its Affiliates shall terminate, amend, waive or otherwise modify (or provide consent with respect to any termination, amendment, waiver or modification of) the rights under any Existing Third Party
In-License Agreement in any manner that materially diminishes the licenses or rights granted to Genentech hereunder, materially impairs Genentech’s ability to perform its obligations hereunder or
otherwise materially adversely affects, or is likely to materially adversely affect, Genentech’s rights hereunder; in all cases, without the prior written consent of Genentech. In the event of any notice of breach or notice of termination
received by BioNTech or any of its Affiliates, as applicable, under the provisions of any Existing Third Party In-License Agreement, BioNTech shall immediately notify Genentech in writing and if BioNTech or
its Affiliate fails to cure such breach, Genentech shall have the right, but not the obligation, to cure such breach on behalf of BioNTech or its Affiliates, as applicable, and to offset any reasonable amounts incurred or paid by Genentech in
connection with the cure of such breach against any amounts otherwise payable by Genentech to BioNTech under this Agreement until fully offset. 

  
 - 90 - 

			
	Confidential	  	Execution Copy

  

 (d) Enforcement of Existing Third Party
In-License Agreements. In the event that BioNTech is of the opinion that the other party of any applicable Existing Third Party In-License Agreement has breached its
obligations under such agreement, BioNTech shall notify Genentech in writing, and the Parties shall promptly discuss and agree on such actions as may be necessary or useful to enforce such Existing Third Party
In-License Agreement, including injunctive or other equitable relief with respect to breach of obligations related to confidentiality or exclusivity. Without limiting the foregoing, in the event an Existing
Third Party In-License Agreement expires or terminates during the Term, any sublicense(s) granted from BioNTech to Genentech under any such Existing Third Party
In-License Agreement hereunder shall survive (to the extent permitted under the Existing Third Party In-License Agreements). Any Existing Third Party In-License Agreement Royalty Payment that Genentech shall pay to such Third Party under such sublicense(s) for activities performed in accordance with this Agreement shall constitute an “Allowable Expense”
in the Net Profit/Net Loss calculation pursuant to Section 8.4 or in the event of an Opt-Out by BioNTech pursuant to Section 8.5 or a Deemed Opt-Out pursuant
to Section 8.5.3, shall be offset against any amounts otherwise payable by Genentech to BioNTech under this Agreement until fully offset, and any other amounts that Genentech shall pay to such Third Party under such sublicense shall be offset
against any amounts otherwise payable by Genentech to BioNTech under this Agreement until fully offset. 
 12.2.3 Regulatory. 

(a) Regulatory Documentation. BioNTech and its Affiliates have generated, prepared, maintained, and retained all Regulatory
Documentation that is required to be maintained or retained pursuant to and in accordance with cGLPs and cGCPs and in compliance with Applicable Law, and all such information is true and complete and accurate and what it purports to be. 

(b) No Misrepresentation to Regulatory Authority. Neither BioNTech nor any of its Affiliates, nor any of its or their respective
officers, employees, or agents has made an untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect to the Development or Manufacture of the Collaboration Products, failed to disclose a
material fact required to be disclosed to the FDA or any other Regulatory Authority with respect to the Development or Manufacture of the Collaboration Products, or committed an act, made a statement, or failed to make a statement with respect to
the Development or Manufacture of the Collaboration Products that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”,
set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies in the Territory. 
 (c)
No Debarment. Neither BioNTech nor any of its Affiliates has been debarred or is subject to debarment and neither BioNTech nor any of its Affiliates will use in any capacity, in connection with the services to be performed under this
Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA, or who is the subject of a conviction described in such section. BioNTech agrees to inform Genentech in writing immediately if it or any Person who is performing
services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the knowledge of BioNTech and its Affiliates, is
threatened, relating to the debarment or conviction of BioNTech or any Person performing services hereunder. 

  
 - 91 - 

			
	Confidential	  	Execution Copy

  

 (d) Development of Collaboration Product. BioNTech and its Affiliates have at all
times conducted and will conduct, and their respective subcontractors and consultants have at all times conducted and will conduct, all Development of the Collaboration Products (i) in accordance with cGLP and cGCP (to the extent applicable,
and it being understood that Development of Collaboration Product has as of the Effective Date solely been conducted in accordance with respective European standards) and in compliance with Applicable Law including applicable Compliance
Requirements, (ii) in accordance with the applicable protocol and good scientific practices and (iii) maintaining standard operating procedures with respect to clauses (i) and (ii). BioNTech has at all times conducted and will
conduct, and has caused and will cause its subcontractors and consultants to conduct at all times, any and all preclinical and Clinical Studies related to the Collaboration Products in accordance with cGLP and cGCP (to the extent applicable, and it
being understood that preclinical and Clinical Studies related to the Collaboration Products have as of the Effective Date solely been conducted in accordance with respective European standards) and in compliance with Applicable Law including
applicable Compliance Requirements, (ii) in accordance with the applicable protocol and good scientific practices and (iii) maintaining standard operating procedures with respect to clauses (i) and (ii). BioNTech and its Affiliates
have employed (and, with respect to such tests and studies that BioNTech will perform, will employ) Persons with appropriate education, knowledge and experience to conduct and to oversee the conduct of the preclinical and Clinical Studies with
respect to the Collaboration Products. 
 (e) Safety Reporting. BioNTech and its Affiliates are, and at all times have been, in
compliance with all adverse event reporting requirements applicable to the Collaboration Products. Schedule 12.2.3(e) sets forth a complete and accurate list of all (i) adverse drug experience information; (ii) material events and
matters concerning or affecting safety or lack of efficacy; and (iii) medical inquiries and complaints, in each case, relating to the Collaboration Products. Neither BioNTech nor any of its Affiliates has any knowledge of any scientific or
technical facts or circumstances that would adversely affect the scientific, therapeutic, or commercial potential of Collaboration Products. Neither BioNTech nor any of its Affiliates is aware of anything that could adversely affect the acceptance,
or the subsequent approval, by any Regulatory Authority of any filing, application or request for Regulatory Approval. 
 (f) Manufacture
of Collaboration Product. BioNTech and its Affiliates have at all times conducted, and their respective subcontractors and consultants have at all times conducted, all Manufacture of the Collaboration Products in accordance with the applicable
Compliance Requirements. The processes used to Manufacture the Collaboration Products are adequate to ensure that the Collaboration Products meet the specifications established therefor. 

  
 - 92 - 

			
	Confidential	  	Execution Copy

  

 (g) Manufacturing Facility. Unless otherwise disclosed in
Schedule 12.2.3(g), neither BioNTech nor its Affiliates have received: (i) (A) any FDA Form 483 Notice of Observation, or similar notice from any other Regulatory Authority, relating to the Collaboration Products or
the facilities in which the Collaboration Products are Manufactured; (B) any FDA “Notices of Adverse Findings,” or similar notice from any other Regulatory Authority, with respect to the Collaboration Products; or (C) any
“warning letters,” or “untitled letters,” or other similar Regulatory Authority notice of inspectional observations or deficiencies or other written correspondence from the FDA or any other Regulatory Authority concerning the
Collaboration Products or the facilities in which the Collaboration Products are Manufactured; and (ii) there has not been a recall or withdrawal or replacement of any Collaboration Product by, or on behalf of, BioNTech or any of its
Affiliates, whether voluntary or involuntary. 
 12.2.4 Accuracy of Information. The representations and warranties of
BioNTech in this Agreement, and the information, documents and materials furnished to Genentech in connection with its period of diligence prior to the Execution Date, do not, taken as a whole, (a) contain any untrue statement of a material
fact, or (b) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading. 

12.2.5 Effective Date. During the period from the Execution Date until the Effective Date, BioNTech shall promptly inform
Genentech in writing if and when BioNTech or any of its Affiliates becomes aware that the representations and warranties made by BioNTech pursuant to Sections 12.1 and 12.2 as of the Execution Date are no longer true and correct in any material
respects if made on and as of the date of such notice. Upon receipt of such notice, Genentech shall have the right, on written notice to BioNTech, to terminate this Agreement, and upon receipt of such notice by BioNTech, this Agreement shall be null
and void and have no further force and effect; provided, however, Sections 9.6, 11.7 and 14.1 and Article 13 (other than Section 13.7) shall survive with respect any rights that accrued to the benefit of a Party prior to such termination. 

12.3 Additional Representations and Warranties by Genentech. Genentech further represents and warrants to BioNTech, as of
the Execution Date, and covenants, as follows: 
 12.3.1 Intellectual Property. 

(a) Title. All Patents Controlled by Genentech that are to the knowledge of Genentech necessary to research, develop, manufacture,
commercialize, make, have made, use, offer for sale, sell and import Pharmaceutical Products comprising one or more Neoepitope RNA(s) [***] are listed on Schedule 1.156. Genentech is the sole and exclusive owner of the entire right, title and
interest in the Genentech Core Patent listed on Schedule 1.156; and Genentech is entitled to grant the rights and licenses (or sublicenses) specified in this Agreement and the Ancillary Agreements, including the rights of Prosecution and
Maintenance specified in this Agreement, in each case, free of any encumbrance, lien, or claim of ownership by any Third Party or Affiliate and, without payment of any royalties, license fees or other amounts to any person. 

  
 - 93 - 

			
	Confidential	  	Execution Copy

  

 (b) Valid and Enforceable. To the knowledge of Genentech, all Genentech Core Patents
are subsisting, and all necessary Prosecution and Maintenance fees in connection with such Genentech Core Patents have been paid, and all necessary documents and certificates in connection with such Genentech Core Patents have been filed with the
relevant Governmental Authorities for the purposes of Prosecuting and Maintaining such Genentech Core Patents and Genentech has complied with its duty to disclose material information to the U.S. Patent and Trademark Office and other foreign patent
authorities in connection with such Genentech Core Patents. To the knowledge of Genentech and except as may be disclosed from Genentech to BioNTech or BioNTech to Genentech through their respective outside counsel, the Genentech Core Patents owned
by Genentech are not invalid or unenforceable. 
 (c) Rights of Prosecution and Enforcement. To the knowledge of Genentech, Genentech
has not (i) granted any Person the right to control the Prosecution and Maintenance of any of the Genentech Core Patents, (ii) granted any Person the right to bring infringement actions with respect to, or otherwise to enforce rights with
respect to, any of the Genentech Core Patents, or (iii) expressly agreed not to sue or to indemnify any Person against any charge of infringement of any of Genentech Core Patents. 

(d) No Infringement of Genentech IP. To the knowledge of Genentech, no Person is infringing or threatening to infringe or
misappropriating or threatening to misappropriate the Genentech Core Patents (including pending applications and registrations therefor as if such applications or registrations were to issue or become registered) or any Neoepitope Prediction
Algorithm within the Genentech IP. 
 (e) No Infringement of Third Party IP. To the knowledge of Genentech and except as may be
disclosed from Genentech to BioNTech or BioNTech to Genentech through their respective outside counsel, (i) the conception, reduction to practice or creation of the Genentech Core Patents, any Neoepitope Prediction Algorithm within the
Genentech IP and the Exploitation of Collaboration Products based upon the Genentech Core Patents, any Neoepitope Prediction Algorithm within the Genentech IP do not and will not infringe or misappropriate any intellectual property right (including
pending applications and registrations thereof as if such applications or registrations were to issue or become registered) of any Person or otherwise violate any intellectual property right of any Person under the Applicable Laws of any
jurisdictions, and (ii) the Genentech Core Patents are not dominated by any Patent (including pending applications and registrations therefor as if such applications or registrations were to issue or become registered) of any Person and not
Controlled by Genentech. 
 (f) Assignments. To the extent the assignment of inventions to Genentech or its Affiliates is not
effected by statutory law (e.g. the Statute of German Employees’ Inventions Act), all current and former officers, employees, agents and consultants of Genentech or any of its Affiliates or, to the knowledge of Genentech and its Affiliates,
their respective subcontractors who are inventors of or have otherwise contributed in a material manner to the creation or development of any Genentech IP have, directly or indirectly, agreed to protect such Genentech IP as proprietary information
and assign any and all rights in and to such Genentech IP to Genentech or such Affiliate or such subcontractor (as 

  
 - 94 - 

			
	Confidential	  	Execution Copy

  

 
applicable), by execution and delivery to Genentech or such Affiliate or subcontractor of an assignment or other agreement or otherwise. To the knowledge of Genentech and its Affiliates, no
current officer, employee, agent, or consultant of Genentech or any of its Affiliates or their respective subcontractors is in violation of any term of any assignment or other agreement regarding the protection of Patents or other intellectual
property or proprietary information of Genentech or such Affiliate or of any employment contract or any other contractual obligation relating to the relationship of any such Person with Genentech. 

(g) Confidentiality of Genentech Know-How. Except as disclosed in scientific publications
generally made available to the public, Genentech and its Affiliates have maintained the Genentech Know-How at all times as confidential and only disclosed the Genentech
Know-How to Third Parties under obligations of confidentiality. To the knowledge of Genentech, no such Third Party has used or disclosed Genentech Know-How in breach of
its confidentiality obligations. 
 (h) Neoepitope Prediction Algorithm. To the knowledge of Genentech and except as disclosed on
Schedule 12.3.1(h), (i) Genentech owns or has sufficient rights in any Neoepitope Prediction Algorithm within the Genentech IP as of the Execution Date to disclose and provide copies of such Neoepitope Prediction Algorithm and grant the
rights and licenses (and sublicenses) provided to BioNTech under this Agreement, free of any encumbrance, lien, or claim of ownership by any Third Party or Affiliate and without payment of any royalties, license fees or other amounts to any Person,
and (ii) the use and other exploitation of such Neoepitope Prediction Algorithm in the Exploitation of Collaboration Products will not depend on the acquisition of rights from any Third Party. 

(i) No Viruses. To the knowledge of Genentech and its Affiliates, any Neoepitope Prediction Algorithm within the Genentech IP as of the
Execution Date does not contain or incorporate any code, lock, authorization key, disabling code, or similar device or code that is intended to impair, disable or otherwise impede the operation of software or hardware or any “back door,”
“time bomb,” “Trojan horse,” “drop-dead device,” “virus” or other software routines or code or hardware components designed to permit unauthorized access, to send information to a Third Party(ies) without the
user’s consent, to disable or erase software, hardware or data, or to contaminate, corrupt, or damage information technology systems or architecture or to perform any other similar actions. 

(j) No Copyleft. To the knowledge of Genentech and its Affiliates, any Neoepitope Prediction Algorithm within the Genentech IP and the
Neoepitope Prediction Software used by Genentech in its Neoepitope Prediction Algorithm as of the Execution Date are not, do not contain or incorporate, and are not bundled, combined, or linked with, any software or other materials in a form or
manner which creates, or purports to create, obligations (i) for a licensee to license its own intellectual property rights, including Patents, to any Third Parties or (ii) that a licensee’s software or other materials must:
(A) be disclosed or distributed in source code form; (B) be licensed for the purpose of making derivative works; or (C) be redistributable at no charge. Without limiting the foregoing: 

(i) To the knowledge of Genentech and its Affiliates and to the extent that, at any time prior to the Execution Date, any mechanism was used
to facilitate communication between (i) the Neoepitope Prediction Software owned by Genentech within the Genentech IP and (ii) any Copyleft Software, or other software disclosed on Schedule 12.3.1(h), the mechanism that was used was
a command line argument and the semantics of the communication did not involve the exchange of complex data structures. 

  
 - 95 - 

			
	Confidential	  	Execution Copy

  

 (ii) To the knowledge of Genentech, the Neoepitope Prediction Software used by Genentech in
its Neoepitope Prediction Algorithm as of the Execution Date has not been transferred from one location to another location. 
 (iii) In the
development of the Neoepitope Prediction Software used by Genentech in its Neoepitope Prediction Algorithm as of the Execution Date, Genentech has followed standard operating procedures with respect to software development that control and document
the use of Copyleft Software. During the Term, Genentech will maintain and enforce standard operating procedures with respect to the use of Copyleft Software in association with the development of the Neoepitope Prediction Software used in the
development of Collaboration Products under this Agreement. Such standard operating procedures shall require that the Committee Co-Chairs of the JRC and the JDC be notified of any anticipated use or transfer
of Copyleft Software and that to the extent that any communication mechanism is implemented between (x) the Neoepitope Prediction Software owned by Genentech within the Genentech IP and (y) any Copyleft Software or other software disclosed
on Schedule 12.3.1(h), that mechanism shall be a command line argument and the semantics of the communication shall not involve the exchange of complex data structures. Any variation from these standard operating procedures must be approved
in writing by the JRC and the JDC. 
 (k) No Other Claims. To the knowledge of Genentech, there are no claims, judgments, or
settlements against, or amounts with respect thereto, owed by Genentech or any of its Affiliates relating to the Genentech Core Patents, any Neoepitope Prediction Algorithm within the Genentech IP or the Regulatory Documentation or the Exploitation
of Collaboration Products. 
 (l) Disclosure. There are no agreements between Genentech or any of its Affiliates with any Third
Parties (i) pursuant to which Genentech or its Affiliate has obtained, or has a right to obtain, a license under or rights to use the Genentech Core Patents that is relevant to this Agreement or the Ancillary Agreements or (ii) pursuant to
which Genentech or its Affiliate otherwise owes, or would otherwise owe, payments to a Third Party as a result of the Exploitation of Collaboration Products or other activities conducted hereunder (whether by BioNTech or Genentech or their
respective (sub)licensees), including the grant of rights and licenses under the Genentech Core Patents to BioNTech. 
 12.4 DISCLAIMER OF
WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY
SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER 

  
 - 96 - 

			
	Confidential	  	Execution Copy

  

 
WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 EACH PARTY FURTHER DISCLAIMS ALL OTHER
WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE COLLABORATION PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE
ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE COLLABORATION PRODUCTS. 

12.5 Disclosures. The inclusion of, or reference to, any item or information in any schedule referenced in this Article 12
herein, or otherwise disclosed through outside counsel, does not and shall not (a) constitute an admission or (b) otherwise imply that such item or information (i) is material or (ii) meets all criteria set forth in the
applicable section in this Article 12 for inclusion in such section. 
 ARTICLE 13. 

INDEMNITY AND INSURANCE 

13.1 Indemnification of BioNTech. Genentech shall indemnify BioNTech, its Affiliates and their respective directors,
officers, employees, and agents, and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs, and expenses (including reasonable attorneys’ fees and expenses) (collectively,
“Losses”) in connection with any and all suits, investigations, claims, or demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: 

(a) the breach by Genentech of its obligations under this Agreement or any Ancillary Agreement; 

(b) the breach of any of the warranties or representations made by Genentech to BioNTech under this Agreement or any Ancillary Agreement; 

(c) the negligence or willful misconduct on the part of Genentech or its Affiliates or their respective directors, officers, employees, and
agents in performing its or their obligations under this Agreement or any Ancillary Agreement; or 
 (d) the use of any Product Trademarks
(including the IVAC Trademark to the extent Genentech uses it as a Product Trademark hereunder) by Genentech or BioNTech in accordance with this Agreement and the Ancillary Agreements; and 

  
 - 97 - 

			
	Confidential	  	Execution Copy

  

 (e) (i) the use by BioNTech or its Affiliate of a Combination Agent Controlled by
Genentech or its Affiliates in a Clinical Study of a Collaboration Product hereunder, or [***] 
 except in the case of clauses (a) through (e) above,
for those Losses for which BioNTech has an obligation to indemnify Genentech pursuant to Section 13.2, as to which Losses each Party shall indemnify the other to the extent of their respective liability for the Losses. 

13.2 Indemnification of Genentech. BioNTech shall indemnify Genentech, its Affiliates and their respective directors,
officers, employees, and agents, and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a result of: 

(a) the breach by BioNTech of its obligations under this Agreement or any Ancillary Agreement; 

(b) the breach of any of the warranties or representations made by BNT or RNP to Genentech under this Agreement or any Ancillary Agreement; or

 (c) the negligence or willful misconduct on the part of BioNTech or its Affiliates or its or their respective directors, officers,
employees, and agents in performing its obligations under this Agreement or any Ancillary Agreement; 
 (d) (i) the use by Genentech or
its Affiliate of a Combination Agent Controlled by BioNTech or its Affiliates in a Clinical Study of a Collaboration Product hereunder, or [***]; 
 except,
in the case of clauses (a) through (d) above, for those Losses for which Genentech has an obligation to indemnify BioNTech pursuant to Section 13.1, as to which Losses each Party shall indemnify the other to the extent of their respective
liability for the Losses. 
 13.3 Certain Losses. Any Losses, other than those Losses for which indemnification is provided in
Section 13.1 or Section 13.2, in connection with any Third Party Claim brought against either Party resulting directly or indirectly from (a) the performance of the Joint Development Activities by either Party (or its Affiliates,
employees, or agents) in accordance with the GDP shall be included as a Shared Development Cost or (b) the Commercialization of a GDP Collaboration Product, or the Manufacture of a GDP Collaboration Product in support of such Commercialization
shall be included as an Allowable Expense. If either Party learns of any Third Party Claim with respect to Losses covered by this Section 13.3, such Party shall provide the other Party with prompt written notice thereof. The Parties shall
confer with respect to how to respond to such Third Party Claim and how to handle such Third Party Claim in an efficient manner. In the absence of such an agreement, each Party shall have the right to take such action as it deems appropriate. 

13.4 Notice of Claim. All indemnification claims in respect of a Party, its Affiliates, or their respective directors, officers,
employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification Claim
Notice”) of any 

  
 - 98 - 

			
	Confidential	  	Execution Copy

  

 
Losses or discovery of fact upon which such indemnified Party intends to base a request for indemnification under this Article 13, but in no event shall the indemnifying Party be liable for any
Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such
time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

13.5 Control of Defense. 

13.5.1 In General. At its option, the indemnifying Party may assume the defense of any Third Party Claim by giving written notice to
the Indemnified Party within [***] days after the indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed as an acknowledgment that
the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for
indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying Party
assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party
Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in Section 13.5.2, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such
Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically requested in writing by the indemnifying Party. In the event that it is ultimately determined that the indemnifying Party is not
obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs
of suit) and any Losses incurred by the indemnifying Party in its defense of the Third Party Claim. 
 13.5.2 Right to Participate in
Defense. Without limiting Section 13.5.1, any Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided,
however, that such employment shall be at the Indemnified Party’s own expense unless (a) the employment thereof has been specifically authorized by the indemnifying Party in writing, (b) the indemnifying Party has failed to
assume the defense and employ counsel in accordance with Section 13.5.1 (in which case the Indemnified Party shall control the defense), or (c) the interests of the indemnitee and the indemnifying Party with respect to such Third Party
Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles. 

  
 - 99 - 

			
	Confidential	  	Execution Copy

  

 13.5.3 Settlement. With respect to any Losses relating solely to the payment of money
damages in connection with a Third Party Claim and that shall not result in the Indemnified Party’s becoming subject to injunctive or other relief, and as to which the indemnifying Party shall have acknowledged in writing the obligation to
indemnify the Indemnified Party hereunder, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole
discretion, shall deem appropriate; provided that the judgment, settlement or other disposition does not and will not (a) result in a finding or admission of any violation of any Applicable Law or any violation of the rights of any person, or
(b) result in the Indemnified Party’s rights under this Agreement being adversely affected. In all other cases, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 13.5.1, the
indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Third Party Claim; provided it obtains the prior written consent of the Indemnified Party (which consent
shall not be unreasonably withheld or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend against such Third Party Claim; provided that the
Indemnified Party shall not settle any Third Party Claim without the prior written consent of the indemnifying Party, not to be unreasonably withheld or delayed. 

13.5.4 Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified
Party shall, and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials
and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided
hereunder, and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 

13.5.5 Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the
Indemnified Party in connection with any claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and
subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 
 13.6
Limitation of Liability. IN NO EVENT SHALL EITHER BIONTECH OR GENENTECH BE LIABLE FOR INDIRECT DAMAGES (INDIREKTE SCHÄDEN/MITTELBARE SCHÄDEN/WEITERE SCHÄDEN ALS SCHÄDEN MIT LANGEM KAUSALZUSAMMENHANG) OR CONSEQUENTIAL DAMAGES
(MANGELFOLGESCHÄDEN, SEKUNDÄRE SCHÄDEN, FOLGESCHÄDEN UND SCHÄDEN, DIE SICH AUS EINEM DIREKTEN SCHADEN/UNMITTELBAREN SCHADEN ERGEBEN) INCLUDING LOST PROFIT (ENTGANGENER GEWINN) ARISING FROM OR RELATED TO BREACH OF THIS
AGREEMENT, WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY, EXCEPT TO THE EXTENT SUCH DAMAGES OR LOST PROFIT ARE DUE TO THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THE OTHER PARTY; PROVIDED, HOWEVER, THAT NOTHING IN THIS SECTION 13.6 IS
INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER SECTIONS 13.1, 13.2, 13.3, 13.4 and 13.5.  

  
 - 100 - 

			
	Confidential	  	Execution Copy

  

 13.7 Insurance. 

13.7.1 Each Party shall maintain insurance coverage as set forth in this Section 13.7 at its own cost; provided, however,
Genentech has the right, in its sole discretion, to self-insure, in part or in whole, for any such coverage. The following provisions of this Section 13.7 shall not apply with respect to BioNTech’s Conduct of any Ongoing Clinical Study.

 (a) Each Party shall maintain commercial general liability (“CGL”) insurance, including contractual liability, combined single
limit for bodily injury and property damage liability, in the minimum amount per occurrence of: (i) [***] with respect to Genentech and [***] with respect to BioNTech, commencing as of the Effective Date; (ii) [***] with respect to Genentech and
[***] with respect to BioNTech, commencing at least [***] days prior to any period during which a Party (or its Sublicensees or permitted subcontractors) is conducting a clinical trial with any Collaboration Product; and (iii) [***] with respect to
Genentech and [***] with respect to BioNTech, commencing at least [***] prior to any period during which a Party (or its Sublicensees) is selling any Collaboration Product, provided, however, that, in each case, the total amount of insurance
coverage to be maintained by either Party for all occurrences per Calendar Year shall be limited to [***] of the minimum amounts per occurrence set forth above. 

(b) Each Party shall maintain products liability insurance, including contractual liability, combined single limit for bodily injury and
property damage liability, for all occurrences per Calendar Year in the minimum amount of: (i) [***] with respect to Genentech and [***] with respect to BioNTech commencing at least [***] days prior to any period during which a Party (or its
Sublicensees or permitted subcontractors) is conducting a clinical trial with any Collaboration Product and (ii) [***] with respect to Genentech and [***] Euro with respect to BioNTech commencing at least [***] prior to any period during which
a Party (or its Sublicensees) is selling any Collaboration Product; provided, however, the JDC may, via mutual agreement, upon [***] days’ notice to the Parties, increase such minimum amount, taking into account the particular Collaboration
Products then being Developed under the GDP and the methods of administration, Indications in clinical trials and projected sales thereof and, in the event the Parties enter into a Co-Promotion Agreement, the
JCC may, via mutual agreement, upon [***] days’ notice to the Parties, increase such minimum amount, taking into account the particular Collaboration Products then being co-promoted under a Co-Promotion Agreement and the methods of administration, Indications approved and projected sales thereof. 

(c) Workers’ Compensation and Employers’ Liability Insurance. Each Party shall maintain
(i) to the extent not covered by applicable statutory law (e.g. in Germany), workers’ compensation insurance in accordance with Applicable Law and (ii) employers’ liability insurance, in the minimum amount of [***] or [***]. Each
Party agrees to waive its right of subrogation with respect to workers’ compensation claim. 

  
 - 101 - 

			
	Confidential	  	Execution Copy

  

 13.7.2 Additional Requirements. Except to the extent that a Party self-insures, the
following provisions shall apply. 
 (a) All insurance coverage shall be primary insurance with respect to each Party’s own
participation under this Agreement and shall be maintained with an insurance company or companies having an A.M. Best’s rating (or its equivalent) of A XII. 

(b) The insurance policies shall be under an occurrence form, but if only a claims made form is available to a Party, such Party shall
maintain the insurance coverage for at least [***] years after such Party completes performance of its obligations under this Agreement. 

(c) Each Party’s aggregate deductibles under its CGL and Products Liability and insurance policies shall be satisfactory to the other
Party. 
 (d) On request, each Party shall provide to the other Party certificates of insurance evidencing the insurance coverage required
under this Section 13.7. Each Party shall provide to the other Party at least [***] days’ prior written notice of any cancellation, nonrenewal or material change in any of the required insurance coverages. 

ARTICLE 14. 
 TERM AND
TERMINATION 
 14.1 Term. 

14.1.1 HSR and Other Governmental Filings. The Parties shall each, as promptly as practicable after the Execution Date, file or cause
to be filed with the U.S. Federal Trade Commission and the U.S. Department of Justice and any relevant foreign governmental authority any notifications required to be filed under the HSR Act (the “HSR Filing”) or any similar
applicable foreign law or regulation with respect to the transactions contemplated hereby; provided that the Parties shall each make the HSR Filing within [***] Business Days after the Execution Date and shall each file any notifications or
filings required to be filed under any competition, antitrust or similar applicable foreign laws and regulations as promptly as reasonably practicable. The Parties shall use commercially reasonable efforts to respond promptly to any requests for
additional information made by such agencies, and to cause the waiting period (and any extension thereof) under the HSR Act to terminate or expire at the earliest possible date and obtain any required authorization or clearance under any
competition, antitrust or similar applicable foreign law or regulation (“Required Clearances”) after the date of filing. [***] In addition, each Party is responsible for the costs and expenses of its own legal and other advice in
preparing and conducting the HSR Filing or any equivalent foreign filing. 

  
 - 102 - 

			
	Confidential	  	Execution Copy

  

 14.1.2 Term. Notwithstanding anything in this Agreement to the contrary, this
Agreement (other than this Section 14.1, and Sections 9.6, 11.4.2 and 11.7, and Article 13 (other than Section 13.7) which are binding and effective as of the Execution Date) shall not become effective until the later of (a) the
expiration or earlier termination of the waiting period (or any extension thereof) under the HSR Act in the United States and the receipt of any Required Clearances and (b) the date on which each of the closing conditions set forth on
Schedule 14.1.2 are met or waived in writing by Genentech (the date when (a) and (b) are first both satisfied, the “Effective Date”), and upon the Effective Date the full Agreement and all its terms and provisions shall
be automatically effective and binding on both Parties. If, on the [***]day after the date of the HSR Filing, the waiting period required thereunder has not expired or any Required Clearances shall not have been obtained, either Party shall have the
right, on written notice to the other Party, to terminate this Agreement, and upon receipt of such notice by such other Party, this Agreement shall be null and void and have no further force and effect; provided, however, the aforesaid Sections and
Article shall survive with respect any rights that accrued to the benefit of a Party prior to such termination. If, by [***]days after the Execution Date, each of the closing conditions set forth on Schedule 14.1.2 have not been met or waived
in writing, then at any time prior to each such closing condition having been met or waived in writing, Genentech shall have the right by delivery of written notice to BioNTech to terminate this Agreement effective immediately, and upon receipt of
such notice by BioNTech, this Agreement shall be null and void and have no further force and effect; provided, however, the aforesaid Sections and Article shall survive with respect any rights that accrued to the benefit of a Party prior to such
termination. This Agreement shall commence on the Effective Date (other than the provisions effective as of the Execution Date as designated above) and, unless earlier terminated in accordance herewith, shall continue in force and effect until the
date of expiration of the Collaboration Term (or the date of expiration of the last Royalty Term for a Royalty Product, if BioNTech has exercised its Opt-Out (or a Deemed
Opt-Out has occurred pursuant to Section 8.5.3)) (such period, the “Term”). 

14.1.3 Effect of Expiration of the Term. Following the expiration of the Term, the grants in Article 9 shall become fully-paid,
royalty-free and irrevocable. 
 14.2 Termination by Either Party for Material Breach. If either Party (the “Non-Breaching Party”) believes that the other Party (or any of its Affiliates or permitted subcontractors or sublicensees) (the “Breaching Party”) has materially breached one or more of its
material obligations under this Agreement (a “Material Breach”), then the Non-Breaching Party may deliver notice of a Material Breach to the Breaching Party (a “Default
Notice”). If the Breaching Party does not dispute that it has committed a Material Breach, then if the Breaching Party fails to cure such Material Breach, or fails to take steps as would be considered reasonable to effectively cure such
Material Breach, within [***] days after receipt of the Default Notice or such other period as mutually agreed by the Parties, the Non-Breaching Party may terminate this Agreement upon written notice to the
Breaching Party. If the Breaching Party disputes that it has committed a Material Breach, the dispute shall be resolved in good faith pursuant to Section 15.7.1, or pursuant to Section 15.7.2(g), if necessary. If, as a result of the
application of such dispute resolution procedures, the Breaching Party is determined to be in Material Breach (an “Adverse Ruling”), then the Non-Breaching Party may terminate this Agreement
upon written notice to the Breaching Party. 

  
 - 103 - 

			
	Confidential	  	Execution Copy

  

 14.3 Additional Termination Rights by Genentech. 

14.3.1 For Non-Achievement of Targets. Genentech may terminate this Agreement in its entirety
upon [***] days’ prior written notice to BioNTech in the event that (a) the Core Facility and the EUFETS Facility have not achieved Operational Readiness with respect to the IVAC 2.0 Process by October 31, 2017, (b) the Clinical
Facilities have not achieved Operational Readiness with respect to the IVAC 2.1 Process by May 31, 2018, (c) BioNTech fails to achieve [***], or (d) Genentech in good faith believes that [***] 

14.3.2 For Convenience. At any time [***], Genentech may terminate this Agreement in its entirety for any or no reason, upon [***]
days’ prior written notice to BioNTech. 
 14.4 Termination for Insolvency. In the event that either entity included
within a Party (a) files for protection under bankruptcy or insolvency laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its property
that is not discharged within [***] days after such filing, (d) proposes a written agreement of composition or extension of its debts, (e) proposes or is a party to any dissolution or liquidation, or (f) files a petition under any
bankruptcy or insolvency act or has any such petition filed against that is not discharged within [***] days of the filing thereof, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such
Party. 
 14.5 Effects of Termination. In the event of a termination of this Agreement after the Effective Date for any reason,
then, from and after the effective date of termination, the provisions of this Section 14.5 shall apply. 
 14.5.1 Termination of
Licenses and Rights of Reference. As of the effective date of such termination, (a) all licenses and Rights of Reference granted by BioNTech hereunder shall immediately terminate other than the license set forth in Section 9.1.2, and
(b) all licenses and Rights of Reference granted by Genentech hereunder shall immediately terminate other than the license set forth in Section 9.2.2; except to the extent reasonably necessary for the licensee Party to fulfill its
post-termination obligations under this Section 14.5. 
 14.5.2 Wind-Down of Clinical Studies. Subject to Sections 14.5.3 and
14.5.5, except as may be otherwise agreed in writing by the Parties, each Party will be responsible for an orderly wind-down of any ongoing Clinical Studies it is Conducting as of the date of termination of this Agreement (other than those that may
be transferred under Section 14.5.3) (and, in the case of a GDP Collaboration Product, any wind-down costs associated therewith shall be included as Shared Development Costs, unless an Opt-Out has
occurred), in accordance with accepted pharmaceutical industry norms and ethical practices, including with respect to any on-going Clinical Studies hereunder. In connection with such wind-down, if one Party is
then supplying the other Party with clinical supplies for such Clinical Studies, then such supplying Party shall supply the other Party under such agreement with continued quantities of clinical supplies to fulfill demand for such clinical supplies
until [***] (and in the case of a GDP Collaboration Product if an Opt-Out has not occurred the Fully-Burdened Manufacturing Costs with respect thereto shall be included as Shared Development Costs). 

  
 - 104 - 

			
	Confidential	  	Execution Copy

  

 14.5.3 Transfer of Clinical Studies. In the event of a termination of this Agreement
by Genentech pursuant to Sections 14.3.1 or 14.3.2 or by BioNTech pursuant to Section 14.2, then, provided that [***] and except as may be otherwise agreed in writing by the Parties, upon written request of BioNTech to be delivered no later
than [***] days following the delivery of relevant termination notice, Genentech shall [***] Any transfer costs associated with such Clinical Studies shall be included as Shared Development Costs. 

14.5.4 Post-Term License. 

(a) In the event of a termination of this Agreement by Genentech pursuant to Sections 14.3.1 or 14.3.2 or by BioNTech pursuant to
Section 14.2, provided that the termination is not due to the demonstration of an unfavorable safety profile of Collaboration Product(s), then upon BioNTech’s written request to be delivered no later than [***] days following the delivery
of a notice of termination by Genentech under Section 14.3.1 or 14.3.2 or by BioNTech under Section 14.2 (“Post-Term License Notice”), Genentech shall grant to BioNTech pursuant to a separate written agreement [***] If
Genentech and BioNTech have not entered into such agreement until the effective date of termination, [***] 
 (b) In the event a
timely-delivered Post-Term License Notice requests a license under [***] In the event the Parties are unable to agree on such reasonable economic terms, the dispute shall be resolved in accordance with Section 15.7; provided that in the event
the dispute is arbitrated, the Arbitrators shall be required to adopt the economic terms proposed by one Party or the other Party, without modification, that best reflect commercially reasonable terms (i.e., baseball-style arbitration). [***] 

(c) Pursuant to mutual, good faith discussions, Genentech will transfer to BioNTech or grant a royalty-free license to BioNTech under
the trademark(s) Controlled by Genentech and solely relating to the Terminated Product(s) that has been approved by the applicable Regulatory Authority (where approval is required) and used in connection with the Commercialization of any Terminated
Product. 
 14.5.5 Transfer of Data and Regulatory Rights. In the event of a termination of this Agreement by Genentech pursuant to
Sections 14.3.1 or 14.3.2 or by BioNTech pursuant to Section 14.2, then, if prior to the effective date of termination, any IND has been filed by Genentech and provided that the termination [***], then upon written request of BioNTech to be
delivered no later than [***] days following the delivery of relevant termination notice (a) subject to Section 14.5.11, to the extent permitted by Applicable Law, such INDs and any Regulatory Approvals solely related to the applicable
Termination Products held by Genentech or its Affiliates or Sublicensees shall be transferred to BioNTech or its designee, and [***] 

  
 - 105 - 

			
	Confidential	  	Execution Copy

  

 14.5.6 Collaboration Patent Prosecution and Maintenance and Enforcement Rights. [***]

 14.5.7 Clinical Supply. In the event of a termination of this Agreement by Genentech pursuant to Sections 14.3.1 and 14.3.2 or by
BioNTech pursuant to Section 14.2 and provided that (i) Genentech has been performing Clinical Manufacture and supply of a Termination Product before the effective date of termination of this Agreement and (ii) [***], then at
BioNTech’s written request, Genentech shall, [***], continue to perform such Clinical Manufacture and supply of Termination Product, subject to any applicable surviving provisions of the Ancillary Agreements (pursuant to Section 14.5.12)
including the patient demand forecasting provisions of the MDSA. The following shall apply in respect of any activities performed by Genentech under this Section 14.5.7: 

(a) BioNTech shall pay Genentech a supply price for Collaboration Product equal to [***] 

(b) BioNTech may at any time after the effective date of termination of this Agreement, terminate the clinical supply of Collaboration
Products under this Section 14.5.7 upon [***] months’ written notice. 
 (c) During such time as Genentech is obligated to provide
clinical supply of Termination Products, it shall perform the Clinical Manufacture of Termination Product in accordance with the requirements of the MDSA (including for the avoidance of doubt with respect to Capacities and forecasting) and the
Quality Agreement. 
 14.5.8 Commercial Supply. In the event of a termination of this Agreement by Genentech pursuant to Sections
14.3.1 and 14.3.2 or by BioNTech pursuant to Section 14.2 and provided that (i) Genentech has established one or more Manufacturing Facilities that have received Licensure to provide commercial supply of a Termination Product and BioNTech
has not established any Manufacturing Facilities that have received Licensure and have sufficient Capacities for commercial supply of such Termination Product and (ii) [***], then, subject to any applicable surviving provisions of the Ancillary
Agreements (pursuant to Section 14.5.12) including the patient demand forecasting provisions of the MDSA, at BioNTech’s written request, Genentech shall: 

[***] 
 14.5.9 [***] 

14.5.10 Confidential Information. Except as otherwise necessary to continue exercising any ongoing licenses under this Agreement or any
ongoing license mutually agreed upon pursuant to Section 14.5.4, each Party will return (or destroy, as directed by the other Party) all data, files, records and other materials containing or comprising the other Party’s Confidential
Information. Notwithstanding the foregoing, (a) in respect of physical embodiments of information, the Parties will be permitted to retain one copy of such data, files, records, and other materials for
non-commercial archival purposes, and (b) in respect of any information stored electronically or in other non-physical media, it will be sufficient for such Party
to procure that access to such information is restricted to non-commercial archiving purposes only. 

  
 - 106 - 

			
	Confidential	  	Execution Copy

  

 14.5.11 Limitation. For clarity, Genentech’s obligations pursuant to Sections
14.5.2 through 14.5.10, including the licenses contemplated by Section 14.5.4 (and including Genentech’s obligation with respect to Regulatory Approvals and Regulatory Documentation pursuant to Section 14.5.5, and Genentech’s
supply obligations set forth in Sections 14.5.7 and 14.5.8), shall apply with respect to Terminated Products (or, solely to the extent expressly provided pursuant to this Section 14.5, Reversion Products) only, and shall not, for clarity,
impose any obligation on Genentech or grant any rights to BioNTech with respect to any Combination Agent except as [***] expressly and mutually agreed by the Parties in connection with a termination of this Agreement. 

14.5.12 Effect on Ancillary Agreements. In the case of termination of this Agreement for any reason, all other Ancillary Agreements
shall terminate as of the effective date of the termination of this Agreement (or such longer period as may be required to allow the Parties to comply with their obligations under Applicable Law), except that the Manufacturing Development and Supply
Agreement, the Commercial Manufacturing Agreement and the Quality Agreement(s), shall survive termination of this Agreement solely to the extent that, and as along as, BioNTech or Genentech is obliged to Manufacture and supply (clinical or
commercial) Collaboration Products pursuant to Sections 14.5.2, 14.5.7 or 14.5.8, and shall terminate thereafter. 
 14.6 Rights in
Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Genentech or BioNTech are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous
provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this
Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of
(or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly
delivered to it (a) upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to
perform all of its obligations under this Agreement, or (b) if not delivered under clause (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. The Parties acknowledge and agree that only payments under Section 8.6, royalty payments with respect to BioNTech Collaboration Product [***] pursuant to Section 5.3 and [***] shall
(i) constitute royalties within the meaning of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction or (ii) relate to licenses of intellectual property hereunder. To the extent
permitted by applicable law, the non-subject Party shall have the right but not the obligation to take over the entire ownership of the Collaboration IP in consideration for a fair compensation. 

  
 - 107 - 

			
	Confidential	  	Execution Copy

  

 14.7 Remedies. Except as otherwise expressly provided herein, termination of
this Agreement (either in its entirety or with respect to one or more country(ies)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. 

14.8 Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement (either in its entirety or with
respect to one or more country(ies)) for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from
obligations that are expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, [***] 

ARTICLE 15. 

MISCELLANEOUS 
 15.1
Force Majeure. Neither Party shall be deemed to have breached this Agreement for failure to perform its obligations under this Agreement to the extent such failure results from causes beyond the reasonable control of the affected
Party, such causes including acts of God, earthquakes, fires, floods, embargoes, wars, acts of terrorism, insurrections, riots, civil commotions, omissions or delays in action by any governmental authority, acts of a government or agency thereof and
judicial orders or decrees. If a force majeure event occurs, the Party unable to perform shall promptly notify the other Party of the occurrence of such event, and the Parties shall meet (in person or telephonically) promptly thereafter to discuss
the circumstances relating thereto. The Party unable to perform shall (a) provide reasonable status updates to the other Party from time to time; (b) use commercially reasonable efforts to mitigate any adverse consequences arising out of
its failure to perform; and (c) resume performance as promptly as possible. 
 15.2 Change in Control of BioNTech. 

15.2.1 Notice. 
 (a)
BioNTech (or its successor) shall provide Genentech with written notice of any [***] Change in Control within [***] following [***] 
 (b)
The Parties shall agree on a process to have mutually agreed outside counsel assist in making a determination as to whether [***] 

15.2.2 [***] Change in Control. In the event of any [***] Change in Control, then notwithstanding anything to the contrary
contained in this Agreement, each of the following consequences shall apply effective as of the closing date of such Change in Control, or such later date as applicable pursuant to Section 15.2.2(k): 

(a) BioNTech shall not have the right to Initiate any BioNTech Study without the prior written consent of Genentech. BioNTech may Conduct
BioNTech Study(ies), subject to all applicable provisions of this Agreement (including Section 4.5) and any Ancillary Agreements, solely in the event that any such BioNTech Study was Initiated prior to the closing date of such Change in
Control. 

  
 - 108 - 

			
	Confidential	  	Execution Copy

  

 (b) BioNTech shall no longer have the right to [***]. 

(c) BioNTech’s rights under Section 6.5, including its Co-Promotion Option for all
Indications, shall terminate, all Co-Promotion Agreements already executed shall terminate and BioNTech shall have no further Co-Promotion Option rights for any
Indication under Section 6.5. 
 (d) BioNTech’s rights to build any Commercial Facilities for inclusion in the Manufacturing
Network pursuant to Section 2.2.2 of the MDSA and any Independent Facilities outside of the Manufacturing Network (including for the Manufacture of BioNTech Collaboration Products under [***] pursuant to Section 2.2.5 of the MDSA,
respectively, shall terminate upon the closing date of a [***] Change in Control, [***] 
 (e) Each of the provisions of this Agreement
providing for any delivery by Genentech to BioNTech of Information relating to activities contemplated by this Agreement (including Sections 2.19.2(a) and 2.19.2(b)), save only for the provisions of Sections 5.8 and 5.9, shall terminate. 

(f) Genentech may request that BioNTech (including EUFETS) perform, to the extent not already completed and to enable Genentech to perform the
Clinical Manufacture of Collaboration Product at a facility to be designed, constructed, Commissioned, and Qualified by Genentech and to continue to develop the Manufacturing Process and Technology Platform, a Technology Transfer of the
Manufacturing Process from the Clinical Facilities or the Pilot Facility to Genentech, including the Development of the Manufacturing Process, Manufacturing Documentation and BioNTech Know-How and any other
reasonable activities, including any such activities that may be on-going in support of the Technology Platform Strategy and Technology Platform Roadmap. Such activities shall be included within Shared
Development Costs (except in the case of an Opt-Out, in which case the financial provisions of Section 7.3 shall apply). Genentech may, at any time, terminate such Technology Transfer activities under
this Section 15.2.2(f) upon [***] days’ written notice. BioNTech shall perform such activities in accordance with the requirements of the MDSA and the Quality Agreement. 

(g) BioNTech shall perform Clinical Manufacture and supply the quantities of Collaboration Products for Clinical Studies contemplated by the
GDP (as amended until the closing date of a Class A Competitor Change in Control) or for Genentech Studies pursuant to the applicable provisions (including patient demand forecasting provisions) of the MDSA; provided that, in the event
Genentech requests Technology Transfer, BioNTech may cease such Clinical Manufacture and supply [***] years following the first commercial launch of a Collaboration Product other than a BioNTech Collaboration Product. The following shall apply in
respect of any activities performed by BioNTech (including EUFETS) under this Section 15.2.2(g): 
 (i) Genentech shall pay BioNTech a
supply price for Collaboration Product equal to [***] 

  
 - 109 - 

			
	Confidential	  	Execution Copy

  

 (ii) Genentech may at any time after the closing date of the Class A Competitor Change
in Control terminate the clinical supply of Collaboration Product upon [***] written notice. 
 (iii) During such time as BioNTech is
obligated to provide clinical supply of Collaboration Products, it shall perform Clinical Manufacture of Collaboration Product in accordance with the requirements of the MDSA (including for the avoidance of doubt with respect to Capacities and
forecasting) and the Quality Agreement. 
 (h) The MDSA, the Commercial Manufacturing Agreement (to the extent a BioNTech Commercial
Facility within the Manufacturing Network has been Commissioned or received Licensure) and the respective Quality Agreement(s) shall survive solely to the extent that, and as long as, BioNTech provides Technology Transfer services or Manufacturing
and supply services under this Section 15.2.2, and shall terminate thereafter except for those provisions specified in the MDSA, the Commercial Manufacturing Agreement and the respective Quality Agreement(s) which expressly survive termination.

 (i) Subject to Section 15.2.2(d), each of the Committees and Teams (other than the JMT and the JMC) shall be disbanded and their
activities terminated. Genentech shall have the sole right to make the decisions assigned to the disbanded Committees and Teams and the JMC and JMT solely and exclusively by itself. Nothwithstanding the foregoing, Genentech may request in writing
that BioNTech continue its participation in any Committee or Team scheduled for automatic disbandment. In such a case, Genentech shall be responsible for the cost and expense of BioNTech’s participation in such Committee or Team based on
BioNTech’s then current FTE Rate. The JMT and JMC shall remain in effect for so long as Technology Transfer or supply of Collaboration Product by BioNTech to Genentech is ongoing or has not been completed. Thereafter, the applicable provisions
of Section 2.8.2(g) shall apply. 
 (j) BioNTech shall, and shall cause the Change in Control party to, promptly adopt and implement
and subsequently maintain and comply with written [***] Firewall procedures reasonably acceptable to Genentech. 
 (k) [***] 

15.2.3 Change in Control [***] In the event of any Change in Control other than a Class A Competitor [***], then
notwithstanding anything to the contrary contained in this Agreement, each of the following consequences shall apply effective as of the closing date of such Change in Control, subject to Section 15.2.2(k): 

(a) BioNTech shall not have the right to Initiate any BioNTech Study without the prior written consent of Genentech. BioNTech may Conduct
BioNTech Study(ies), subject to all applicable provisions of this Agreement (including Section 4.5) and any Ancillary Agreements, solely in the event that any such BioNTech Study was Initiated prior to the closing date of such Change in
Control. 

  
 - 110 - 

			
	Confidential	  	Execution Copy

  

 (b) BioNTech shall no longer have the right to seek a [***] 

(c) BioNTech’s rights to build any Commercial Facilities for inclusion in the Manufacturing Network pursuant to Section 2.2.2 of the
MDSA and any Independent Facilities outside of the Manufacturing Network (including for the Manufacture of BioNTech Indications under [***] pursuant to Section 2.2.5 of the MDSA, respectively, shall terminate upon the closing date of such
Change in Control, [***] Section 2.2.5(e) of the MDSA regarding support by Genentech with respect to Independent Facilities shall terminate upon the closing date of such Change in Control. [***] In addition, BioNTech’s JMC decision-making
rights as set forth in Section 2.8.2 shall terminate and become Genentech decision-making rights (other than with respect to [***] 

(d) [***] 
 (e) Genentech may
request that BioNTech (including EUFETS) perform, to the extent not already completed and to enable Genentech to perform the Clinical Manufacture of Collaboration Product at a facility to be designed, constructed, Commissioned, and Qualified by
Genentech and to continue to develop the Manufacturing Process and Technology Platform, a Technology Transfer of the Manufacturing Process from the Clinical Facilities or the Pilot Facility to Genentech, including the Development of the
Manufacturing Process, Manufacturing Documentation and BioNTech Know-How and any other reasonable activities, including any such activities that may be on-going in
support of the Technology Platform Strategy and Technology Platform Roadmap. Such activities shall be included within Shared Development Costs (except in the case of an Opt-Out, in which case the financial
provisions of Section 7.3 shall apply). Genentech may, at any time, terminate such Technology Transfer activities under this Section 15.2.3(e) upon [***] days’ written notice. BioNTech shall perform such activities in accordance with
the requirements of the MDSA and the Quality Agreement. 
 (f) BioNTech shall perform Clinical Manufacture and supply the quantities of
Collaboration Products for Clinical Studies contemplated by the GDP (as amended until the closing date of a non-Class A Competitor Change in Control) or for Genentech Studies pursuant to the applicable
provisions (including patient demand forecasting provisions) of the MDSA; provided that, in the event Genentech requests Technology Transfer, BioNTech may cease such Clinical Manufacture and supply [***] following the first commercial launch of a
Collaboration Product other than a BioNTech Collaboration Product. The following shall apply in respect of any activities performed by BioNTech (including EUFETS) under this Section 15.2.3(f): 

(i) Genentech shall pay BioNTech a supply price for Collaboration Product equal to [***] 

(ii) Genentech may at any time after the closing date of the Class A Competitor Change in Control terminate the clinical supply of
Collaboration Product upon [***] written notice. 

  
 - 111 - 

			
	Confidential	  	Execution Copy

  

 (iii) During such time as BioNTech is obligated to provide clinical supply of Collaboration
Products, it shall perform Clinical Manufacture of Collaboration Product in accordance with the requirements of the MDSA (including for the avoidance of doubt with respect to Capacities and forecasting) and the Quality Agreement. 

(g) The JCC shall disband, except to the extent relating to Co-Promotion by the Parties as set forth
in Section 6.5 or under any Co-Promotion Agreement. The JMT and JMC shall remain in effect for so long as Technology Transfer or supply of Collaboration Product by BioNTech to Genentech is ongoing or has
not been completed. Thereafter, the applicable provisions of Section 2.8.2(g) shall apply.     
 (h) In the event
of a Change in Control that occurs prior to [***], BioNTech shall, and shall cause the Change in Control party to, promptly adopt and implement and subsequently maintain and comply with written Change in Control Firewall procedures reasonably
acceptable to Genentech. 
 15.2.4 [***] 

15.2.5 [***] 
 15.3
Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each
Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export
requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law. 

15.4 Assignment. Except as otherwise expressly provided in this Agreement, neither Party may assign any of its rights or
obligations under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed. Either Party may assign this Agreement, in its entirety, to an acquirer of all its capital stock (by
reverse triangular merger or otherwise) or all or substantially all its assets relating to the subject matter of this Agreement and the MDSA, provided, in each case, that the party to which this Agreement is assigned expressly agrees in writing to
assume and be bound by the obligations of the assigning Party under this Agreement and is also assigned the MDSA in its entirety in accordance with the terms of Section 10.3 of the MDSA. A copy of such writing shall be provided to the non-assigning Party within [***] days of the assignment. Subject to the foregoing, this Agreement will inure to the benefit of and bind the Parties’ successors and assigns. Any assignment or delegation in
contravention of the foregoing shall be null and void. For clarity, Section 15.2 applies in the event of a Change in Control. 
 15.5
Severability. If any of the provisions of this Agreement are held to be illegal, invalid or unenforceable, such illegal, invalid or unenforceable provisions shall be replaced by legal, valid and enforceable provisions that will
achieve to the maximum extent possible the intent of the Parties, and the other provisions of this Agreement shall remain in full force and effect. 

  
 - 112 - 

			
	Confidential	  	Execution Copy

  

 15.6 Governing Law and Service. 

15.6.1 Governing Law. This Agreement shall be governed by and construed under the laws of Switzerland, without regard to conflict of
laws principles. For the avoidance of doubt, the joint ownership in the Collaboration IP, as a property right, shall be governed by the laws of Switzerland. The Parties hereby exclude from this Agreement the application of the United Nations
Convention on Contracts for the International Sale of Goods. 
 15.6.2 Service. Each Party further agrees that service of any
process, summons, notice or document by registered mail to its address set forth in Section 15.8.2 shall be effective service of process for any action, suit, or proceeding brought against it under this Agreement in any such court. 

15.7 Dispute Resolution. 

15.7.1 Internal Resolution. Except as otherwise expressly provided in this Agreement (including as otherwise expressly provided with
respect to audit disputes in Section 8.17, and Committee, Team or Working Group disputes as set forth in Article 2), any Disputes shall be first referred to a [***] for resolution, prior to proceeding under the other provisions of
Section 15.7. A Dispute shall be referred to such executives upon one Party providing the other Party with notice that such Dispute exists, and such executives (or their designees) shall attempt to resolve such Dispute through good faith
discussions. In the event that such Dispute is not resolved within [***] days of such other Party’s receipt of such notice, subject to Section 15.7.3, either Party may initiate the Dispute resolution provisions in Section 15.7.2. 

15.7.2 Arbitration. 
 (a)
Rules. Except as otherwise expressly provided in this Agreement (including under Section 15.7.3), the Parties agree that any Dispute not resolved internally by the Parties pursuant to Section 15.7.1 shall be finally resolved through
binding arbitration according to the International Chamber of Commerce (ICC) Rules of Arbitration, as applicable on the date of commencement of the arbitration proceedings. Place of arbitration shall be Zurich, Switzerland. Exclusive language of the
proceedings shall be English. In addition to the ICC Rules of Arbitration, the procedural law in force at the seat of arbitration shall apply. 

(b) Arbitrators; Language. Each Party shall select [***], and the [***] so selected shall choose a [***]. All [***] arbitrators shall
serve as neutrals and have at least ten (10) years of (i) dispute resolution experience (which may include judicial experience) or (ii) legal or business experience in the biotechnology or pharmaceutical industry. In any event, at
least one (1) arbitrator shall satisfy the foregoing experience requirement under clause (ii). If a Party fails to nominate its arbitrator, or if the Parties’ arbitrators cannot agree on the [***], the necessary appointments shall be made
in accordance 

  
 - 113 - 

			
	Confidential	  	Execution Copy

  

 
with the Rules. Once an arbitrator is appointed by a Party, such Party shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings and all pleadings and
written evidence shall be in the English language. Any written evidence originally in another language shall be submitted in English translation accompanied by the original or a true copy thereof. 

(c) Procedures; Awards. Each Party agrees to use reasonable efforts to make all of its current employees available, if reasonably
needed, and agrees that the arbitrators may deem any party as “necessary.” The arbitrators shall be instructed and required to render a written, binding, non-appealable resolution and award on each
issue that clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than [***] days after conclusion of the hearing,
unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for enforcement. Each Party agrees that,
notwithstanding any provision of applicable law or of this Agreement, it will not request, and the arbitrators shall have no authority to award any damages for which a Party may not be liable to the other Party under Section 13.6. 

(d) Costs. The “prevailing” Party, as determined by the arbitrators, shall be entitled to (i) its share of fees and
expenses of the arbitrators and (ii) its attorneys’ fees and associated costs and expenses. In determining which Party “prevailed,” the arbitrators shall consider (A) the significance, including the financial impact, of the
claims prevailed upon and (B) the scope of claims prevailed upon, in comparison to the total scope of the claims at issue. If the arbitrators determine that, given the scope of the arbitration, neither Party “prevailed,” the
arbitrators shall order that the Parties (x) share equally the fees and expenses of the arbitrators and (y) bear their own attorneys’ fees and associated costs and expenses. 

(e) Interim Equitable Relief. Notwithstanding anything to the contrary in this Section 15.7.2, in the event that a Party
reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in Article 15, such Party may seek a temporary injunction or other interim equitable relief in a court of competent jurisdiction pending
the opportunity of the arbitrators to review the decision under this Section 15.7.2. Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of temporary injunction or other interim equitable relief.
 
 (f) Protective Orders; Arbitrability. At the request of either Party, the arbitrators shall enter an appropriate
protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings. The arbitrators shall have the power to decide all questions of arbitrability. 

(g) Expedited Dispute Resolution Procedure. In the event that a Breaching Party under Section 14.2 disputes that it has committed
a Material Breach or a dispute arises under Section 4.5.4(g), and such dispute is not resolved pursuant to Section 15.7.1, then non-breaching Party under Section 14.2 or the objecting Party
under Section 15.7.2(g) may invoke the expedited dispute resolution procedure set forth in Schedule  

  
 - 114 - 

			
	Confidential	  	Execution Copy

  

 
15.7.2(g). In such a case, the expedited dispute resolution shall be limited to the issues, as applicable, of (i) whether a Material Breach was committed, whether a cure is possible
and what actions the Breaching Party must complete to effect such cure or (ii) compliance with Applicable Law in connection with a Clinical Study Conducted by BioNTech. In such a case, any other issues may be resolved through the standard
arbitration provisions set forth herein. 
 15.7.3 Subject Matter Exclusions. Notwithstanding the provisions of Section 15.7.2,
any Dispute not resolved internally by the Parties pursuant to Section 15.7.1 that involves the validity, infringement or enforceability of a Patent included in a license granted in this Agreement (a) that is issued in the United States
shall be subject to actions before the United States Patent and Trademark Office or submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants reside and (b) that is issued in any other
country (or region) shall be brought before an appropriate regulatory or administrative body or court in that country (or region), and in all cases, the Parties hereby consent to the jurisdiction and venue of such courts and bodies. 

15.8 Notices. 
 15.8.1
Notice Requirements. Except as otherwise expressly provided in this Agreement, any notice required under this Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent in accordance with the provisions of this
Section 15.8. Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in person; (b) on the date of receipt, if sent by a facsimile (including a PDF image delivered via
email); or (c) on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested (or its equivalent). Any notice sent via facsimile shall be followed by a copy of such notice by private
express courier or by first class mail. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this Section 15.8 by sending written notice to the other Party. For
clarity, notice to Genentech shall require notice to both GNE and Roche, and notice to BioNTech shall require notice to both BNT and RNP. 

15.8.2 Addresses for Notices. 

If to RNP, to: 
 BioNTech RNA
Pharmaceuticals GmbH 
 An der Goldgrube 12 

55131 Mainz 

Attention:    Managing Director 

Facsimile:    [***] 

  
 - 115 - 

			
	Confidential	  	Execution Copy

  

 If to BNT, to: 

BioNTech AG 
 An der Goldgrube
12 
 55131 Mainz 

Attention:    [***] 

Facsimile:    [***] 

If to GNE, to: 
 Genentech, Inc.

 1 DNA Way 
 South San
Francisco, CA 94080 
 Attn: [***] 

Fax: [***] 
 with a copy (which
shall not constitute notice) to: 
 Genentech, Inc. 

1 DNA Way 
 South San Francisco,
CA 94080 
 Attn: [***] 
 Fax:
[***] 
 If to Roche, to: 
 F. Hoffmann-La Roche Ltd 
 [***] 

[***] 
 [***] 

Attn: [***] 
 Fax: [***] 

with a copy (which shall not constitute notice) to: 

F. Hoffmann-La Roche Ltd 

[***] 
 [***] 

Attention: [***] 
 Fax: [***]

 15.9 Entire Agreement. This Agreement (including the Schedules hereto), together with the Ancillary Agreements,
constitute the entire understanding between the Parties with respect to the subject matter hereof and supersede and terminate all prior agreements, understandings and arrangements between the Parties with respect to such subject matter, whether
written or oral. The Parties agree that, effective as of the Effective Date, the Confidentiality Agreements shall be superseded by this Agreement, and that disclosures made prior to the Effective Date pursuant to the Confidentiality Agreements shall
be subject to the confidentiality and non-use provisions of this Agreement. [***]  

  
 - 116 - 

			
	Confidential	  	Execution Copy

  

 15.10 English Language. This Agreement shall be written and executed in, and
all other documents or communications issued or created under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict
in interpretation between the English version and such translation, the English version shall control. 
 15.11 Equitable
Relief. Each Party acknowledges and agrees that the restrictions set forth in Article 10 and Article 11 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered
into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any provision of such Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event
of a breach or threatened breach of any provision of such Articles, the non-breaching Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether
preliminary or permanent, specific performance, and an equitable accounting of all earnings, profits, and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or equity. Both Parties agree to waive any requirement that the other (a) post a bond or other security as a condition for obtaining any such relief, and (b) show
irreparable harm, balancing of harms, consideration of the public interest, or inadequacy of monetary damages as a remedy. Nothing in this Section 15.11 is intended, or should be construed, to limit either Party’s right to equitable relief
or any other remedy for a breach of any other provision of this Agreement. 
 15.12 Amendment; Waiver. Except as otherwise
expressly provided in this Agreement, no amendment to this Agreement, including this Section 15.12, shall be effective unless made in writing and executed by an authorized representative of each Party. A Party’s failure to exercise, or
delay in exercising, any right, power, privilege or remedy under this Agreement shall not (a) operate as a waiver thereof or (b) operate as a waiver of any other right, power, privilege or remedy. A waiver will be effective only upon the
written consent of the Party granting such waiver. 
 15.13 No Benefit to Third Parties. Except as provided in Article
13, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons. 

15.14 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such
further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

  
 - 117 - 

			
	Confidential	  	Execution Copy

  

 15.15 Relationship of the Parties. Except as provided in Section8.13.4,
it is expressly agreed that BioNTech, on the one hand, and Genentech, on the other hand, shall be independent contractors and that the relationship between BioNTech and Genentech shall not constitute a partnership, joint venture, or agency. Neither
BioNTech, on the one hand, nor Genentech, on the other hand, shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent
of the other Party to do so. It is expressly agreed that each Party shall solely act in its own name when dealing with any Third Party. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and
obligations incurred by reason of any such employment shall be for the account and expense of such Party.
 15.16 Counterparts; Facsimile
Execution. This Agreement may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. A facsimile (including a PDF image
delivered via email) of this Agreement, including the signature pages hereto, will be deemed to be an original. Notwithstanding the foregoing, the Parties shall deliver original execution copies of this Agreement to one another as soon as
practicable following execution thereof. 
 15.17 References. Unless otherwise specified, (a) references in this
Agreement to any Article, Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section, and (c) references to
any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or
supplemented and in effect at the relevant time of reference thereto. 
 15.18 Schedules. In the event of any inconsistencies
between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. 
 15.19
Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used
in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define,
describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall mean including, without
limiting the generality of any description preceding such term. The term “comprising” (or “comprise,” or “comprises” as used herein) shall mean “comprising, without limitation”. The language of this Agreement
shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. The phrase “by or on behalf” of a Party is not intended to include activities conducted by
the other Party or its Affiliates or Sublicensees hereunder or under any Ancillary Agreement. The term “incurred” includes “accrued”. Where a provision refers to the consent or agreement of a Party, then the consent of either
entity included within such Party shall be deemed consent of both entities included within such Party. 

  
 - 118 - 

			
	Confidential	  	Execution Copy

  

 15.20 Actions of Affiliates. Genentech may exercise its rights or perform its
obligations under this Agreement personally or through one or more Affiliates, provided that Genentech shall nonetheless be primarily liable for the performance of its Affiliates and for any failure by its Affiliates to comply with the restrictions,
limitations and obligations set forth in this Agreement. 
 [SIGNATURE PAGE FOLLOWS.] 

  
 - 119 - 

			
	Confidential	  	Execution Copy

  

 IN WITNESS WHEREOF, the Parties have caused their duly authorized officers to execute and acknowledge this
Agreement as of the date first written above. 
  

									
	GENENTECH, INC.	 		 		 	 BIONTECH RNA
 PHARMACEUTICALS
GMBH

			
	By: [***]	 		 	By: [***]
			
	Name: [***]	 		 	Name: [***]
			
	Title: [***]	 		 	Title: [***]
				
	F. HOFFMANN-LA ROCHE LTD	 		 		 	BIONTECH AG
			
	By: [***]	 		 	By: [***]
			
	Name: [***]	 		 	Name: [***]
			
	Title: [***]	 		 	Title: [***]

  

			
	F. HOFFMANN-LA ROCHE LTD
	
	By: [***]
	
	Name: [***]
	
	Title: [***]

 [SIGNATURE PAGE TO COLLABORATION
AGREEMENT] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.8 

Financial Terms 
 [***] 

  
 1.8-1 

			
	Confidential	  	Execution Copy

  

 Schedule 1.20 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.42 

BNT and RNP Existing Shareholders 
  

			
	 Person
	  	Percentage
	 Medine GmbH
	  	25.0% of BNT
	 C.Huber2008 GmbH
	  	1.5% of BNT
	 AT Impf GmbH
	  	62.8% of BNT
	 MIG GmbH & Co. Fonds 7
	  	3.3% of BNT
	 Helmut Jeggle
	  	0.2% of BNT
	 Klaus—J. Krauth
	  	0.0% of BNT
	 MIG GmbH & Co. Fonds 8
	  	1.1% of BNT
	 MIG GmbH & Co. Fonds 9
	  	3.8% of BNT
	 RLG GmbH
	  	0.6% of BNT
	 Salvia GmbH
	  	1.4% of BNT
	 Tofino GmbH
	  	0.4% of BNT
	 BNT
	  	100% of RNP

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.43 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.97 

Corporate Names 
 For GNE: 

“Genentech, a member of the Roche Group” 

“Genentech, Inc.” 
 For Roche: 

“Roche” 
 “F. Hoffmann-La Roche Ltd” 
 For RNP: 

“BioNTech RNA Pharmaceuticals GmbH” 

For BNT: 
 “BioNTech AG 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.132 

Existing Third Party In-License Agreement Royalty Payments 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.150 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.156 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.167 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 1.190 

IVAC Trademark 
  

															
	 Trademark
	  	 Country
	  	 Application
Number
	  	Application
Date	  	Registration
Number	  	Registration
Date	  	 Owner
	  	 Designated Countries

	IVAC	  	WO	  	1 103 583	  	10.10.2011	  	1 103 583	  	10.10.2011	  	BioNTech RNA Pharmaceuticals GmbH	  	CN, CH, EM, JP, US (US 4,797,141);
	IVAC	  	DE	  	30 2011 020 675.9 / 05	  	11.04.2011	  	30 2011 020
675	  	21.06.2011	  	BioNTech RNA Pharmaceuticals GmbH	  	

  

			
	Confidential	  	Execution Copy

  

 [***] 

Schedule 1.248 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 2.2 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 2.19.1(a) 

BioNTech Initial Knowledge Transfer Items 
  

													
	 No.
	  	 Document to be transfered:
	  	 Request by Genentech
	  	 Document in
German
	  	 30d transfer target
	  	60d
transfer
targe	 	90d
transfer
target
		  	A Preclinical and Clinical Data / D Regulatory and Clinical Items / F Non Clinical Items	  		  		  		  		 	
	 1
	  	NGS Data	  	 (1) All whole exome sequence data from tumor and matched normal sample-clinical (raw fast files and alignment files (bam)).

(2) All whole exome sequence data from preclinical tumor models (raw fastq files and alignment files (bam)).

(3) Mutation calls for all samples with tumor and normal exome-seq data.

(4) All whole transcriptome RNA sequence data from tumor – clinical and preclinical tumor models (raw fastq files and alignment files (bam))
	  		  	X (2; 3, 4)	  	X (1)	 	
	 2
	  	Bioinformatics software and source code	  	 All source code, objects, scripts and executables underlying the Neoepitope Prediction Algorithm within BioNTech IP, including the following
software packages (but excluding any Third Party software programs as disclosed on Schedule 12.2.1(i)):
 [***]
	  		  	X (or as otherwise may be extended as mutually agreed upon by the Parties pursuant to Section 10.9)	  		 	
	 3
	  	IVAC-B16-129    B16-M30 ELIspot Mut vs WT peptide,
B16-M30 ELISpot of truncated variants	  	All relevant preclinical Antigen Immunogenicity data	  		  	X	  		 	
	 4
	  	IVAC-B16-160    B16-M30 therapeutic vaccination (RNA,
B16F10-WT, s.c.) including depetion of CD4/8 T cells	  	All relevant preclinical Antigen Immunogenicity data	  		  	X	  		 	
	 5
	  	IVAC-B16-220    Spontaneous induction T-cell responses against B16F10 mutations	  	All relevant preclinical Antigen Immunogenicity data	  		  	X	  		 	
	 6
	  	IVAC-B16-193    B16-M30 TIL ELISpot after therapeutic vaccination (RNA, B16F10-WT)	  	All relevant preclinical Antigen Immunogenicity data	  		  	X	  		 	
	 7
	  	IVAC-B16-198    B16-M30 tumor FACS after therapeutic vaccination (RNA, B16F10-WT)	  	All relevant preclinical Antigen Immunogenicity data	  		  	X	  		 	
	 8
	  	IVAC-CT26-027    CT26 pentatope RNA vs. mixed monotope ELISpot	  	All relevant preclinical Antigen Immunogenicity data	  		  	X	  		 	

  

			
	Confidential	  	Execution Copy

  

 [***] 

  

			
	Confidential	  	Execution Copy

  

													
	 93
	  	GA-RB-007-01B_Prüfablaufprotokoll IFNg-ELISPOT-hu	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 94
	  	SOP-030-012-V.01, Auftauen von humanen PBMCs	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 95
	  	SOP-030-033-V.01, Elektroporation	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 96
	  	LA-50-234-000	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 97
	  	LA-50-236-000	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 98
	  	SOP-030-008	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 99
	  	LA-50-229-000	  	BioNTech ́s expertise to enable GNE to perform the immune monitoring assays	  		  		  	X	  	
	 100
	  	Will be provided	  	Preclinical tumor lines for which neoantigens have been identified for preclinical studies	  		  		  	X	  	
	 C
	  	RNA Platform/Liposome for Pre-Clinical Studies	  		  		  		  		  	
	 100
	  	Fluid_Path_FD.ppt	  	Relevant information of how to manufacturing liposomal-based mRNA vaccine for preclinical use	  		  		  	X	  	
	 101
	  	Material_List.doc	  	Relevant information of how to manufacturing liposomal-based mRNA vaccine for preclinical use	  		  		  	X	  	
	 102
	  	Fluid_Path_FD.ppt	  	Know-how including documents and materials to enable synthesis of mRNA vaccines at GNE for pre-clinical assessment Protocol of the lipoplex
formulation	  		  		  	X	  	
	 103
	  	Lipo_IVAC_Data_FD.ppt	  	Know-how including documents and materials to enable synthesis of mRNA vaccines at GNE for pre-clinical assessment Protocol of the lipoplex
formulation	  		  	X	  		  	
	 104
	  	 SOP_RB_F&E_033_de Codonoptimierung von Nukleinsäuren:

- procedure for codon optimization of epitope-encoding region
	  	Procedure for mRNA optimization	  	X	  	X	  		  	

  

			
	Confidential	  	Execution Copy

  

													
	 105
	  	pIVAC001_Dummy_Cassette	  	 Promoter nucleotide sequences necessary for in vitro transcription of the IVAC from a DNA template 5’ and 3’ UTR nucleotide
sequences
 Nucleotide sequences appended to IVACs Linker element nucleotide sequences, which will separate the neoepitopes within a given IVAC
	  		  	X	  		  	

 [***] 

  

			
	Confidential	  	Execution Copy

  

 [***] 
  

													
	 137
	  	 SOP_RB_FuE_046 - PCR-basierte Amplifikation mit
pEX-Primer
 - SOP PCR-based amplification using pEX primers
	  	DNA template is linearized plasmid - protocols and reagent summary reports to be provided	  	X	  	X	  		  	
	 138
	  	P_BM_11_05 Amplification & purification of plasmid DNA used as template in GMP process	  	DNA template is linearized plasmid - protocols and reagent summary reports to be provided	  		  	X	  		  	
	 139
	  	P_BM_11_06 Linearization & purification of plasmid DNA used as template in GMP process at Eufets	  	DNA template is linearized plasmid - protocols and reagent summary reports to be provided	  		  	X	  		  	

  

			
	Confidential	  	Execution Copy

  

													
	 140
	  	Ribonucleotide summary report	  	Ribonucleotides summary report	  		  	X	  		  	
	 141
	  	5’-Cap Summary Report	  	5’ cap summary report	  		  	X	  		  	
	 142
	  	Description of manufacturing process	  	In vitro transcription synthesis kit summary report and step-by-step protocol for in vitro mRNA synthesis	  		  	X	  		  	
	 143
	  	 HAN-31-04

- EUFETS SOP for RNA manufacturing
	  	In vitro transcription synthesis kit summary report and step-by-step protocol for in vitro mRNA synthesis	  	X	  	X	  		  	
	 144
	  	 FOR_RB_FuE_003A-T7 Transcription BioNTech

- Form for R&D RNA manufacturing
	  	In vitro transcription synthesis kit summary report and step-by-step protocol for in vitro mRNA synthesis	  	X	  	X	  		  	
	 145
	  	RNA purification synthesis and purification_raw materials_reagents	  	In vitro transcription synthesis kit summary report and step-by-step protocol for in vitro mRNA synthesis	  		  	X	  		  	
	 146
	  	FOR_RB_FuE_007E-magnetic bead purification_BioNTech	  	In vitro synthesized mRNA purification system summary report and step-by-step protocol for mRNA purification and quality control of the final
product.	  		  	X	  		  	
	 D
	  	Regulatory and Clinical Items	  		  		  		  		  	
	 147
	  	IMPD initial version and all amended versions RB_0003; RB_0004; BN_0002; RB_0001 (only final valid version)	  	 IMPDs of relevant clinical trials
 CTA for RB_0003-01/Lipo-MERIT, RB_0004-01/IVAC, BN_0002-01/TNBC-MERIT

Selected Trial Master File documents for relevant studies
	  		  	X	  		  	
	 148
	  	IB initial version and all amended versions RB_0003; RB_0004; BN_0002; RB_0001 (only final valid version)	  	 CTA for RB_0003-01/Lipo-MERIT, RB_0004-01/IVAC, BN_0002-01/TNBC-MERIT
 IBs for all relevant studies

Selected Trial Master File documents for relevant studies
	  		  	X	  		  	
	 149
	  	Clinical Study Protocol and Appendix initial version and all amended versions RB_0003; RB_0004; BN_0002; RB_0001 (only final valid version)	  	 CTA for RB_0003-01/Lipo-MERIT, RB_0004-01/IVAC, BN_0002-01/TNBC-MERIT
 Protocols and amendments for all relevant RNA vaccine clinical studies

Selected Trial Master File documents for relevant studies
	  		  	X	  		  	

  

			
	Confidential	  	Execution Copy

  

 [***] 

  

			
	Confidential	  	Execution Copy

  

													
	 173
	  	Questions and Company’s Position RB_0004; BN_0002	  	Health authority meeting briefing material and meeting minutes	  		  	X	  		  	
	 174
	  	Presentation for Scientific Advice RB_0004; BN_0002	  	Health authority meeting briefing material and meeting minutes	  		  	X	  		  	
	 175
	  	Minutes of Scientific Advice RB_0004; BN_0002	  	Health authority meeting briefing material and meeting minutes	  		  	X	  		  	
	 176
	  	IMGM No. RS-220VS    Validation of a quantitative Real-time PCR method for the determination of RBL001 and RBL002 in mouse blood and organs	  	Bioanalytical reports and validation reports included in the CTA	  		  	X	  		  	
	 177
	  	CSR draft version RB_0001	  	CSR draft for RB_0001/MERIT	  		  		  	X	  	
	 178
	  	Periodic Update Report DSUR current version RB_0001; RB_0003; RB_0004	  	Underlying data of current IB and any completed CSRs	  		  		  	X	  	
	 179
	  	SAE reports (not related to IMP) RB_0001; RB_0004	  	 Selected Trial Master File documents for relevant studies

Safety database-safety reports, safety correspondence
	  	(only applicabel for item 24: safety correspondance might be in german)	  		  		  	X
		  	CMC documents for the end-to-end process for clinical manufacturing	  		  		  		  		  	
	 180
	  	Current status of process UMLs can be provided	  	Current process UML diagrams	  		  	X	  		  	
	 181
	  	 Forms and Templates mentioned for Item 43 for patients uID004, uID005 and uID010

- as indicated for the blank documents for item 43, many of these are in German

- with the translated individual blank forms, the process can be easily followed
	  	 Clinical manufacturing protocols or batch records for each step of the
end-to-end IVAC1.0 manufacturing process

In-process tests including protocols and specifications for the end-to-end IVAC1.0 manufacturing process
 Completed batch records for example clinical IVAC1.0 drug substance and
drug product lots
	  	X (partly)	  	X	  		  	

  

			
	Confidential	  	Execution Copy

  

													
	 182
	  	RB_0004 In process controls DS and DP	  	In-process tests including protocols and specifications for the end-to-end IVAC1.0 manufacturing process	  		  	X	  		  	
	 183
	  	RB_0004_Release_tests_RNA_DS_DP	  	 Release tests including protocols and specifications for the IVAC1.0 drug substance and drug product

Analytical methods and protocols used for the characterization of IVAC1.0 drug substance/drug product lots
	  		  	X	  		  	

 [***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 2.19.1(c) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 [***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 3.1.2 

Research Plan 
 Introduction

 Research Collaboration Objectives 
 [***] 

Key Components of the Research Collaboration and Associated Activities 

[***] 
 I. [***] for [***] and
Prioritization 
 Background 
 [***] 

Proposed areas for potential improvement 
 [***] 

Proposed Initial Studies/Activities 
 [***] 

II. Preclinical Research 
 Background 

[***] 
 Proposed Initial Research Studies/Activities 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 4.3.1 

Ongoing Clinical Studies 
  

					
	 Study Number
	  	 RB_0004-01
	  	
BN_0002-01

	Study Name	  	IVAC MUTANOME	  	TNBC-MERIT
			
	EudraCT Number	  	2013-001645-13	  	2014-002274-37
			
	Study Title	  	Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with
IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002 vaccine in patients with advanced melanoma	  	 First-in-human clinical study with RNA-Immunotherapy combination of IVAC_W_bre1_uID and IVAC_M_uID
 for Individualized Tumor Therapy in Triple
Negative Breast Cancer Patients

			
	Phase	  	I	  	I
			
	Investigational Medical Product(s)	  	 RBL0001/RBL0002
 IVAC MUTANOME
(RBMv1.0_uID_A/RBMv1.0_uID_B)
	  	 IVAC_W_bre1_uID

IVAC_M_uID

 Note: 
 For study BN_0002-01/TNBC-MERIT the following amended versions of CTA documents are being drafted and do not require additional approval of the JDC. 
  

	 	1.	 CSP: V6.0 First-in-human
clinical study with RNA-Immunotherapy combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients 

 

	 	2.	 CSP: V7.0 First-in-human
clinical study with RNA-Immunotherapy combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients 

 

	 	3.	 IMPD: V8.0 BN_0002-01/TNBC-MERIT Mutanome Engineered RNA
Immuno-Therapy IVAC_W_bre1_uID IVAC_M_uID 

  

	 	4.	 IB: V6.0 BN_0002-01/TNBC-MERIT 

  
 4.3.1-1 

			
	Confidential	  	Execution Copy

  

 For study RB_0004-01/IVAC-MUTANOME, the following amended versions of
CTA documents are being drafted and do not require additional approval of the JDC. 
 [***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 4.4.1 

Initial GDP 
 Draft Global Development
Plan and Estimated Timelines 
 [***] 
 Non-Clinical GDP Activities 
 [***] 

Introduction 
 Key Components of the Non-Clinical Development Plan and Associated Activities 
 [***] 

 

	I.	 [***] 

[***] 
 II. Clinical [***] 

Background 
 [***] 

Proposed Initial Studies/Activities 
 [***] 

III. Non-Clinical Research 

Non-Clinical [***] studies 

Background 
 [***] 

Proposed Initial Non-Clinical Studies/Activities 

[***] 

  
 4.4.1-1 

			
	Confidential	  	Execution Copy

  

 Appendix 4.4.1(I) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 5.3 

Key Terms for the Amendment of the Agreement in the event of a BioNTech [***] 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 6.5.3 

Key Terms of Co-Promotion Agreement 

This Exhibit sets forth material terms and conditions that, together with the terms of Section 6.5.4 of the Agreement, shall be incorporated into a Co-Promotion Agreement to be negotiated and entered into by the Parties regarding each Collaboration Product and each Indication for which BioNTech exercises its option to
Co-Promote in accordance with Section 6.5 of the Agreement (each such Collaboration Product and Indication, the “Co-Promotion Product”). 

 

	1.	 Sales Force 

  

	 	i.	 Establishment [***] 

 

	 	ii.	 Qualification [***] 

 

	 	iii.	 Product-Specific Training [***]

 

	2.	 Commercialization Activities [***] 

 

	3.	 Sales Activity Tracking [***] 

 

	4.	 Promotional Materials and Standards [***] 

 

	5.	 Sales Information Integration [***] 

 

	6.	 [***]Commercialization Responsibilities [***] 

 

	7.	 Miscellaneous [***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 8.4 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 8.4.1 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 8.9 

Bank Accounts 
 [***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 9.1.4 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 10.3.1(c)(i) 

[***] 

  

 Execution Copy 

Schedule 11.2.4 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 11.4.2 

Form of Press Release 

BioNTech to enter into worldwide strategic collaboration with Genentech to develop individualized mRNA cancer therapies 

Collaboration will draw upon Genentech’s leading position in cancer immunotherapy and BioNTech’s premier clinical mRNA vaccine
platform 
 Mainz, Germany September 21, 2016: BioNTech AG, a fully integrated private biotechnology company developing personalized cancer
immunotherapies, today announced that it will enter into a worldwide strategic collaboration with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel messenger RNA (mRNA)-based, individualized cancer vaccines. The
collaboration will combine Genentech’s leading cancer immunotherapy portfolio and research program with BioNTech’s proprietary mRNA cancer vaccine technology platform, and personalized medicine expertise. Together, the two companies will
develop individually tailored cancer immunotherapies against a broad range of cancers to potentially provide a new treatment paradigm for cancer patients. 

The collaboration will focus on the development of mRNA cancer vaccines targeting neoantigens, based upon BioNTech’s Individualized
Vaccines Against Cancer (IVAC®) MUTANOME clinical platform for the potential treatment of multiple cancers. A patient’s cancer genome can be rapidly sequenced with
next generation technology to define a spectrum of unique mutations known as “neoantigens” or “neoepitopes” present in a particular patient’s tumor (the “mutanome”). An mRNA vaccine encoding selected neoepitopes
can be manufactured for each individual tumor’s mutanome signature, which may trigger an immune response highly specific to the tumor resulting in precisely targeted cancer cell death. 

Initial clinical development will focus on combination studies using IVAC® MUTANOME in a variety
of cancer types. 
 Under the terms of the agreement Genentech will pay BioNTech $310 million in upfront and near-term milestone payments. The two
companies will equally share all development costs and any potential profits for certain programs under the agreement. BioNTech has the right to co-promote certain products that arise from the agreement in the
United States and certain countries, including Germany and other major European markets. Under certain circumstances, BioNTech may have sole commercialization rights for other products that Genentech elects not to commercialize. BioNTech will
manufacture mRNA cancer vaccines for clinical studies. Genentech will manufacture mRNA cancer vaccines for commercial supply and BioNTech will have the right to manufacture commercial product as part of the global supply network. 

  

			
	Confidential	  	Execution Copy

  

 Professor Dr. Ugur Sahin, CEO of BioNTech AG commented: “We are delighted to
collaborate with a leading cancer immunotherapy company such as Genentech. Supported by its extensive tumor immunology understanding, BioNTech has been building clinical experience with its proprietary mRNA vaccines in a number of cancer types over
several years. Combining BioNTech’s broad proprietary capabilities in the design, formulation, manufacturing and clinical testing of individualized neoantigens-based mRNA vaccines with Genentech’s eminent cancer immunotherapy, diagnostic,
manufacturing and commercial expertise, will allow us, on a global scale, to drive forward the development of individualized vaccines to the market to treat a broad range of cancers. Sean Marett, COO of BioNTech added: ”This alliance
underpins BioNTech’s strategy of collaborating with companies that are committed to developing truly disruptive immunotherapies and its long term ambitions of bringing its own products to market .” 

“Unlike any medicine we have ever developed, virtually all cancer patients may potentially benefit from a custom built cancer vaccine,” said
James Sabry, M.D., Ph.D., Senior Vice President and Global Head of Genentech Partnering. “By collaborating with BioNTech on this cutting edge approach, we hope to truly advance cancer treatments by using a common molecular backbone
– mRNA – that is uniquely tailored to an individual patient.” 
 BioNTech will continue to develop its
non-neoepitope mRNA cancer vaccines outside of the collaboration. 
 The completion of the agreement is subject to
customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to occur in the fourth quarter of 2016. 

For more information, please contact: 
  

					
	BioNTech AG	  	 	  	Hume Brophy, for BioNTech AG
			
	Regina Jehle	  		  	Mary Clark, Eva Haas, Alexia Faure
			
	Tel: +49 (0) 6131 9084 1273	  		  	Tel: +44 (0) 20 7862 6381
			
	Email: Regina.Jehle@biontech.de	  		  	Email: biontech@humebrophy.com

 About BioNTech AG 

BioNTech AG is an immunotherapy leader with bench-to-market capabilities,
developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through
innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an
in-house molecular diagnostics unit whose products include MammaTyper® a molecular in-vitro diagnostic kit, marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held and shareholders include the MIG Fonds, Salvia, and the Strüngmann
Family Office, with the Strüngmann Family Office as the majority shareholder. 
 Information about BioNTech is available at www.biontech.de.

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.2.1(a) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.2.1(c) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.2.1(i) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.2.2(a) 

Existing Third Party In-License Agreements 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.2.3(e) 

Safety Reporting 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.2.3(g) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 12.3.1(h) 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 14.1.2 

Closing Conditions 
  

	 	 	 [***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 14.3.1 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 14.5.4 

[***] 

  

			
	Confidential	  	Execution Copy

  

 Schedule 15.7.2(g) 

Expedited Arbitration 
  

	[***]EX-10.15

 Exhibit 10.15 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

Patent Sublicense Agreement 

This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a
place of business at 726 Post Road, Madison, WI 53713, USA, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and BioNTech AG, a German corporation having its
principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”). This Agreement is effective as of July 14, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to
herein as a “Party” and collectively as the “Parties”. 
 BACKGROUND 

WHEREAS, mRNA RiboTherapeutics, Inc. (“mRNA RiboTherapeutics”) has an exclusive license from the Trustees of the University of
Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) for certain intellectual property comprising patents, patent applications and technology relating to [***] and certain other intellectual property comprising patents,
patent applications and technology relating to [***], as stated in the second amended and restated patent license agreement which became effective December 20, 2016 (the “Penn License Agreement”), under which, Cellscript has a
sublicense from mRNA RiboTherapeutics in certain fields of use as stated in the amended and restated patent sublicense agreement which became effective December 20, 2016 (the “Cellscript Sublicense Agreement”) as amended on
June 25, 2017, under which Cellscript has the right to further sublicense all or any part of the rights granted to Cellscript to other parties; and 

WHEREAS, Company desires a sublicense from Cellscript under Patents Rights (as defined below) for in vivo uses in humans and non-human animals and certain other uses pertaining thereto and Cellscript is willing to grant to Company a sublicense under Patents Rights for such uses under the terms and conditions herein; 

NOW, THEREFORE, in consideration of the mutual obligations contained in this Agreement, and intending to be legally bound, the Parties agree
as follows: 
  

	1	 SUBLICENSE 

1.1 Sublicense Grant. Cellscript hereby grants to Company and Company hereby accepts from Cellscript a worldwide, non-exclusive sublicense under the Patent Rights during the Term to make, have made, import, use, offer for sale, sell and/or have sold Licensed Products according to the terms and conditions herein: (1) in
Field of Use B for all uses in the In Vivo Field of Use, including: (a) all therapeutic and prophylactic uses in humans; (b) all non-therapeutic and non-prophylactic uses in humans; and (c) all uses, including therapeutic and prophylactic uses (e.g., Veterinary Products), in non-human animals; and (2) in Field
of Use A for: research and screening uses, including pre-clinical research and screening comprising ex vivo uses in human or non-human animal cells and in
vivo uses in animals that pertain to and support research, development, manufacture, regulatory approval and commercialization of Licensed Products for use in humans and non-human animals in the In
Vivo Field of Use in (1)(a) through (1)(c), as all Fields of Use in (1) and (2) (collectively, the “Sublicensed Fields of Use”) and as said other terms which are not defined in this Section 1.1 are defined in Sections
1.2 and 6.1 herein (the “Sublicense”). The Sublicense includes the right for Company to grant sublicenses to its affiliates and Third Parties for all or any part of the rights and fields of use granted to Company, under terms that
are consistent with this Agreement. No other rights or licenses are granted to Company hereunder by Cellscript. [***] 

  
 1 

 1.2 Related Definitions. 

Whenever the words or terms “comprising,” “containing,” “having,” “include,” includes,”
“including,” “such as,” “for example,” “an example,” “examples,” “e.g.,” “for further clarification” or the like are used in this Agreement, they shall be understood to be
followed by the words “without limitation” or “but without limitation”. The terms “a,” “an,” and “the” and the use of such terms or nouns in definitions in either the singular or the plural are to be
construed to cover both the singular and the plural unless otherwise noted. 
 “Licensed Products” means products that are
made, made for, used, imported, offered for sale or sold by Company or its Affiliates or Third Party sublicensees and that, in the absence of a license to Patent Rights, (i) would infringe (or, in the case of pending patent applications, upon
issuance, would infringe) at least one claim of the Patent Rights or (ii) use a process or machine covered by a claim of Patent Rights, whether the claim is issued or pending. For clarity, Licensed Products includes any method, procedure or
process, the use of which by Company or its Affiliates or Third Party sublicensees, in the absence of a license to Patent Rights by the user, would infringe, induce to infringe or contribute to infringing one or more claims of Patent Rights whether
the claim is issued or pending. 
 “Exhibit A-1 Patent Rights” means [***] 

“Exhibit A-2 Patent Rights” means [***] 

“Patent Rights” means Exhibit A-1 Patent Rights and/or Exhibit A-2 Patent Rights. 
 “Exhibit D Patents” means all of Penn’s patent rights
represented by or issuing from: (a) the United States patents and patent applications listed in Exhibit D; (b) any continuation, divisional, reexamination, and re-issue applications of (a); and
(c) any extensions (a) or (b). 
 “Affiliate” means a legal entity that is controlling, controlled by or under
common control with Company and that has executed either this Agreement, a sublicense for at least a portion of the rights granted to Company under this Agreement, or a written joinder agreement agreeing to be bound by all of the terms and
conditions of this Agreement. The uncapitalized term “affiliate” means, with respect to a first legal entity, any other legal entity that is controlling, controlled by or under common control with said first legal entity. For
purposes of the definitions of “Affiliate” and “affiliate” herein, the word “control” means (x) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal
entity, (y) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. 

“Field of Use A” means and is limited to internal laboratory research or screening [***] For clarity, Field of Use A includes
laboratory research use in animals or human or animal cells, living or dead, from any source, including for pre-clinical laboratory research in laboratory animals or cultured human or non-human animal cells for the purpose of generating data and information prior to use in clinical trials for a use that requires approval by the FDA or another regulatory organization. For further clarity, a party
that has a sublicense in Field of Use A pertaining to a sublicensed therapeutic or prophylactic or diagnostic or prognostic use in Field of Use B shall have the right to perform pre-clinical research in Field
of Use A comprising in vivo uses in non-human animals or ex vivo uses in human or non-human animal cells in order to obtain data and information to support
pre-clinical development of such therapeutic, prophylactic, diagnostic or prognostic products. 

  
 2 

 [***] 

“Field of Use B” means the field other than Field of Use A and includes but is not limited to therapeutic, prophylactic,
diagnostic, prognostic and cosmetic uses in humans and agricultural, animal improvement and veterinary uses in animals. For clarity, Field of Use B includes any and all fields of use, including the In Vivo Field of Use and Ex Vivo
Field of Use, other than for Field of Use A. 
 “Fields of Use” means Field of Use A and Field of Use B. 

“Ex Vivo Field of Use” is a subfield of Field of Use A or Field of Use B wherein a product or method that is
covered by Patent Rights (or Exhibit D Patents) is used in cells, tissues or organs that are ex vivo or outside of a living human or animal body or organism, whether those cells, tissues or organs are subsequently used only ex vivo,
such as in culture, or are subsequently introduced into, used in or administered or applied to or on a living body or organism. [***] 

“In Vivo Field of Use” is a subfield of Field of Use A or Field of Use B wherein a product or method that is
covered by Patent Rights (or Exhibit D Patents) is used in vivo, [***] 
 “Diagnostic and Prognostic Field of Use”
is a subfield of use within Field of Use B wherein a product or service covered by Patent Rights (or Exhibit D Patents) is used for diagnosis, prognosis or testing of a human or non-human animal or a sample
therefrom in order to detect, identify, determine a cause, evaluate, analyze, understand, predict, rule in, or rule out a medical condition or disease or to predict an effect or response to treatment, and/or to monitor the effect of a treatment of
such medical condition or disease. For clarity, a party that has a sublicense to make, have made, import, use, offer to sell and/or sell a Licensed Product for the Diagnostic and Prognostic Field of Use in conjunction with or pertaining to a product
covered by Patent Rights (or Exhibit D Patents) for the In Vivo Field of Use in Field of Use B shall have the right to use said Licensed Product for diagnosis, prognosis or testing of a human or
non-human animal or a sample therefrom, whether said diagnosis, prognosis or testing is performed in vitro, in vivo and/or ex vivo. 

“Veterinary Product” means a product that is covered by Patent Rights (or Exhibit D Patents) which is used for the care,
treatment, breeding or use of livestock or companion animals. 
 “Third Party” means any person, corporation, partnership,
association, consortium or business, legal or governmental entity other than Penn, Cellscript, Company or any of their respective affiliates. 

“Infectious Disease Vaccine Subfield” is a subfield of Field of Use B wherein a product that is covered by Patent Rights is
used as a vaccine for prevention or treatment of one or more infectious disease(s) caused by an infectious agent or agents consisting of viruses, bacteria, fungi, protozoa or parasites. For clarity, the Infectious Disease Vaccine Subfield does not
include the right to use Patent Rights to make, have made, import, use, offer for sale, sell and/or have sold any product that is covered by Patent Rights for prevention or treatment of any cancer (e.g., as a therapeutic or prophylactic cancer
vaccine) in humans or animals. 
 1.3 Reservation of Rights by Penn. Penn reserves the right to use, and to permit other non-commercial entities to use, the Patent Rights for educational and non-commercial research purposes. 

[Remainder of page left blank] 

  
 3 

 1.4 U.S. Government Rights. The Parties acknowledge that the United States government
retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement
that products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States. To the extent any such U.S. manufacturing requirements apply, Cellscript shall, upon request of
Company, use commercially reasonable efforts to cause Penn to seek a waiver from the United States government for Company in respect of such U.S. manufacturing requirements. 

1.5 Sublicense Conditions. Company’s right to extend any or all of the rights granted to Company by Cellscript via a sublicense to
affiliates or Third Parties is subject to each of the following conditions:  
 1.5.1 Company will have the right to
grant further sublicenses to its affiliates and to Third Parties (“sub-sublicensees”) that permit multiple levels of sublicensing, including in Third Party
sub-sublicenses that permit further levels of sublicensing (e.g., to “sub-sub-sublicensees”). In each further sub-sublicense agreement to an affiliate or Third Party, Company will require the sub-sublicensee to comply with terms and conditions that are consistent with this Agreement,
and in each agreement for further sublicensing (e.g., by a sub-sublicensee of Company to a sub-sub-sublicensee), the party
granting the further sublicense will require the party receiving the further sublicense to comply with terms and conditions that are consistent with its sub-sublicense agreement from Company. Except when used
to clarify the meaning of the different terms in this Section 1.5.1, the term sublicense in this Agreement includes any permitted sub-sublicense, sub-sub-sublicense, etc. and the term sublicensee includes any permitted sub-sublicensee,
sub-sub-sublicensee, etc. 
 1.5.2 Within [***] days after
Company enters into a sublicense agreement, Company will deliver to Cellscript a complete and accurate copy of the entire sublicense agreement written in the English language, provided that Company will have the right to redact the terms and
conditions of such sublicense agreement that are not necessary for Cellscript to confirm compliance with all terms and conditions required under this Sublicense, including Section 1.5 hereof. Cellscript’s receipt of the sublicense
agreement will not constitute a waiver of any right or obligation of Cellscript or of Company under this Agreement. 
 1.5.3 In the event
that Company causes or experiences a Trigger Event (as defined in Section 6.4), to the extent permissible by law, all payments due to Company from its direct sublicensees pursuant to a sublicense to this Agreement that are payable by Company to
Cellscript hereunder, including milestone payments and royalty payments, will, upon notice from Cellscript to such sublicensees, become payable directly to Cellscript for the account of Company. Upon receipt of any such funds, Cellscript will remit
to mRNA RiboTherapeutics the amounts owed to mRNA RiboTherapeutics and will remit to Company the amount (if any) by which such payments from such sublicensees exceed the amounts owed by Company to Cellscript hereunder. Still

  
 4 

 
further, in the event that mRNA RiboTherapeutics causes or experiences a trigger event according to the terms of the Penn License Agreement, Cellscript agrees that, upon notification from Penn,
Cellscript will remit to Penn all amounts payable by Cellscript to mRNA RiboTherapeutics under the Cellscript Sublicense Agreement (including but not limited to all milestone payments and royalty payments) for the account of mRNA RiboTherapeutics.

 1.5.4 Company’s execution of a sublicense agreement will not relieve Company of any of its obligations under this Agreement. Company
is primarily liable to Cellscript for any act or omission of a sublicensee that would be a breach of this Agreement if performed or omitted by Company, and Company will be deemed to be in breach of this Agreement as a result of such act or omission.
Upon learning of any such breach of this Agreement due to an act or omission of a sublicensee of Company, Company will immediately take appropriate actions to stop such act or omission, including termination of the sublicense by Company. Provided
that Company takes such appropriate actions and stops such act or omission, a breach by said sublicensee shall not be considered a breach by Company that will be considered a cause for termination of this Agreement under Section 6.3. 

1.5.5 A sublicense granted by the Company or a further sublicensee thereof will not be assignable or transferable by said sublicensee or
further sublicensee thereof without the prior written consent of Cellscript, except to an affiliate of the sublicensee of Company or an affiliate of said further sublicensee thereof, or to a Third Party company that: (i) can demonstrate based
on reliable financial information that it has all technical knowledge, capabilities and/or financial resources needed to perform in all respects in the place and stead of said sublicensee or further sublicensee thereof; (ii) agrees to assume
all duties and responsibilities under the sublicense; (iii) warrants that it will invest an amount of money that Company agrees is sufficient to develop and/or commercialize the sublicensed Licensed Product(s); (iv) purchases more than fifty
percent (50%) of all of the sublicensee’s or the further sublicensee’s shares or assets to which the sublicense pertains; and (v) agrees in writing to be bound by all of the terms and conditions of the sublicense and a copy of such
written undertaking is promptly provided to Company, which will provide a copy to Cellscript, which, in turn, will provide a copy to mRNA RiboTherapeutics. 

1.6 No License by Implication. Nothing in this Agreement confers by estoppel implication or otherwise, any license or rights under any
Penn patent other than rights granted under patents included in the Patent Rights and Exhibit D Patents, regardless whether such patents are dominant or subordinate to the Patent Rights and Exhibit D Patents. 

1.7 License to the Exhibit D Patents. Whereas Cellscript has an exclusive license from Penn for certain other U.S. patents and patent
applications listed in Exhibit D attached hereto, including any continuation, divisional, reexamination, and re-issue applications and any patents or extensions of any of the foregoing (collectively referred
to as “Exhibit D Patents” herein), which Exhibit D Patents are not included in Patent Rights herein; and whereas, Company desires a sublicense to Exhibit D Patents in the Sublicensed Fields of Use during the Term and Cellscript is
willing to grant such a sublicense in the Sublicensed Fields of Use according to the terms and conditions herein, now, therefore, Cellscript hereby grants to Company and Company hereby accepts from Cellscript a limited worldwide, non-exclusive sublicense under Exhibit D Patents during the Term to make, have made, import, use, offer for sale, sell and/or have sold products comprising mRNA containing pseudouridine solely in the Sublicensed
Fields of Use, and according to the terms and conditions herein. The sublicense includes the right for Company to grant sublicenses to its Affiliates and Third Parties for all or any part of the rights granted to Company in the Sublicensed
Fields of Use, under terms that are consistent with this Agreement. 

  
 5 

 
No other rights or licenses pertaining to Exhibit D Patents are granted by Cellscript to Company under this Agreement. For clarity, no rights or licenses are granted by Cellscript to Company:
(x) in Field of Use A for the Research Products Field of Use; or (y) in Field of Use B for any use in humans or non-human animals for (i) the Ex Vivo Field of Use, or (ii) the
Diagnostic and Prognostic Field of Use, or (iii) to make, have made, import, use, offer for sale, sell and/or have sold any product covered by Exhibit D Patents which does not comprise or use mRNA comprising pseudouridine. Company understands
and agrees that, since the products sublicensed to Company pursuant to this Section 1.7 comprise or use mRNA comprising pseudouridine (which products are also covered by Patent Rights), Company shall pay to Cellscript the same milestone and
other fees and royalties owed by Company pursuant to Article 3 of this Agreement; however, Company shall not owe any additional milestone or other fees or royalties for products covered by Exhibit D Patents in addition to the amounts owed by Company
pursuant to Article 3 of this Agreement. 
 1.8 Relation of this Agreement to mRNA RiboTherapeutics Sublicense Agreement. Concurrent
with the execution of this Agreement, Company is entering into a separate sublicense agreement with mRNA RiboTherapeutics (the “mRNA RiboTherapeutics Sublicense Agreement”), pursuant to which mRNA RiboTherapeutics is granting
Company a sublicense under Patent Rights with respect to certain fields of use that are different from and are not included within the scope of the Sublicense granted to Company in this Agreement. 

 

	2	 DILIGENCE 

2.1 Development Plan and Sublicense Disclosure Report. By [***] and by [***] of every calendar year thereafter that encompasses the
Term, Company will deliver to Cellscript: (1) a copy of an annual development plan, including a projected timeline, for the Patent Rights and a summary of material development efforts for Licensed Products since the last development plan
(“Development Plan”); and [***] certified as correct by the accounting services manager or chief financial officer, that includes all additional information as listed on Exhibit B for the period since the last SDR. 

2.2 Company’s Efforts. Company will use commercially reasonable efforts to develop, commercialize, market and sell Licensed
Products in the Sublicensed Fields of Use in a manner consistent with the Development Plan. In addition to Company’s own efforts to develop, commercialize, market and sell Licensed Products, the efforts of other parties, including Affiliates,
Third Party sublicensees, contractors, Third Parties funded by Company under a research or service agreement, and distributors, will also be deemed as efforts of Company. 

2.3 Diligence Events. Company, whether itself, or through its Affiliates, Third Party sublicensees, contractors, or Third Parties funded
by Company under a research or service agreement, will use commercially reasonable efforts to achieve each of the milestone diligence events by the applicable completion date listed in the table below for the first Licensed Product for human
therapeutic or prophylactic use in Field of Use B. Company will provide Cellscript with written notice within [***] days of first completion of each milestone diligence event for a Licensed Product for human therapeutic or prophylactic use in Field
of Use B by Company or an Affiliate or Third Party sublicensee. 
 [Remainder of page left blank] 

  
 6 

 [***] 

2.4 Diligence Resources. Until the first Sale of the first Licensed Product in Field of Use B, Company will expend financial resources for the
development and commercialization of the Licensed Products in amounts not less than the diligence minimums specified in the table below (“Development Expenditures”) in each [***] month period following the Effective Date.
Development Expenditures shall include all research and development expenditures directly relating to Licensed Products, including salaries, overhead, sponsored research payments, contract research, regulatory expenses, and documented external
consulting payments. Company’s expenditures of financial resources for the development and commercialization of Licensed Products in Field of Use B in amounts not less than the specified Development Expenditures will be deemed commercially
reasonable efforts to develop, commercialize, market and sell Licensed Products in Field of Use B. If Company’s total expenditures for development and commercialization of Licensed Products in any [***] month period ending on an anniversary of
the Effective Date do not meet or exceed the applicable diligence minimum, then Company will pay to Cellscript the amount of the shortfall. Company will make any payments of the shortfall to Cellscript together with the next Development Plan due to
Cellscript under Section 2.1. 
 [***] 
  

	3	 FEES AND ROYALTIES 

3.1 Sublicense Grant Fees. In partial consideration for the Sublicense, Company will pay to Cellscript: (i) [***]; and (ii) [***] and
(iii) [***] 
 [Remainder of page left blank] 

  
 7 

 3.2 Sublicense Maintenance Fees. In partial consideration of the Sublicense, Company
will pay to Cellscript [***] on each anniversary of the Effective Date during the Term until the date of first Sale of the first Licensed Product in Field of Use B, regardless of whether the Sale is achieved by Company, Cellscript, or an affiliate
or sublicensee of any of the foregoing. For clarity, the next annual sublicense maintenance fee under this Agreement is payable to Cellscript on [***] if no Sale of a Licensed Product in Field of Use B occurs prior to [***] 

3.3 Milestone Payments. In partial consideration of the Sublicense, Company will pay to Cellscript any milestone payment that is
applicable to a Licensed Product developed by the Company under any of the tables in this Section 3.3 the first time after achieving each milestone event for each said Licensed Product in Field of Use B, regardless of whether the milestone is
achieved by Company, an Affiliate or a Third Party sublicensee. Company will provide Cellscript with written notice within [***] days after each milestone is achieved by Company or a sublicensee and Company will pay to Cellscript all applicable
milestone payments owed therefor within [***] days of the end of the calendar quarter in which the milestone event is achieved. For clarity, each time a milestone is achieved with respect to a Licensed Product, then any other milestone payments with
respect to earlier milestones that have not yet been paid will be due and payable together with the milestone payment that is actually achieved. For clarity, if a Licensed Product being developed by Company or its sublicensees does not fall into one
of the categories in the tables below, Company will notify Cellscript promptly after identifying the Licensed Product and the Parties will negotiate in good faith appropriate milestones based on the relative value of the product category and the
development pathway. 
  

			
	 Section 3.3 Table A

MILESTONES for each Licensed Product for

human therapeutic or prophylactic use in the In Vivo Field of
Use

 [***] 

  
 8 

			
	 Section 3.3 Table C

MILESTONES for each Licensed Product that is a Veterinary Product

[***] 
 3.4 Earned
Royalties. In partial consideration of the Sublicense, Company will pay to Cellscript royalties on Net Sales of Licensed Products in the Sublicensed Fields of Use as stated below. 

3.4.1 Earned Royalties on Licensed Products in Field of Use A. In partial consideration of the Sublicense, Company will pay to
Cellscript a [***] royalty on Net Sales of Licensed Products by Company or its Affiliates or Third Party sublicensees for use in the Sublicensed Fields of Use in Field of Use A during the Quarter. For the avoidance of doubt, if Company or any
Affiliate or Third Party sublicensee sells or is reimbursed for the costs of providing a Licensed Product for use in Field of Use A to another party with which it has a contract to collaborate or work together on researching, developing or screening
related to a product for human therapeutic or prophylactic use in the In Vivo Field of Use, then Company will pay to Cellscript a [***] royalty on all such Net Sales of Licensed Products for use in Field of Use A by Company or by said
sublicensees. For clarity, Company and its Affiliates or Third Party sublicensees shall only have the right to sell Licensed Products for use in Field of Use A to Third Parties that have either a sublicense from or a contract with Company or an
Affiliate or Third Party sublicensee to research, develop, test, evaluate, screen, manufacture and/or commercialize a Licensed Product for use in the In Vivo Field of Use in Field of Use B. 

3.4.2 Earned Royalties on Licensed Products Field of Use B. In partial consideration of the Sublicense, Company will pay to Cellscript a
[***] royalty on Net Sales of Licensed Products in Field of Use B for all uses in the In Vivo Field of Use, including: (a) all therapeutic or prophylactic uses in humans; (b) all
non-therapeutic or non-prophylactic uses in humans; and (c) all uses, including therapeutic and prophylactic uses (e.g., Veterinary Products), in non-human animals during the Quarter. For the avoidance of doubt, if Company or its Affiliates or Third Party sublicensees grant sublicenses to sell Licensed Products for any such uses in Field of Use B, Company
will pay to Cellscript a [***] royalty on Net Sales of all such Licensed Products sold by said sublicensees. For clarity, no royalties are due under this Agreement for Sales of Licensed Products in the Diagnostic and Prognostic Field of Use, which
are sublicensed to Company in the Sublicense Agreement from mRNA RiboTherapeutics. 
 3.4.3 Royalty Reduction. If Company or an
Affiliate or Third Party sublicensee of Company is obligated to pay Third Party Royalties (defined below) for a Licensed Product in Field of Use B, then Company may deduct [***] of such Third Party Royalties from any royalties on Net Sales in Field
of Use B due to Cellscript under Section 3.4.2 of this Agreement, provided that: 
 (a) On an ongoing basis and prior to
reduction of any royalty on Net Sales for a given calendar quarter, Company first provides written evidence to Cellscript of Company’s or applicable sublicensee’s obligation to pay such Third Party Royalties; and 

  
 9 

 (b) In no event shall royalties on Net Sales due to Cellscript in any
reporting period be so reduced to less than [***] for Licensed Products for use in the In Vivo Field of Use in Field of Use B. 

“Third Party Royalties” means any royalty obligation in excess of [***] that Company or an Affiliate or a Third Party
sublicensee owes to one or more other parties pursuant to one or more licenses for patent rights comprising [***] and that are determined to be necessary to avoid infringement-related litigation with respect to the manufacture, use or sale of any
Licensed Product. 
 3.5 Related Definitions. 

3.5.1 The term “Sale” means any bona fide transaction for which consideration is received or expected by Company or its
Affiliates or Third Party sublicensees for the sale, use, lease, transfer or other disposition of a Licensed Product to a Third Party. A Sale is deemed completed at the time that Company or an Affiliate or Third Party sublicensee invoices, ships or
receives payment for a Licensed Product, whichever occurs first. 
 3.5.2 The term “Quarter” means each three-month period
beginning on the first day of January, April, July or October. 
 3.5.3 The term “Net Sales” means the consideration
received or expected from, or the fair market value attributable to, each Sale, less Qualifying Costs that are directly attributable to a Sale, specifically identified on an invoice or other documentation and actually borne by Company or its
Affiliates or Third Party sublicensees. For purposes of determining Net Sales, the words “fair market value” mean the cash consideration that Company or its Affiliates or Third Party sublicensees would realize from an unrelated
buyer in an arm’s length sale of an identical item sold in the same quantity and at the time and place of the transaction. 
 3.5.4 The
term “Qualifying Costs” means: (a) credits or refunds for claims or returns that do not exceed the original invoice amount; (b) prepaid outbound transportation expenses and transportation insurance premiums; and
(c) sales and use taxes and other fees imposed by and indefeasibly paid to a governmental agency. 
 3.6 Minimum Royalties. In
partial consideration of the Sublicense, [***] Company will pay to Cellscript the amount, if any, by which the applicable minimum royalties listed in the tables below exceed Company’s or its Affiliates’ or Third Party sublicensees’
actual earned royalties under Section 3.4 for each Quarter after the first Sale of a Licensed Product by Company or its Affiliates or Third Party sublicensees in the applicable Categories. The minimum royalties are divided into two Categories
and outlined in the tables below and are tiered, cumulative and individually payable after first Sale of Licensed Product in each of the three respective Categories. For clarity, the highest minimum royalty owed by Company to Cellscript under this
Agreement would be [***] For additional clarification, Company is not obligated to pay minimum royalties to Cellscript for Licensed Products in Category 1 until after the first Sale of a Licensed Product in Field of Use A by Company or its
Affiliates or Third Party sublicensees; Company is not obligated to pay minimum royalties to Cellscript for Licensed Products in Category 2 until after the first Sale of a Licensed Product in Field of Use B for human therapeutic or prophylactic use
in the In Vivo Field of Use by Company or its Affiliates or Third Party sublicensees; and Company is not obligated to pay minimum royalties to Cellscript for Licensed Products in a Category 3 until after the first Sale of Licensed Product in
Field of Use B that is not a humans therapeutic or prophylactic by Company or its Affiliates or Third Party sublicensees. 

  
 10 

 Category 1 - Licensed Products in Field of Use A 

 

									
	QUARTER:	  	First Four
Quarters	 	 	All Subsequent
Quarters	 
	 MINIMUM:
	  	 	[	***] 	 	 	[	***] 

 Category 2 - Licensed Products in Field of Use B 

For Therapeutic or Prophylactic Use in Humans 
  

									
	QUARTER:	  	First Four
Quarters	 	 	All Subsequent
Quarters	 
	 MINIMUM:
	  	 	[	***] 	 	 	[	***] 

 Category 3 - Licensed Products in Field of Use B 

That Are NOT 
 For
Therapeutic or Prophylactic Use in Humans 
  

									
	QUARTER:	  	First Four
Quarters	 	 	All Subsequent
Quarters	 
	 MINIMUM:
	  	 	[	***] 	 	 	[	***] 

  

	4	 REPORTS AND PAYMENTS 

4.1 Royalty Reports. Within [***] days after the end of each Quarter following the first Sale, Company will deliver to Cellscript a
report, certified as accurate by the accounting services manager or chief financial officer of Company, detailing the calculation of all royalties, fees and other payments due to Cellscript for such Quarter. The report will include, at a minimum,
the following information for the Quarter, each listed by product, by country: [***] 
 [Remainder of page left blank] 

  
 11 

 4.2 Payments. Company will pay all royalties, fees and other payments due to
Cellscript under Sections 3.3, 3.4 and 3.6 within [***] days after the end of the Quarter in which the royalties, fees or other payments accrued. Cellscript agrees that it will pay all such amounts to mRNA RiboTherapeutics according to and within
the time periods required by the Cellscript Sublicense Agreement, and mRNA RiboTherapeutics will pay to Penn all royalties, fees and other payments due to Penn according to and within the time periods required by the Penn License Agreement. For
clarity, only one royalty will be due with respect to the Sale of the same unit of Licensed Product. 
 4.3 Records. Company will
maintain, and will cause its Affiliates and Third Party sublicensees to maintain, complete and accurate books, records and related background information to verify Sales, Net Sales, and all of the royalties, fees, and other payments due or paid
under this Agreement, as well as the various computations reported under Section 4.1. The records for each Quarter will be maintained for at least [***] years after submission of the applicable report required for Section 4.1. 

4.4 Audit Rights. Upon reasonable prior written notice to Company, Company and its Affiliates and Third Party sublicensees will provide
Penn and its accountants (or Cellscript and its accountants in the event that Cellscript is Penn’s designated auditor) with access to all of the books, records, key personnel and related background information required by Section 4.3 to
conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to
facilitate such accountant’s review or audit without unreasonable disruption to Company’s business; and (c) no more than once each calendar year during the Term (as defined below) and for a period of [***] years thereafter. Company
will promptly pay to Cellscript the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Company has underpaid any payment by [***] or more, then Company will also promptly pay
the costs and expenses of the auditing party’s accountants in connection with the review or audit. In addition, once annual Sales of Licensed Products exceed [***] Company will conduct, at least once every [***] years at its own expense, an
independent audit of Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement for the period since the last such audit. Promptly after completion of the audit, Company will provide to Cellscript a copy of
the report of the independent auditors along with any underpayments and interest thereon. 
 4.5 Currency. All dollar amounts referred
to in this Agreement are expressed in United States dollars. All payments will be made in United States dollars. If Company receives payment from a sublicensee in a currency other than United States dollars for which a royalty or fee is owed under
this Agreement, then (a) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which
the payment was received by Company, and (b) the conversion computation will be documented by Company in the applicable report delivered to Cellscript under Section 4.1. 

[Remainder of page left blank] 

  
 12 

 4.6 Place of Payment. All payments by Company to CELLSCRIPT, LLC and will be made to
the following addresses: 
 [***] 

4.7 Interest. All amounts that are not paid by Company when due will accrue interest from the date due until paid at a rate equal to
[***] (or the maximum allowed by law, if less). 
  

	5	 CONFIDENTIALITY AND USE OF NAMES 

5.1 Confidentiality. Each Party agrees that it will not, under this Agreement, provide to the other Party or its affiliates any
Confidential Information of such Party unless (i) such Party has first identified the general nature of such Confidential Information to such other Party in writing and such other Party has affirmatively agreed in writing to receive such
Confidential Information, or (ii) such other Party has specifically requested such Confidential Information in writing. For clarity, any such consent or request issued by email or other written electronic means shall satisfy the foregoing
“writing” requirements. Any Confidential Information disclosed by a Party to the other Party other than in accordance with this Section 5.1 will be deemed not to be Confidential Information of such Party. Notwithstanding the
foregoing, Cellscript is obligated to accept and treat as confidential any Confidential Information disclosed by Company in the reports or notices required by Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.5, 4.6 and 6.6, which information Company
agrees Cellscript may disclose to mRNA RiboTherapeutics or Penn without the prior written consent of Company. 
 5.2 Confidential
Information. Each Party (“Disclosing Party”) may disclose to the other Party (“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under the Agreement, certain
proprietary or confidential information of Disclosing Party in connection with this Agreement. The term “Confidential Information” shall mean all ideas and information of any kind, whether in written, oral, graphical,
machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party in accordance with Section 5.1. 

5.3 Restrictions. During the Term and for [***] years thereafter, Receiving Party shall keep all Disclosing Party’s
Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information. Receiving Party shall not use Disclosing Party’s Confidential Information except in connection with the
performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent, to the extent and only
to the extent reasonably necessary, to Receiving Party’s affiliates and their employees, subcontractors, consultants or agents who have a need to know such Confidential Information in order to perform Receiving Party’s obligations
or exercise Receiving 

  
 13 

 
Party’s rights under this Agreement, provided said affiliates and their employees, subcontractors, consultants or agents are required to comply with a written confidentiality
agreement having restrictions on use and disclosure of Disclosing Party’s Confidential Information which are no less stringent than those in this Section 5.3. Receiving Party assumes responsibility for compliance with such restrictions by
its affiliates and their employees, subcontractors, consultants or agents. 
 5.4 Exceptions. Receiving Party’s obligation of
nondisclosure and the limitations upon the right to use the Disclosing Party’s Confidential Information shall not apply to the extent that Receiving Party can demonstrate, as evidenced by contemporaneous written records, that the Disclosing
Party’s information: (i) was known to Receiving Party or any of its affiliates prior to the time of disclosure; (ii) is or becomes public knowledge through no fault or omission of Receiving Party or any of its affiliates;
(iii) is obtained by Receiving Party or any of its affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; (iv) has been independently developed by employees, subcontractors, consultants or agents of
Receiving Party or any of its affiliates without the aid, application or use of Disclosing Party’s Confidential Information or (v) is not Confidential Information under Section 5.1. 

5.5 Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the extent (and only to the
extent) such disclosure is reasonably necessary in the following instances: 
 5.5.1 in order to comply with applicable law (including any
securities law or regulation or the rules of a securities exchange) or with a legal or administrative proceeding; 
 5.5.2 in connection with
prosecuting or defending litigation, regulatory approvals and other regulatory filings and communications, and filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and

 5.5.3 in connection with exercising its rights hereunder, to its affiliates; to potential and future collaborators and sublicensees;
permitted acquirers or assignees; and investment bankers, investors and lenders, except that Cellscript will obtain the prior written consent of Company before disclosing any information disclosed to Cellscript pursuant to Sections 2.1, 2.3, 3.3,
3.4.3(a), 4.1, 4.4, 4.6 and 6.6; 
 provided that (1) with respect to Sections 5.5.1 or 5.5.2, where reasonably possible,
Receiving Party shall notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem
appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Section 5.5.3, each of those named people and entities are required to comply with the restrictions on use and disclosure in
Section 5.3 (other than investment bankers, investors and lenders, which must be bound prior to disclosure by commercially reasonable obligations of confidentiality). 

5.6 Terms of this Agreement. The Parties agree that the terms of this Agreement shall be treated as Confidential Information of both
Parties, and thus may be disclosed only as permitted by Section 5.5. Each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or the terms hereof without the prior written consent of
the other Party not to be unreasonably withheld. 

  
 14 

 5.7 Relationship to the Confidentiality Agreement. This Agreement is in addition to
certain “Confidentiality Agreements” between the Parties dated the 1st of January, 2014, and the 4th of January, 2017, and
(a) all “Confidential Information” as defined therein that is disclosed or received by the Parties prior to the Effective Date shall continue to be subject to the terms and conditions of the Confidentiality Agreement and
(b) all Confidential Information disclosed or received by the Parties following the Effective Date shall be subject to the terms and conditions of this Agreement. For the avoidance of doubt, all other confidentiality agreements concluded
between Cellscript and Company prior to the Effective Date of this Agreement shall be superseded by this Agreement. 
 5.8 Use of
Penn’s, Cellscript’s or Company’s Name. Company and its Affiliates, Third Party sublicensees, employees, and agents are not granted any rights hereunder to use the name, logo, seal, trademark, or service mark (including any
adaptation of them) of Penn or any Penn school, or their respective organizations, employees, students or representatives, without the prior written consent of Penn. Except to the extent permitted pursuant to this Article 5, neither Party shall have
any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name or trademark of the other Party for any Purpose, except as may be required by applicable law or regulation. 

 

	6	 TERM AND TERMINATION 

6.1 Term. This Agreement will commence on the Effective Date and terminate upon the expiration or abandonment of the last patent to
expire or become abandoned of the Patent Rights and Exhibit D Patents (the “Term”). 
 6.2 Early Termination by
Company. Company may terminate this Agreement at any time effective upon completion of each of the following conditions: (a) providing at least [***] days prior written notice to Cellscript of such intention to terminate; (b) ceasing
to make, have made, use, import, offer for sale and sell all Licensed Products under the Sublicense; (c) providing documentation stating that all sublicenses granted by Company which are still in force at the date of termination can be assigned to
Cellscript and working with Cellscript to assign or terminate such sublicenses based on the specific circumstances related thereto; and (d) paying all amounts owed to Cellscript under this Agreement through the effective date of termination. For
clarity, Company may individually terminate either the Sublicense to Exhibit A-1 Patent Rights or the Sublicense to Exhibit A-2 Patent Rights or the Sublicense to
Exhibit D Patents provided that each of the conditions stipulated in Section 6.2 is met with respect to the Patent Rights and Exhibit D Patents terminated from the Sublicense. [***] 

6.3 Early Termination by Cellscript. Cellscript may, to the extent permissible by law, terminate this Agreement if: (a) Company is
more than [***] late in paying to Cellscript any amounts owed under this Agreement and does not pay Cellscript in full, including accrued interest, within [***] after receiving written notice of the breach from Cellscript (a “Payment
Default”); or (b) other than a Payment Default, Company materially breaches this Agreement and Company does not cure the breach within [***] after receiving written notice of the breach from Cellscript; or (c) Company causes or
experiences a Trigger Event, or an Affiliate or Third Party sublicensee of Company commences or causes a Patent Challenge (as defined Section in 6.4 below) and Company does not terminate the sublicense or cause the Patent Challenge to be terminated
prior to or promptly upon learning of said Patent Challenge. It is understood that, with respect to both of (a) and (b), Company is also responsible for its Affiliates and Third Parties sublicensees. 

  
 15 

 6.4 Trigger Event. The term “Trigger Event” means any of the
following: (a) Company (i) becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers
the appointment of a custodian, receiver or trustee for its assets and, if appointed without its consent, not discharged [***], (v) makes an assignment of its assets for the benefit of creditors, or (vi) suffers proceedings being instituted
against it under any law related to bankruptcy, insolvency, dissolution, liquidation or the reorganization, readjustment or release of multiple debtors and, if contested by it, not dismissed or stayed within [***]; (b) the institution or
commencement by Company of any proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of multiple debtors; (c) the entering of any order for relief relating to any of the
proceedings described in Section 6.4(a) or (b) above; (d) the calling by Company of a meeting of multiple creditors with a view to arranging a composition of adjustment of its debts; (e) the act or failure to act by Company that
results in its consent to, approval of, or acquiescence in any of the proceedings described in Section 6.4(a) - (d) above; or (f) the commencement by Company or an Affiliate or Third Party sublicensee of Company of any action against Penn
to declare or render invalid or unenforceable the Patent Rights or Exhibit D Patents or any claim thereof, including but not limited to an action for declaratory judgment (a “Patent Challenge”). 

6.5 Effect of Termination. 

6.5.1 Effect of Termination Except under Section 6.2. Upon the termination of this Agreement prior to expiration of
the Term for any reason except pursuant to Section 6.2: (a) the Sublicense to the Patent Rights and Exhibit D Patents will terminate; (b) Company and all its Affiliates will cease all making, having made, using, importing, offering for
sale and selling of all Licensed Products with respect to Patent Rights and Exhibit D Patents under the Sublicense, except to the extent permitted by Section 6.5.1(f) and Section 6.6; (c) Company will pay to Cellscript all amounts,
including accrued interest, owed to Cellscript under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6,
whether or not payment is received prior to termination or expiration of the sell off period permitted by Section 6.6; (d) Company will, at Cellscript’s request, return to Cellscript all Confidential Information of Cellscript (if any)
related to exploitation of Patent Rights and Exhibit D Patents and provide to Cellscript one summary of all work related thereto for Licensed Products generated by Company during the Term in order to facilitate the further development of the
technology licensed under this Agreement; (e) in the case of termination under Section 6.3, all duties of Cellscript and all rights (but not duties) of Company under this Agreement immediately terminate without further action required by
either Cellscript or Company; and (f) all outstanding Third Party sublicenses, to the extent each is not in default, will be assigned by Company to Cellscript, such assignment will be accepted by Cellscript, and each Third Party sublicense
agreement will remain in full force and effect with Cellscript as the sublicensor instead of Company, but the duties and obligations of Cellscript under the assigned sublicense agreements will not be greater than the duties of Cellscript under this
Agreement and the rights of Cellscript under the assigned sublicenses will not be less than those of Cellscript under this Agreement, including all financial consideration and other rights of Cellscript, and Cellscript may, at its sole discretion,
amend such assigned agreements to contain terms and conditions found in this Agreement. [***] 

  
 16 

 6.5.2 Effect of Termination under Section 6.2. Upon the
termination of this Agreement under Section 6.2: (a) the Sublicense to Company and all further sublicenses to Affiliates and Third Parties terminate (except to the extent that said Third Party sublicenses become direct sublicenses of Cellscript
pursuant to Section 6.5.2(e)); (b) Company, its Affiliates and Third Party sublicensees will cease all making, having made, using, importing, offering for sale and selling all Licensed Products under the Sublicense, except to the extent
permitted pursuant to Section 6.5.2(e) and Section 6.6; (c) Company will pay to Cellscript all amounts, including accrued interest, owed to Cellscript under this Agreement through the date of termination, including royalties on Licensed
Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6, whether or not payment is received prior to termination or expiration of the sell off period permitted by Section 6.6, and
(d) Company will, at Cellscript’s request, return to Cellscript all confidential information of Cellscript; and (e) all outstanding sublicenses of Company to Third Parties and all outstanding sublicenses of Company’s Affiliates
to Third Parties, to the extent each is not in default, will be assigned by Company or its Affiliates to Cellscript (and Company will contractually obligate its Affiliates to make or cause such assignments and work with Cellscript to effect such
assignments), and each such assigned sublicense agreement will remain in full force and effect (including for sublicensed Exhibit A-1 Patent Rights and Exhibit A-2
Patent Rights and Exhibit D Patents) with Cellscript as the sublicensor instead of Company, but the duties and obligations of Cellscript under the assigned sublicense agreements will not be greater than the duties and obligations of Company under
this Agreement, and the rights of Cellscript under the assigned sublicense agreements will not be less than the rights of Company under this Agreement, including all financial consideration and other rights of Company, and Cellscript may, at its
sole discretion, amend such assigned sublicense agreements to contain financial or other terms and conditions found in this Agreement (excluding payment obligations which have already been satisfied by Company). 

[Remainder of page left blank] 

  
 17 

 6.6 Inventory & Sell Off. Subject to the remainder of this
Section 6.6, upon the termination of this Agreement for any reason, Company will: (1) cause physical inventories to be taken immediately of: (a) all completed Licensed Products on hand under the control of Company and its Affiliates
and Third Party sublicensees and (b) such Licensed Products as are in the process of manufacture and any component parts on the date of termination of this Agreement; (2) deliver promptly to Cellscript a copy of said written inventory,
certified by an officer of Company; (3) promptly remove, efface or destroy or require or cause to be removed, effaced or destroyed all references to Penn and Cellscript from any advertising, labels, web sites or other materials used in the
promotion of the business of Company or its Affiliates or Third Party sublicensees; and (4) not represent in any manner that it has rights in or to the Patent Rights or Exhibit D Patents or the Licensed Products under this Sublicense and cause
its Affiliates and Third Party sublicensees not to represent that they have any rights in or to the Patent Rights or Exhibit D Patents or the Licensed Products. Subject to this Section 6.6, Company and its Affiliates and Third Party
sublicensees may sell off its inventory of Licensed Products existing on the date of termination for a period of [***] months and pay Cellscript royalties on Sales of such inventory within [***] days following the expiration of such [***] month
period. Notwithstanding the foregoing: (i) Company’s obligations under this Section 6.6 will not apply to the Sublicense or to Company’s sublicense agreements if the Sublicense is assigned to mRNA RiboTherapeutics pursuant to
Section 6.5.1; and (ii) the obligations of each of Company’s sublicensees pursuant to this Section 6.6 will not apply to Company’s or its Affiliates’ or Third Party sublicensees’ sublicense agreements that are
assigned to Cellscript pursuant to Sections 6.5.1(f) or 6.5.2(e); and, (iii) Company’s and its Affiliates’ and Third Party sublicensees’ obligations under this Section 6.6 will not apply with respect to any Licensed Product
that is for use in a Field of Use for which Company (and its Affiliates or Third Party sublicensees) has a different sublicense agreement (e.g., under the mRNA RiboTherapeutics Sublicense Agreement). 

6.7 Survival. Company’s obligation to pay all amounts, including accrued interest, owed to Cellscript under this Agreement will
survive the termination of this Agreement for any reason. Articles 5, 6, 11, 12 and 13 and Sections 4.1 (until all Licensed Products which have been manufactured during the Term have been Sold), 4.2, 4.3 (for the time period set forth therein for
all Sales of Licensed Products which have been manufactured during the Term), 4.4 (for the time period set forth therein) and 4.5-4.7, 9.1.1, 9.1.4 (for all amounts paid by Company to Cellscript following
termination that are payable to mRNA RiboTherapeutics), 9.2.2, 9.2.4 (for all amounts that are payable to Penn which are paid by Company and received by mRNA Therapeutics from Cellscript following termination), and 9.1.8, 9.2.7, 9.3.3, and 9.7 will
survive the termination of this Agreement in accordance with their respective terms. The Parties acknowledge and agree that the Sublicense is, for the purposes of section 365(n) of the U.S. Bankruptcy Code, a license to “intellectual
property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties intend that all payments under Article 3 of this Agreement constitute “royalties” within the meaning of section 365(n) of the U.S. Bankruptcy
Code. 
  

	7	 PATENT PROSECUTION AND MAINTENANCE 

7.1 Patent Control for Patent Rights. Penn and mRNA RiboTherapeutics control the preparation, prosecution and maintenance of the Patent
Rights and the selection of patent counsel, subject to the remainder of this Section 7.1. For purposes of this Section 7.1, the word “maintenance” includes any interference negotiations, claims, or proceedings, in any forum,
brought by Penn, or its exclusive licensee, mRNA RiboTherapeutics (if so authorized by Penn), a Third Party, or the United States Patent and Trademark Office or any foreign equivalent pertaining to Patent Rights, and any requests by Penn or mRNA
RiboTherapeutics (if so authorized by Penn) 

  
 18 

 
that the United States Patent and Trademark Office or any foreign equivalent reexamine or reissue any patent in the Patent Rights. Notwithstanding the foregoing, Cellscript will provide Company
and its counsel with reasonable opportunities to consult with Cellscript regarding prosecution and maintenance of Patent Rights. 
 7.2
Patent Control for Exhibit D Patents. Penn and Cellscript control the preparation, prosecution and maintenance of the Exhibit D Patents and the selection of patent counsel, subject to the remainder of this Section 7.2. For purposes of
this Section 7.2, the word “maintenance” includes any interference negotiations, claims, or proceedings, in any forum, brought by Penn, or its exclusive licensee, Cellscript (if so authorized by Penn), a Third Party, or the United
States Patent and Trademark Office pertaining to Exhibit D Patents, and any requests by Penn or Cellscript (if so authorized by Penn) that the United States Patent and Trademark Office reexamine or reissue any patent in the Exhibit D Patents.
Notwithstanding the foregoing, Cellscript will provide Company and its counsel with reasonable opportunities to consult with Cellscript regarding prosecution and maintenance of Exhibit D Patents. 

 

	8	 INFRINGEMENT 

8.1 Control. Company shall not have any right to initiate litigation with respect to infringement of the Patent Rights or Exhibit D
Patents. 
 8.2 Cooperation. In any litigation under this Article 8, each Party, at the reasonable request and sole expense of
the other Party, will provide reasonable cooperation to such other Party. This Article 8 will not be construed to require either Party to undertake any activities, including legal discovery, at the request of any Third Party, except as may be
required by lawful process of a court of competent jurisdiction. 
  

	9	 COVENANTS, REPRESENTATIONS, WARRANTIES AND DISCLAIMER OF WARRANTIES 

9.1 Covenants of Cellscript. Cellscript covenants to Company that, during the Term: 

9.1.1 Cellscript will take all reasonable actions necessary to maintain Cellscript’s rightsunder the Cellscript Sublicense Agreement and,
to the extent within its power, will ensure that the rights granted to Company herein are maintained. In the event of termination of the Cellscript Sublicense Agreement, this Agreement will be assigned to mRNA RiboTherapeutics without any further
action by the Parties, and the sublicenses granted hereunder, to the extent they are not in breach or default, will remain in full force and effect with respect to the sublicensed Exhibit A-1 Patent Rights,
Exhibit A-2 Patent Rights. 
 9.1.2 Cellscript will use diligent efforts not to breach the Cellscript
Sublicense Agreement in any manner that could result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement, and, in the event of any such breach, Cellscript will use diligent efforts to expeditiously cure
Cellscript’s breach of the Cellscript Sublicense Agreement. 
 9.1.3 Upon Cellscript learning of any breach of a sublicense agreement by
any sublicensee of Cellscript or any of its further sublicensees in any manner that could result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement, Cellscript will expeditiously take appropriate actions to
stop such act or omission, up to and including termination of the applicable sublicense, as stated in Section 1.5.4 of the Cellscript Sublicense Agreement. 

  
 19 

 9.1.4 Cellscript will make all payments due under the Cellscript Sublicense Agreement, and
will make all required disclosures to mRNA RiboTherapeutics in connection therewith, in each case in a timely manner in accordance with the terms thereof. 

9.1.5 Promptly following Cellscript’s receipt of any material written notice or correspondence pertaining to the Sublicense that could
reasonably be expected to adversely affect Company’s rights under this Agreement, Cellscript will, to the extent permissible, furnish a copy of such notice or correspondence to Company, provided that Cellscript may redact portions of any such
written notice or correspondence that does not relate to or impact Company’s rights hereunder. 
 9.1.6 Cellscript acknowledges and
agrees that, to the extent that Company reasonably and in good faith requests that the Parties engage with mRNA RiboTherapeutics to seek a reasonable amendment or modification to a provision of the Cellscript Sublicense Agreement that is applicable
to Company, the Parties will engage with mRNA RiboTherapeutics to discuss such amendment or modification. 
 9.1.7 To the extent permissible,
Cellscript will promptly notify Company if Cellscript receives a notice from mRNA RiboTherapeutics of intent to terminate the Penn License Agreement 

9.1.8 Cellscript agrees that it will not sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third
Party sublicensees, or their successors in ownership (to which this Agreement or a sublicense under this Agreement is assigned according to terms and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for
infringement of or misappropriation of Patent Rights or Exhibit D Patents that are used by Company or its Affiliates or Third Party sublicensees or their successors in ownership solely in and for the Sublicensed Fields of Use under this Agreement,
as Fields of Use are defined in Section 1.2, or the fields of use sublicensed to Company under the mRNA RiboTherapeutics Sublicense Agreement. [***] This covenant shall terminate with the termination of this Agreement unless the
termination is: (a) made under Section 6.3, and (b) within [***] days following receipt of notice by Cellscript of termination under Section 6.3, is either: (i) resolved by Company and Cellscript in writing, or
(ii) Company initiates a state or federal lawsuit contesting said termination (“Contested Termination”). In the event of a Contested Termination, this covenant shall continue to run during the [***] days, and if a
lawsuit is initiated, until said state or federal court enters a final decision from which no appeal has been or can be taken. 
 9.1.9
Cellscript will not amend the Cellscript Sublicense Agreement in any manner that would negatively affect the rights and/or obligations of the Company under this Agreement. 

9.1.10 Cellscript will not exercise any right to terminate the Cellscript Sublicense Agreement. 

9.2 Covenants of mRNA RiboTherapeutics. mRNA RiboTherapeutics covenants to Company as follows: 

9.2.1 mRNA RiboTherapeutics will not terminate the Cellscript Sublicense Agreement without good and reasonable cause. 

9.2.2 In the event of termination of the Cellscript Sublicense Agreement, provided that Company did not cause said termination of the
Cellscript Sublicense Agreement and is not in breach or default under this Agreement, this Agreement will be assigned to mRNA RiboTherapeutics without any further action by Cellscript, mRNA RiboTherapeutics will accept

  
 20 

 
assignment of this Agreement from Cellscript and this Agreement, including all of Company’s outstanding Third Party sublicenses thereunder, will remain in full force and effect with respect
to the sublicensed Exhibit A-1 Patent Rights and Exhibit A-2 Patent Rights, with mRNA RiboTherapeutics as the sublicensor instead of Cellscript, but the duties and
obligations of mRNA RiboTherapeutics under the assigned Agreement will not be greater than the duties of Cellscript under this Agreement and the rights (including all financial consideration and other rights) of mRNA RiboTherapeutics under the
assigned Sublicense will not be less than those of Cellscript under this Agreement, and mRNA RiboTherapeutics may, at its sole discretion, amend such assigned agreements to contain terms and conditions found in the Cellscript Sublicense Agreement;
and Cellscript shall grant a separate sublicense to Company to use the Exhibit D Patents in the Sublicensed Fields of Use. 
 9.2.3 Upon mRNA
RiboTherapeutics learning of any breach of a sublicense agreement by any sublicensee or any further sublicensees thereof in any manner that could result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or
Penn having the right to terminate the Penn License Agreement, mRNA RiboTherapeutics will expeditiously take appropriate actions to stop such act or omission, up to and including termination of the applicable sublicense. 

9.2.4 mRNA RiboTherapeutics will make all payments due under the Penn License Agreement and will make all required disclosures to Penn in
connection therewith, in each case in a timely manner in accordance with the terms thereof. 
 9.2.5 Promptly following mRNA
RiboTherapeutics’ or any of its affiliates’ receipt of any material written notice or correspondence pertaining to the Company’s sublicense agreement from Cellscript that would reasonably be expected to adversely affect Company’s
rights thereunder, mRNA RiboTherapeutics will, to the extent permissible, furnish a copy of such notice or correspondence to Cellscript and to Company, provided that mRNA RiboTherapeutics, as applicable, may redact portions of any such notice or
correspondence that do not relate to or impact Company’s rights. 
 9.2.6 mRNA RiboTherapeutics will promptly notify Cellscript and
Company if it receives a notice from Penn of any intent to terminate the Penn License Agreement. 
 9.2.7 mRNA RiboTherapeutics agrees that
mRNA RiboTherapeutics and its affiliates will not sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third Party sublicensees or their successors in ownership (to which this Agreement or a sublicense
under this Agreement is assigned according to terms and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for infringement of or misappropriation of any Patent Rights (as defined in Section 1.2) that are used
by Company or its Affiliates or Third Party sublicensees or their successors in ownership in the In Vivo Field of Use (as defined in Section 1.2) within the Sublicensed Fields of Use. For clarity, the foregoing covenant does not provide
Company or its Affiliates or Third Party sublicensees or their successors in ownership immunity from any suit, action or claim for infringement of or misappropriation of Patent Rights if Company or its Affiliates or Third Party sublicensees or their
successors in ownership use(s) any Patent Rights in a Field of Use that is not sublicensed to Company. For further clarity, the foregoing covenant also does not provide Company or its Affiliates or Third Party sublicensees or their successors in
ownership immunity from any suit, action or claim for infringement of or misappropriation of any patent rights that are not Patent Rights (as defined in Section 1.2) if Company or its Affiliates or Third Party sublicensees or their successors
in ownership use(s) any 

  
 21 

 
such other patent rights, whether alone or in combination with use of Patent Rights. This covenant shall terminate with the termination of this Agreement unless the termination is a Contested
Termination. In the event of a Contested Termination, this covenant shall continue to run during the [***] days, and if a lawsuit is initiated, until said state or federal court enters a final decision from which no appeal has been or
can be taken. 
 9.2.8 mRNA RiboTherapeutics will not amend the Cellscript Sublicense Agreement in any manner that would negatively affect
the rights and/or obligations of the Company under this Agreement. 
 9.3 Covenants of Company. Company covenants to Cellscript and to
mRNA RiboTherapeutics that, during the Term: 
 9.3.1 Company will not breach this Agreement, and to the extent within its power, will ensure
that its Affiliates do not breach or cause breach of any sublicense under this Agreement in a manner that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement, and, in the event of any such breach,
Company will use diligent efforts to cure (or cause to be cured) any such breach of this Agreement by Company or any breach of any sublicense under this Agreement by its Affiliates or Third Party sublicensees. 

9.3.2 Upon Company learning of any breach of a sublicense agreement by any of its Affiliates or Third Party sublicensees or any of their
further sublicensees that results in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement, Company will use diligent efforts to cure (or cause to be cured) any such breach, up to and including termination or
causing termination of the applicable sublicense, as stated in Section 1.5.4 of this Agreement. 
 9.3.3 Company will pay to Cellscript
all payments due under this Agreement pursuant to Article 3 and in accordance with the terms in Articles 3 and Section 4.2 and will provide to Cellscript all information, reports and notices required in accordance with Sections 2.1, 2.3, 3.3,
3.4.3(a), 4.1, 4.4, 4.5 and 6.6 and in the form of the sample report attached as Exhibit C, in each case in accordance with the time periods set forth therein. 

9.3.4 Promptly following mRNA RiboTherapeutics’ or any of its affiliates’ receipt of any material written notice or correspondence
about an issue pertaining to the Sublicense or to any matter that would reasonably be expected to adversely affect in any respect Company’s rights under this Agreement, mRNA RiboTherapeutics will, to the extent permissible, furnish a copy of
such notice or correspondence to Company, provided that mRNA RiboTherapeutics may redact portions of any such notice or correspondence that do not relate to or impact Company’s rights hereunder. 

9.4 Representations and Warranties of Cellscript. As of the Effective Date, Cellscript, on behalf of itself and its affiliates, hereby
represents and warrants to Company that: 
 9.4.1 (a) Cellscript has provided Company a true and correct redacted copy of the Cellscript
Sublicense Agreement (including exhibits and amendments thereto), which has been redacted with respect to amounts paid or payable by Cellscript to mRNA RiboTherapeutics for said sublicense and for milestones and other fees and royalties for Fields
of Use not sublicensed to Company (e.g., the Ex Vivo Field of Use) and certain other terms and conditions that do not pertain to or are immaterial to Company’s rights herein, and (b) except for a separate license agreement from Penn
to CELLSCRIPT, LLC related to certain patents pertaining to 

  
 22 

 
reprogramming to iPS cells (which are the Exhibit D Patents sublicensed to Company solely for the In Vivo Field of Use in Section 1.7 of this Agreement), there are no other license or
sublicense agreements, written or verbal, between Penn and Cellscript or between Cellscript or any affiliate thereof and mRNA RiboTherapeutics or any affiliate thereof. 

9.4.2 Neither mRNA RiboTherapeutics nor Cellscript, nor any affiliate thereof has granted any other license or sublicense in Field of Use B or
given any covenant not to sue for infringement of Patent Rights relating to the Penn License Agreement except for: (i) the Cellscript Sublicense Agreement, (ii) this Agreement, (iii) the mRNA RiboTherapeutics Sublicense Agreement,
(iv) one Human In Vivo Therapeutics Field Sublicense from Cellscript (if any) that will be granted to a Third Party pursuant to Article 10 of this Agreement with respect to the Human In Vivo Therapeutics Field, and (v) one
sublicense (if any) from mRNA RiboTherapeutics to said Third Party for the Diagnostic and Prognostic Field of Use. 
 9.4.3 Cellscript has
not granted any liens or encumbrances in or to its rights in Patent Rights or the Cellscript Sublicense Agreement. 
 9.4.4 Cellscript has
not breached or defaulted under any provision of the Cellscript Sublicense Agreement in any material respect or received any written notice from mRNA RiboTherapeutics of any claims for indemnification pursuant thereto. 

9.4.5 To the knowledge of Cellscript, (a) there are no facts that would preclude Penn from having clear title to the Patent Rights or
Exhibit D Patents, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like procedures involving Patent Rights or Exhibit D Patents, and (c) all of the issued patents within the Patent Rights
or Exhibit D Patents are valid and enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 
 9.4.6
Cellscript believes the terms and conditions of this Agreement are fully consistent with the terms and conditions of the Cellscript Sublicense Agreement and the Penn License Agreement. 

9.4.7 Cellscript has not received any written notice of any claim by any person or entity challenging the sublicense rights of Cellscript or
the validity or enforceability of the Patent Rights or Exhibit D Patents. 
 [Remainder of page left blank] 

  
 23 

 9.4.8 The Fields of Use sublicensed to Company in this Agreement are different and distinct
from and do not overlap with the fields of use sublicensed to Company by mRNA RiboTherapeutics in the mRNA RiboTherapeutics Sublicense Agreement and any products researched, developed, manufactured or commercialized in fields of use granted
under this Agreement are subject only to the payment and other obligations under this Agreement, and are not subject to payment and other obligations under the mRNA RiboTherapeutics Sublicense Agreement. 

9.4.9 Cellscript believes that the representations and warranties of Cellscript in this Agreement, do not, taken as a whole: (i) contain
any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading. Cellscript has not knowingly
withheld any information with respect to the Cellscript Sublicense Agreement, the Penn License Agreement or the Patent Rights or Exhibit D Patents that would reasonably be expected to be material to Company’s decision to enter into this
Agreement. 
 9.5 Representations and Warranties of mRNA RiboTherapeutics. As of the Effective Date, mRNA RiboTherapeutics hereby
represents and warrants to Company that: 
 9.5.1 Either mRNA RiboTherapeutics or Cellscript has provided Company with a true and correct
redacted copy of the Penn License Agreement (including exhibits and amendments thereto) which has been redacted with respect to the amounts paid or payable to Penn by licensee for said license and for milestones and other fees and royalties for
Fields of Use which are not sublicensed to Company herein (e.g., the Ex Vivo Field of Use) and certain other terms and conditions that do not pertain to or are immaterial to Company’s rights in the Sublicensed Fields of Use or the fields
of use sublicensed to Company under the mRNA RiboTherapeutics Sublicense Agreement, and a paragraph describing Penn’s retained right to grant a non-exclusive sublicense to one party for ten products for
humans in the Infectious Disease Vaccine Subfield of Field of Use B. 
 9.5.2 Except for a separate license agreement from Penn to Cellscript
related to certain patents and patent applications pertaining to reprogramming to iPS cells that are not part of Patent Rights herein (which are the Exhibit D Patents which are sublicensed to Company as stated in Section 1.7 of this Agreement),
and the Cellscript Sublicense Agreement, there is no other outstanding license or sublicense agreement in Field of Use B pertaining to Patent Rights nor any covenant, written or verbal, not to sue for infringement of Patent Rights pertaining to
Field of Use B between: (i) Penn and mRNA RiboTherapeutics or any affiliate thereof; or (ii) Penn and Cellscript or any affiliate thereof; or (iii) mRNA RiboTherapeutics or any affiliate thereof and Cellscript or any affiliate
thereof. 
 9.5.3 Neither mRNA RiboTherapeutics nor any affiliate thereof has granted any other license or sublicense or agreed not to sue
for infringement of Patent Rights in Field of Use B relating to the Penn License Agreement, except for: (i) the Cellscript Sublicense Agreement; (ii) this Agreement to Company, (iii) the mRNA RiboTherapeutics Sublicense Agreement to
Company, (iv) one Human In Vivo Therapeutics Field Sublicense from Cellscript (if any) that will be granted to a Third Party pursuant to Article 10 of this Agreement with respect to the Human In Vivo Therapeutics Field, and
(v) one sublicense (if any) from mRNA RiboTherapeutics to said Third Party for the Diagnostic and Prognostic Field of Use. 

  
 24 

 9.5.4 Neither mRNA RiboTherapeutics nor any affiliate thereof has granted any liens or
encumbrances in or to its rights in Patent Rights or the Cellscript Sublicense Agreement. 
 9.5.5 Cellscript has not breached or defaulted
under any provision of the Cellscript Sublicense Agreement in any material respect or received any written notice from mRNA RiboTherapeutics of any claims for indemnification pursuant thereto and mRNA RiboTherapeutics has not breached or
defaulted under any provision of the Penn License Agreement in any material respect or received any written notice from Penn of any claims for indemnification pursuant thereto. 

9.5.6 To the knowledge of mRNA RiboTherapeutics, (a) there are no facts that would preclude Penn from having clear title to the Patent
Rights, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like procedures involving any such Patent Rights and (c) all of the issued patents within the Patent Rights are valid and
enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 
 9.5.7 mRNA RiboTherapeutics believes the
terms and conditions of this Agreement are fully consistent with the terms and conditions of the Cellscript Sublicense Agreement and the Penn License Agreement. 

9.5.8 mRNA RiboTherapeutics has not received, any written notice of any claim by any person or entity challenging the sublicense rights of
Cellscript or the validity or enforceability of the Patent Rights. 
 9.5.9 The fields of use sublicensed to Company in the mRNA
RiboTherapeutics Sublicense Agreement are distinct from and do not overlap with the Fields of Use sublicensed to Company in this Agreement and any products researched, developed, manufactured or commercialized in fields of use granted under
the mRNA RiboTherapeutics Sublicense Agreement are subject only to the payment and other obligations of the mRNA RiboTherapeutics Sublicense Agreement, and are not subject to payment and other obligations under this Agreement. 

9.5.10 mRNA RiboTherapeutics believes that the representations and warranties of mRNA RiboTherapeutics in this Agreement, do not, taken
as a whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading.
mRNA RiboTherapeutics has not knowingly withheld any information with respect to the Cellscript Sublicense Agreement, the Penn License Agreement or the Patent Rights that would reasonably be expected to be material to Company’s decision
to enter into this Agreement. 
 9.6 Representations and Warranties of Company. Company hereby represents and warrants to
Cellscript and to mRNA RiboTherapeutics that, as of the Effective Date: 
 9.6.1 Company is duly organized and validly existing
under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement. 
 9.6.2
Company is in good standing with all relevant governmental authorities. 
 9.6.3 Company has taken all corporate actions necessary to
authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement. 
 9.6.4 The performance
of the obligations of Company under this Agreement do not conflict with or constitute a default under its charter documents, any contractual obligation of Company or any court order. 

  
 25 

 9.6.5 Company and its attorneys have reviewed the patents and patent applications comprising
Patent Rights including both Exhibit A-1 Patent Rights and Exhibit A-2 Patent Rights that are listed in Exhibit A attached hereto. 

9.6.6 Company has experience with and is familiar with the inventions covered by Patent Rights and understands the use, purpose and benefits
thereof. 
 9.6.7 Company has read the redacted copy of the Penn License Agreement (including exhibits and amendments thereto) that was
provided to Company by mRNA RiboTherapeutics or Cellscript. 
 9.6.8 Company has read the redacted copy of the Cellscript Sublicense
Agreement (including exhibits and amendments thereto) that was provided to Company by Cellscript or mRNA RiboTherapeutics. 
 9.6.9
Company believes that the representations and warranties of Company in this Agreement, do not, taken as a whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or
facts contained therein, in light of the circumstances under which they were made, not misleading. Company has not knowingly withheld any information with respect to the any of Company’s above statements that would reasonably be expected to be
material to Cellscript’s decision to enter into this Agreement. 
 9.7 Disclaimer of Warranties. EXCEPT AS SPECIFICALLY SET FORTH
IN THIS ARTICLE 9, NO PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS OR SUFFICIENCY OF PATENT RIGHTS OR EXHIBIT D PATENTS FOR A PARTICULAR PURPOSE, APPLICATION OR
USE, NON-INFRINGEMENT, OR ANY OTHER STATUTORY WARRANTY. 
  

	10	 ADDITIONAL TERMS REGARDING SUBLICENSING 

10.1 Purpose of this Article. This Article 10 sets forth terms and conditions for further sublicensing by Primary Sublicensors in the
Human In Vivo Therapeutics Field, wherein, for the purposes of this Article 10: 
  

	 	(a)	 “sublicensing” herein means any grant of a sublicense, covenant not to sue, or option for
current or future rights under Patent Rights, and the noun “sublicense” herein means a document that grants such sublicense, covenant not to sue, or option for current or future rights under Patent Rights; 

 

	 	(b)	 “Primary Sublicensors” herein means (i) mRNA
RiboTherapeutics,                 (ii) Cellscript, and (iii) any affiliate of (i) or (ii) that is granted a sublicense in the Human In Vivo Therapeutics
Field; and 

  

	 	(c)	 “Human In Vivo Therapeutics Field” herein means any or all therapeutic
and prophylactic use(s) in humans in the In Vivo Field of Use in Field of Use B. 

 For clarity and the absence of
doubt, Article 10 shall not be interpreted in any way so as to limit, restrict or impose any terms or conditions on Primary Sublicensors’ rights to grant sublicenses under Patent Rights to any party at any time for any Field of Use other than
the Human In Vivo Therapeutics Field. 

  
 26 

 10.2 Human In Vivo Therapeutics Field Sublicenses. Subject to
the rights of the Primary Sublicensors and their respective owners under Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date [***], mRNA RiboTherapeutics and Cellscript will not grant and will
ensure that other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses, including this Sublicense, to [***] 

“Human In Vivo Therapeutics Field Sublicense” means a sublicense to make, have made, use, import,
offer for sale, sell and/or have sold any number of products covered by Patent Rights comprising or incorporating modified RNA for the Human In Vivo Therapeutics Field, but excluding Product Sublicenses. 

10.3 Product Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4,
Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], Cellscript and mRNA RiboTherapeutics will (and will ensure that the other Primary Sublicensors will): 

(a) grant Product Sublicenses only to [***], 

wherein “Product Sublicenses” herein mean sublicenses under Patent Rights to research, develop, manufacture and/or
commercialize specific products [***], for a therapeutic or prophylactic use in humans in the In Vivo Field of Use, and 

wherein [***] 
 (b) only
grant Product Sublicenses for a total of [***] products in the aggregate by all of the Primary Sublicensors across all such Product Sublicenses, [***] 

(c) except as set forth in Sections 10.2 and 10.3, not otherwise grant sublicenses under the Patent Rights to research, develop, manufacture
and/or commercialize products comprising or incorporating [***]. 
 10.4 Sale of a Primary Sublicensor. Company understands and
agrees that the owners of each of mRNA RiboTherapeutics and Cellscript shall have the right to sell all or any part of the outstanding stock or ownership interest or the business or the assets thereof, as applicable, of mRNA RiboTherapeutics and/or
Cellscript and/or any of their respective affiliates that [***] at any time and without any conditions pursuant to this Agreement other than the requirements under Section 15.5, 

except that, as a condition to any such sale occurring prior to April 1, 2020: 

(a) the owners of each of mRNA RiboTherapeutics and Cellscript will sell mRNA RiboTherapeutics or Cellscript to only one (1) Third Party
purchaser, [***]; and 
 (b) without in any way negating or ceding or giving up any of their current rights to sell all or any part of
the stock, ownership interest, business or assets of mRNA RiboTherapeutics and/or Cellscript or to discuss any such sale with any potential purchaser at any time, including from the Effective Date of this Agreement until [***], the owners of
mRNA RiboTherapeutics and Cellscript agree not to conduct Active Marketing of such sale of a Primary Sublicensor prior to [***], 

  
 27 

 wherein “[***]” herein means [***]; and 

for the avoidance of doubt, Company agrees that this Section 10.4(a) shall not be interpreted so as to prohibit the owners of mRNA
RiboTherapeutics and/or Cellscript from proposing or discussing [***]; 
 (c) the purchaser of mRNA RiboTherapeutics or Cellscript,
respectively, will pay [***]; 
 (d) on the effective date of any such sale of [***] and the purchaser and their assignees and
successors in ownership thereof shall have all the same rights as are held by Company under this Agreement to: 
  

	 	(i)	 grant Human In Vivo Therapeutics Field Sublicenses to affiliates and Third Parties without being subject
to any restrictions, limitations, or terms and conditions that apply to the Primary Sublicensors under Sections 10.2, and 

  

	 	(ii)	 grant Product Sublicenses to affiliates and any Third Parties to research, develop, manufacture and/or
commercialize any number of products comprising modified RNA covered by Patent Rights for any therapeutic or prophylactic use in humans in the In Vivo Field of Use without being subject to any of the restrictions, limitations or requirements
that the sublicensee is a Small Biotech Company as is required of the Primary Sublicensors in Section 10.3; and 

 (e)
on the effective date of any such sale of more than fifty percent (50%) of the outstanding stock or ownership interest or all of the business or assets of mRNA RiboTherapeutics or Cellscript, all of the rights of the Primary Sublicensors to grant
Product Sublicenses pursuant to Section 10.3 shall remain only with the Primary Sublicensors for which their stock, ownership interest, business and assets were not sold. 

[***] 
 10.5 From
[***], Primary Sublicensors and any owners, assignees or successors in ownership thereof shall have the right to grant any number of Human In Vivo Therapeutics Field Sublicense(s) to any parties without any conditions (other than those
imposed by the Penn License Agreement or the Cellscript Sublicense Agreement) and to grant any number of Product Sublicenses or any other sublicenses of any kind under Patent Rights to any parties without any limitations or restrictions or
requirements whatsoever under this Article 10. 
  

	11	 LIMITATION OF LIABILITY; DISCLAIMER. 

11.1 Limitation of Liability. CELLSCRIPT, mRNA RIBOTHERAPEUTICS AND PENN WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES,
SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE PATENT RIGHTS, EXHIBIT D PATENTS, LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR ARISING FROM THE
COMPANY’S, COMPANY’S AFFILIATES’ OR COMPANY’S SUBLICENSEES’ DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS. NOTWITHSTANDING ANYTHING IN THIS 

  
 28 

 
AGREEMENT OR OTHERWISE, NONE OF CELLSCRIPT, mRNA RIBOTHERAPEUTICS, PENN, OR COMPANY WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY
INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THIS SECTION 11.1 WILL NOT APPLY: (a) TO A PARTY’S INDEMNIFICATION RIGHTS AND
OBLIGATIONS UNDER ARTICLE 12 OR ARTICLE 13; (b) IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES; OR (c) WITH RESPECT TO A PARTY’S LIABILITY FOR BREACH OF ARTICLE 5 or 10. 

11.2 Disclaimer. THE PATENT RIGHTS, EXHIBIT D PATENTS, LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE
PROVIDED ON AN “AS IS” BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NONE OF CELLSCRIPT, mRNA RIBOTHERAPEUTICS, PENN, OR COMPANY MAKE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY
WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT, VALIDITY OR TITLE. 

 

	12	 PENN INDEMNIFICATION 

12.1 Indemnification. Company will defend, indemnify, and hold harmless each Penn Indemnified Party from and against any and all Penn
Liabilities with respect to an Indemnification Event. The term “Penn Indemnified Party” means each of Penn and its trustees, officers, faculty, students, employees, contractors, and agents. For clarity, Cellscript is not a Penn
Indemnified Party. The term “Penn Liabilities” means all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and
expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by a Penn Indemnified Party or awarded or otherwise required to be paid to Third Parties by a Penn
Indemnified Party. The term “Indemnification Event” means any Claim against one or more Penn Indemnified Parties arising out of or resulting from: [***]. The term “Claim” in this Article 12 means any
charges, complaints, actions, suits, proceedings, hearings, investigations, claims or demands. 
 12.2 Reimbursement of Costs. Company
will pay directly all Penn Liabilities incurred for defense or negotiation of any Claim or will reimburse Penn for all documented Penn Liabilities incident to the defense or negotiation of any Claim within [***] days after Company’s
receipt of invoices for such fees, expenses and charges. 
 12.3 Control of Litigation. Company controls any litigation or potential
litigation involving the defense of any Claim, including the selection of counsel, with input from Penn. Penn reserves the right to protect its interest in defending against any Claim by selecting its own counsel, with any attorneys’ fees and
litigation expenses paid for by Company, pursuant to Sections 12.1 and 12.2. 

  
 29 

 12.4 Other Provisions. Company will not settle or compromise any Claim giving rise to
Penn Liabilities in any manner that imposes any restrictions or obligations on Penn or grants any rights to the Patent Rights, Exhibit D Patents or the Licensed Products without Penn’s prior written consent. If Company fails or declines to
assume the defense of any Claim within [***] days after notice of the Claim, or fails to reimburse a Penn Indemnified Party for any Penn Liabilities pursuant to Sections 12.1 and 12.2 within the [***] day time period set forth in
Section 12.2, then Penn may assume the defense of such Claim for the account and at the risk of Company, and any Penn Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification rights of the Penn
Indemnified Parties under this Article 12 are in addition to all other rights that a Penn Indemnified Party may have at law, in equity or otherwise. 
  

	13	 OTHER INDEMNIFICATION 

13.1 Indemnification by Company. Company will indemnify, defend and hold harmless Cellscript and its affiliates, and its or their
respective directors, officers, employees and agents (“Cellscript Indemnified Parties”), from and against any and all liabilities, damages, losses, costs and expenses including the reasonable fees of attorneys (collectively
“Losses”) arising out of or resulting from any and all Third Party suits, claims, actions, proceedings, payment obligations or demands (“Claims” in this Article 13) to the extent based upon: 

13.1.1 the gross negligence or willful misconduct of Company, its Affiliates or Third Party sublicensees and its or their respective directors,
officers, employees and agents, in connection with Company’s performance of its obligations or exercise of its rights under this Agreement; 

13.1.2 any breach of any representation or warranty or express covenant made by Company under this Agreement; or 

13.1.3 the development, testing, use, manufacture, commercialization, sale or other disposition of Licensed Products by or on behalf of Company
or its Affiliates or Third Party sublicensees, assignees or vendors or Third Parties, including, but not limited to, for (x) any product liability or other Claim of any kind related to use by a Third Party of a Licensed Product, (y) any
Claim by a Third Party that Company’s practice of any of the Patent Rights or Exhibit D Patents or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or violates any patent, copyright, trade
secret, trademark or other intellectual property right of such Third Party, and (z) any Claim by a Third Party relating to clinical trials or studies for Licensed Products; 

except, in each case above, to the extent such Claim arose out of or resulted from or is attributable to any acts or omissions of Cellscript
or its directors, officers, employees and agents, or other circumstances for which Cellscript has an indemnity obligation pursuant to Section 13.2 below. 

13.2 Indemnification by Cellscript. Cellscript will indemnify, defend and hold harmless Company and its Affiliates, and its or their
respective directors, officers, employees and agents (“Company Indemnified Parties”), from and against any and all Losses arising out of or resulting from any and all Claims to the extent based upon: 

13.2.1 the gross negligence or willful misconduct of Cellscript or its directors, officers, employees and agents, in connection with
Cellscript’s performance of its obligations or exercise of its rights under this Agreement; or 
 13.2.2 any breach of any
representation or warranty or express covenant made by Cellscript under this Agreement; or 

  
 30 

 except, in each case above, to the extent such Claim arose out of or resulted from or is
attributable to any acts or omissions of Company or its Affiliates or Third Party sublicensees or contractors and its or their respective directors, officers, employees and agents or other circumstances for which Company has an indemnity obligation
pursuant to Section 13.1 above. 
 13.3 Procedure. If an Indemnified Party entitled to indemnification under Sections 13.1 or
13.2 seeks such indemnification (wherein “Indemnified Party” in this Article 13 means a “Company Indemnified Party” and/or an “Cellscript Indemnified Party”), such Indemnified Party will: 

(i) inform the indemnifying Party in writing of a Claim as soon as reasonably practicable after such Indemnified Party receives notice of such
Claim; 
 (ii) permit the indemnifying Party to assume direction and control of the defense of the Claim (including the sole right to settle
such Claim at the sole discretion of the indemnifying Party, provided that (a) such settlement or compromise does not admit any fault or negligence on the part of the Indemnified Party, or impose any obligation on, or otherwise
materially adversely affect, the Indemnified Party or other Party and (b) the indemnifying Party first obtains the written consent of the Indemnified Party with respect to such settlement, which consent will not be unreasonably withheld); 

(iii) cooperate as reasonably requested (at the expense of the indemnifying Party) in the defense of the Claim; and 

(iv) undertake reasonable steps to mitigate any Losses with respect to the Claim. 

Notwithstanding anything in this Agreement to the contrary, the indemnifying Party will have no liability under Sections 13.1 or 13.2, as the
case may be, for Claims settled or compromised by the Indemnified Party without the indemnifying Party’s prior written consent. 
  

	14	 INSURANCE 

14.1 Coverages. Company will procure and maintain insurance or self-insurance that covers the following minimum liability amounts with
respect to personal injury, bodily injury and property damage arising out of Company’s performance under this Agreement: (a) during the Term, comprehensive general liability, including broad form and contractual liability, in a minimum
amount of [***] combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving Licensed Products, clinical trials a minimum amount of [***] combined single limit per
occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability a minimum amount of [***] combined single limit per occurrence and in the aggregate. Penn and Cellscript may review periodically
the adequacy of the minimum amounts of insurance or self-insurance for each liability coverage area required by this Section 14.1, and Penn and Cellscript reserve the right to request Company to adjust the limits accordingly to the extent
existing limits are not commercially reasonable. The required minimum amounts of insurance or self-insurance do not constitute a limitation on Company’s liability or indemnification obligations to Penn or Cellscript under this Agreement.

  

	15	 ADDITIONAL PROVISIONS 

15.1 Independent Contractors. The Parties are independent contractors. Nothing contained in this Agreement is intended to create an
agency, partnership or joint venture between the Parties. At no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party. 

  
 31 

 15.2 No Discrimination. Company will not discriminate against any employee or
applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 

15.3 Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its activities or
obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United
States government and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior approval of the agency. Penn and Cellscript do not represent that no license is required, or that, if
required, the license will issue. 
 15.4 Modification, Waiver & Remedies. This Agreement may only be modified
by a written amendment that is executed by an authorized representative of each Party. Any waiver must be express and in writing. No waiver by either Party of a breach by the other Party will constitute a waiver of any different or succeeding
breach. Unless otherwise specified, all remedies are cumulative. 
 [Remainder of page left blank] 

  
 32 

 15.5 Assignment. This Agreement may not be assigned (by operation of law or
otherwise) by either Party without the prior written consent of the other Party (which consent will not be unreasonably withheld); except that, either Party may assign this Agreement without such consent to an affiliate or to a Third Party
successor that purchases greater than fifty percent (>50%) of the outstanding stock or ownership interest or all or substantially all of such Party’s business or assets to which this Agreement relates, whether by sale of shares or ownership
interest, merger, consolidation, sale of assets or otherwise, provided that, prior to said transfer, the intended assignee agrees in writing to be legally bound by this Agreement in the place and stead of the assignor and provides the non-assigning Party with a copy of said assignee’s written undertaking. Neither Party will grant a security interest in the Sublicense or this Agreement during the Term. Any prohibited assignment or security
interest in contravention of the foregoing will be null and void. The rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a
Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Section 15.5. 

15.6 Notices. Any notice or other required communication (each, a “Notice”) must be in writing, addressed to the
Party’s respective Notice Address listed on the signature page, and delivered: (a) personally, with signed receipt; (b) by certified mail, postage prepaid, return receipt requested; (c) by recognized overnight courier service,
charges prepaid; or (d) by facsimile. A Notice will be deemed received: if delivered personally, on the date of delivery; if mailed, [***] days after deposit in the United States mail; if sent via courier, [***] business day after
deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such Notice is sent by certified mail, postage prepaid, return receipt requested. 

15.7 Severability & Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a
court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be automatically revised to be a valid or enforceable provision that comes as close
as permitted by law to the Parties’ original intent. 
 15.8 Headings & Counterparts. The headings of the
articles and sections included in this Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in one or more counterparts, each of which when
executed and delivered by facsimile, electronic transmission, or by mail delivery, will be an original and all of which shall constitute one and the same instrument. 

15.9 Governing Law. This Agreement will be governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving
effect to the conflict of law provisions of any jurisdiction. 
 15.10 Dispute Resolution. If a dispute arises between the Parties
concerning any right or duty under this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the Parties are unable to resolve the dispute amicably, then the Parties will submit to the exclusive
jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania with respect to all disputes arising under this Agreement. Notwithstanding anything herein to the contrary, in the event of an actual or
threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief) in any court of competent jurisdiction to protect the interests of such
Party. 

  
 33 

 15.11 Further Assurance. Each Party shall duly execute and deliver, or cause to be
duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably
request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

15.12 Interpretation. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the
singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or
limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. The
language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. The Parties acknowledge and agree that new products and uses for products
that are covered by Patent rights may be developed based on new advances in scientific knowledge. As such, the Parties’ agree that, if Company is of the opinion that such advances have resulted in changes which warrant interpretation of whether
such new products or uses are included within the Sublicensed Fields of Use granted to Company herein, the Parties agree to discuss and negotiate in good faith the need for an amendment or clarification of the meaning of the rights or Fields of Use
granted to Company in Section 1.1 of this Agreement in order to try to find a solution that is agreeable to the Parties. Then, if the Parties have not agreed on the necessity or the wording of such amendment within [***] days after
beginning good faith discussions, the Parties agree that, either both Parties will jointly agree on and appoint one independent Third Party, or each of the Parties will appoint one independent Third Party and those Third Parties will appoint one
additional independent Third Party (all of which Third Parties will be qualified and skilled in the scientific field and have knowledge of law related to patents and licenses) to decide whether such amendment is required to properly reflect this
intention. If the appointed independent Third Party or Third Parties decide(s) that said amendment is required, the Parties hereby agree to so amend this Agreement accordingly. If the appointed independent Third Party or Third Parties decide(s) that
said amendment is not required, there is no obligation on either Party to amend this Agreement. The costs of the appointed independent Third Party or Third Parties will be borne by the Party whose view has not been confirmed by such Third
Party(ies). 
 15.13 Integration. This Agreement with its Exhibits and the Confidentiality Agreement contain the entire agreement
between the Parties with respect to the Patent Rights, Exhibit D Patents and the Sublicense and supersede all other oral or written representations, statements, or agreements with respect to such subject matter. 

15.14 Condition Precedent to Execution of this Agreement. The Parties understand and agree that each Party’s willingness to enter
into this Agreement is contingent upon the execution of both this Agreement and the mRNA RiboTherapeutics Sublicense Agreement, which grants certain other rights to Company under Patent Rights than the rights granted to Company in this Agreement.

  
 34 

 15.15 Entire Agreement. This Agreement and the separate mRNA RiboTherapeutics
Sublicense Agreement set forth the complete, final and only agreements with respect to the subject matter hereof and supersede all other agreements and understandings between the Parties with respect to the subject matter hereof. The Parties
acknowledge and agree that this Agreement and the mRNA RiboTherapeutics Sublicense Agreement are separate and distinct agreements and there will be no “cross default” with respect to this Agreement and the mRNA RiboTherapeutics Sublicense
Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 35 

 Each Party has caused this Agreement to be executed by its duly authorized representative. 

 

									
	CELLSCRIPT, LLC	  		 	BioNTech AG
					
	By:	  	 [***]
	  		 	By:	  	 [***]

	Name:	  	[***]	  		 	Name:	  	[***]
	Title:  	  	[***]	  		 	Title:  	  	[***]
			
	Address: CELLSCRIPT, LLC	  		 	Address: BioNTech AG
		  	726 Post Road	  		 		  	An der Goldgrube 12
		  	Madison, WI 53713	  		 		  	Mainz
		  	USA	  		 		  	Germany

 mRNA RIBOTHERAPEUTICS, INC., 

which is executing this Agreement solely 
 with respect to the
following provisions: 
  

	 	•	 	 Section 6.5.1, solely with respect to 

acceptance of sublicense agreements 

assigned by Cellscript; 
  

	 	•	 	 Section 9.2 (9.2.1through 9.2.8); 

 

	 	•	 	 Section 9.5 (9.5.1 through 9.5.10); and 

 

	 	•	 	 Article 10. 

  

			
	By:	 	 [***]

	Name:	 	[***]
	Title:	 	[***]
	
	Address: mRNA RiboTherapeutics, Inc.
		 	726 Post Road
		 	Madison, WI 53713
		 	USA

  
 36 

 EXHIBIT INDEX 

 

			
		
	Exhibit A	  	Patents and Patent Applications in Patent Rights
		
	Exhibit B	  	Sublicense Disclosure Report
		
	Exhibit C	  	Form of Royalty Report
		
	Exhibit D	  	Cellscript’s Exhibit D Patents

  

  
 37 

 EXHIBIT A – Patents and Patent Applications in Patent Rights 

[***] 

  
 38 

 EXHIBIT A – Patents and Patent Applications in Patent Rights 

[***] 

  
 39 

 Exhibit B 

Sublicense Disclosure Report 
 [***] 

  
 40 

 EXHIBIT C – Format of Royalty Report 

[***] 

  
 41 

 Exhibit D 

Exhibit D Patents Sublicensed to Company under Section 1.7 

  
 42

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]